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Abstract
Bone fracture healing is a highly complex process involving different cell and tissue types. It
consists of different but overlapping phases that have to be well organized and regulated
for a successful healing outcome. Bone tissue possesses the remarkable capacity to fully
regenerate after injury. However, in 10–15 % of patients, unsuccessful bone repair is still
a preset problem that has to be considered. The bone and the immune system are highly
interconnected. Components of the adaptive immune system play an indispensable role in
bone regeneration, probably due to their cellular interactions and their secreted cytokine
profile. For CD8+ terminally differentiated effector memory T cells (TEMRA), a negative
correlation of an increased amount and an impaired bone repair process was already shown
in patients. The here presented PhD thesis focused on a deeper analysis of the impact of the
adaptive immunity in bone regeneration in order to better understand their influence in
tissue repair. More precisely, the interaction of CD4+ regulatory T cells (TReg) during fracture
healing was evaluated. TReg are a promising candidate for playing a positive modulating
role in bone repair. However, their sole influence in bone regeneration was not analyzed so
far.
In a murine osteotomy model of a non-critical size defect, the spatial and temporal distri-
bution of distinct immune and bone cell subsets was analyzed within the healing tissue
of the osteotomized bone. Cells of the innate (macrophages) and adaptive (T and B cells)
immunity are detectable throughout the whole healing cascade in the injured area. The
appearance of anti-inflammatory M2 macrophages coincided with the formation of new
vessels which reestablished the necessary oxygen and nutrition supply. M2 macrophages
further co-localized with osteoblasts in the fracture gap indicating an orchestrating function
of macrophages for the production of bone by osteoblasts. T and B cells also directly
co-localized with osteoblasts and osteoclasts, respectively, in the early fracture healing phase.
These results highlight the interconnectivity of immune and bone cells during regeneration
which was not analyzed and shown in any other study before.
By adoptive transfer of freshly isolated murine regulatory T cells prior to osteotomy, an
immunomodulatory approach to improve bone healing was conducted. The activation
status of the adaptive immunity prior to surgery was included into this analysis. Mice
possessing an unexperienced immune system (housing in an SPF environment) showed a
consistent improved healing outcome after adoptive transfer of TReg in comparison to the
control group 21 days post-osteotomy. However, mice with a more experienced immune
system (semi-sterile housing environment) receiving an adoptive TReg transfer demonstrated
a controversial healing outcome after 21 days: half of the mice showed a significantly
improved and the other half a significantly poorer healing outcome. In the mice with a
poorer healing outcome, a higher ratio between CD8+ effector T cells and TReg was observed.
In a following proof of concept study, a pre-osteotomy defined ratio of CD8+ effector T
cells and TReg could predict the healing outcome 21 days after adoptive transfer of TReg and
osteotomy.
A potential positive impact of TReg in bone repair was confirmed in this study. However, the
tremendous impact of the environment and thereby of the immune status prior to immunomo-
dulation was also clearly demonstrated. Transferring these findings to the clinical situation
reveals how individually each patient might react to the same immunomodulatory therapy
and how this therapy could affect the results of the treatment in an unfavorable way. Hence,
for the clinic, it is even more important to develop and to apply patient based treatment
approaches in the field of immunotherapy considering the individual immune status of each
patient prior to treatment.
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Zusammenfassung
Die Heilung nach einem Knochenbruch ist ein sehr komplexer Prozess, an dem verschiedenste
Zellen und Gewebe beteiligt sind. Sie verläuft in mehreren in einander übergehenden Phasen,
die für einen erfolgreichen Heilungsverlauf klar reguliert sein müssen. Knochengewebe
besitzt die einzigartige Fähigkeit sich nach einem Bruch komplett zu regenerieren. Dennoch
zeigen 10–15 % der Patienten einen gestörten Heilungsverlauf und Heilungserfolg. Das
Immunsystem ist mit dem Knochengewebe stark vernetzt. Immunzellen spielen eine
entscheidende Rolle in der Frakturheilung durch die Sekretion spezifischer Zytokine. Für
CD8+ T-Zellen konnte bereits ein negativer Einfluss auf den Frakturheilungsprozess gezeigt
werden. Im Rahmen der hier präsentierten Doktorarbeit wurde der Einfluss der adaptiven
Immunität, insbesondere der CD4+ regulatorischen T-Zellen, auf die Knochenheilung
untersucht. Dadurch sollte ein besseres Verständnis über die Wirkung von regulatorischen
T-Zellen in der Regeneration erlangt werden.
Unter Verwendung eines Maus-Osteotomy-Modelles wurde die zeitliche und räumliche
Verteilung ausgewählter Immun- und Knochenzellen im osteotomierten Knochen über
den Heilungsverlauf untersucht. Dabei konnte gezeigt werden, dass sowohl Zellen der
angeborenen (Makrophagen), als auch der adaptiven (B- und T-Zellen) Immunität im
gesamten Heilungsverlauf in der Frakturzone zu finden waren. Hierbei korrelierte das
Auftreten von anti-inflammatorischen M2-Makrophagen mit der Revaskularisierung des
Frakturbereiches. Desweiteren konnten M2-Makrophagen gleichzeitig mit Osteoblasten im
Frakturbereich detektiert werden. Dies lässt eine regulatorische Funktion von Makrophagen
auf die Bildung von neuem Knochengewebe durch Osteoblasten vermuten. B- und T-Zellen
kolokalisierten ebenfalls mit Osteoblasten, aber auch mit Osteoklasten in der frühen Phase
der Frakturheilung. Diese Ergebnisse zeigen deutlich die starke Interaktion zwischen dem
Knochen- und dem Immunsystem. Systemische Veränderungen über den Heilungsprozess
waren vor allem in der Population der Gedächtnis-T-Zellen, als auch der der regulatorischen
T-Zellen zu sehen, und diese vorwiegend im Knochenmark.
Ein adaptiver Transfer frisch isolierter muriner regulatorischer T-Zellen vor dem Setzen der
Osteotomie diente als immunmodulatorischer Ansatz um den Frakturheilungsprozess zu
verbessern. Hierbei wurde desweiteren der Immunstatus der Mäuse vor OP berücksichtigt.
Tiere mit einem weniger stark aktivierten Immunsystem (SPF-Haltung) zeigten nach Transfer
regulatorischer T-Zellen konstant eine Verbesserung der Heilung im Vergleich zur Kontroll-
gruppe. Dem hingegen war bei den Mäusen mit einem stärker aktivierten Immunsystem
(semi-sterile Haltung) ein kontroverser Heilungserfolg zu beobachten. Hierbei heilte eine
Hälfte der Mäuse signifikant besser als die Kontrollgruppe und die andere Hälfte sig-
nifikant schlechter. Die Schlechtheiler zeigten eine höhere Ratio von CD8+ Effektor-T-Zellen
zu regulatorischen T-Zellen im Vergleich zu den Gutheilern. In einer darauffolgenden
Proof-of-concept-Studie konnte gezeigt werden, dass eine prä-OP definierte Ratio von CD8+
Effector-T-Zellen zu regulatorischen T-Zellen mit dem Heilungserfolg nach Osteotomie
korrelierte.
Im Rahmen dieser Doktorarbeit konnte ein potentiell positiver Einfluss von regulatorischen
T-Zellen auf den Frakturheilungsprozess bestätigt werden. Dennoch wurde auch der
enorme Einfluss des prä-OP Immunstatus auf den Heilungserfolg deutlich gezeigt. Mit
Hinblick auf den Patienten in der Klinik wird deutlich wie individuell jeder dieser auf eine
immunmo-dulatorische Therapie reagieren kann und wie dadurch der Erfolg dieser Therapie
(negativ) beeinflusst werden kann. Demzufolge ist es im Rahmen der Immuntherapie umso
wichtiger Patienten-basierte Therapieformen zu entwickeln und anzuwenden, bei denen der
individuelle Immunstatus eines jeden Patienten vor Anwendung der Therapie berücksichtigt
wird.
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1 Introduction
Bone is an impressive tissue because next to liver, it is the only organ that possesses the
capacity to fully self-repair without scar formation after injury. Thus, under normal healing
conditions, after fracture, bone completely regenerates gaining the same biomechanical
properties as the original bone. Although bone repair is for the most part a really efficient
process, delayed or even non-unions are still considerable problems in today’s society,
especially in the aging population, resulting in higher burden for the patient itself but
also for the socio-economic and health system [1, 2]. Therefore, a better understanding of
the principle processes in fracture healing is necessary for the development of new and
improved therapeutic strategies in order to overcome impaired bone repair.
The immune system is highly interconnected with the bone system and vice versa, leading to
the introduction of an own research field at the beginning of the 21th century focusing on the
interplay of both systems: osteoimmunology [3]. Both, the innate and the adaptive immune
systems play important roles in fracture healing, in the early as well as in the later healing
phases [4, 5]. Immune cells are one of the first cells infiltrating the fracture area. Especially T
cells, as part of the adaptive immunity, seem to be one of the key players in bone healing by
determining the local cytokine milieu in the fracture area [6, 7, 8, 9, 10, 11, 12]. A pivotal role
for T cells in the healing outcome of wounds was already shown by Barbul et al. [6] and Efron
et al. [13] without identifying the finally responsible cell subset. For CD8+ T cells, we could
already show that they have a negative impact on successful bone repair [4]. Regulatory T
cells (TReg), a subpopulation of CD4+ T cells, are a promising candidate playing a crucial
positive modulating role in bone regeneration [14, 15, 16, 17, 18]. In a murine calvarial defect
model, the application of TReg together with bone marrow mesenchymal stromal cells led to
advanced bone formation [15, 16, 17]. However, the understanding of the impact and mode
of action of TReg under normal healing conditions is just at the beginning.
In my PhD thesis, a non-critical size defect murine osteotomy model was used in order to
better understand the immune cell composition over the healing cascade of an unaltered
healing process. After analyzing the impact of the immune system in bone regeneration in a
normal healing situation, a possible immunomodulatory therapeutic approach to improve
the healing outcome was investigated. Therefore, an adoptive transfer of regulatory T cells
prior to surgery was done. Hereby, the status of the immune system of the recipient mice
prior to surgery was considered into the analysis, due to a different housing of the mice:
specific pathogen free (SPF) vs. semi-sterile (non-SPF) housing. In this respect, we could
already show that the housing of mice has an influence on the outcome of an unaltered
healing process comparing both conditions [4]. At the end of the project, a potential identified
biomarker determining the healing outcome after osteotomy could be confirmed in a proof
of concept study.
1.1 Bone tissue
Bone tissue serves as a scaffold for the body and is part of its musculoskeletal system enabling
movement. Besides its mechanical function, it also has a protecting function for underlying
organs (e. g. the sternum and the costal arches). It further functions as a reservoir for mineral
salts (e. g. calcium and phosphate), hormones and harbors different cell and tissue types.
Bone is a highly active and adaptable biomaterial in respect of its microarchitecture and
shape, dependent on the mechanical stimuli from the environment the bone is exposed to,
the strain stress [19]. Meaning, the bone is constantly remodeled to adapt to the changing
loading conditions. This is enabled due to its unique structure (Chap. 1.1.1).
1
CHAPTER 1. INTRODUCTION 2
1.1.1 Structure of long bones
There exist two different types of bone in the human body: long bones (e. g. femur, tibia,
humerus) and flat bones (e. g. scull, ileum). Within both bone forms, two main structural
types of mature bone can be distinguished: trabecular (cancellous) bone and compact
(lamellar) bone [20].
In the following, the structure of long bones will be further described. The overall shape of
a long bone can be divided into 5 parts (Fig. 1.1): a proximal and distal epiphysis (ends of
the bone), the adjacent metaphyses and the middle part, the long shaft, the diaphysis. The
outer layer of the bone is the periosteum. The periosteum consists of two layers, harboring
osteogenic (progenitors) cells and fibrous tissue, which enables the bone to widen [21]. The
diaphysis, in which the medullary cavity is enclosed, is also coated with an inner layer,
identified as the endosteum. The bone tissue itself consists of organic material, including
osteogenetic cells (Chap. 1.1.2) and extracellular matrix (30 %), and of an inorganic part
including minerals in the form of hydroxyapartite crystals (70 %) [22]. The extracellular
matrix presents the ground substance of the bone. It mainly contains water, collagen fibers
and proteoglycans, in which different cell types and minerals are embedded. The main
collagen the bone is composed of is collagen type I. In cortical bone, the collagen fibers are
organized as triple-helices which are orientated in regular layers, the lamellae, along the axis
of the bone (Fig. 1.1). Thereby, there are concentrically arranged around a central canal, the
Haversian canal. Next to the collagen fibers, the Haversian system contains blood vessels
and lymphatic nerves (Fig. 1.1). In contrast, in trabeculae bone, the mineralized collagen
fibers are orientated in parallel to each other, aligned along the stress they are exposed to.
The methaphysial shaft of a long bone consists of compact bone, whereas trabecular bone is
found within the ends of long bones. The basic unit of the cortical bone is the osteon (Fig.
1.1). It consists of the Haversian canal that ensures the vascular supply and the surrounding
bone lamellae [23]. This central canal is further connected via canaliculi to osteocytes (Chap.
1.1.2.2) which are located within the concentric lamellae of the compact bone. The osteocytes
itself are also interconnected via their canaliculi.
Figure 1.1: Schematic illustration of the structure of long bones (left) and a more detailed view of
a segment of cortical bone (right). Long bones are divided into epiphyses, metaphysis and the
diaphysis, containing the medullary cavity. Cortical bone is organized by osteons, consisting of an
inner canal, the Haversian canal. The collagen fibers are orientated as concentric lamellae around the
Haversian canal. Osteocytes are interconnected via canaliculi. Picture adapted from Medical Art
(www.servier.de)
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1.1.2 Cells of the bone matrix
The three main cell types of the bone matrix are bone producing osteoblasts (Chap. 1.1.2.1),
osteocytes (Chap. 1.1.2.2) and bone resorbing osteoclasts (Chap. 1.1.2.3). In bone homeostasis,
a close cross-talk between these cell types has to happen in order to enable a balanced bone
resorption and formation at the right time and at the right place of the skeletal system. This
ensures the adaptation of the bone to stress strains from the environment.
Bone is a highly dynamic organ due to its constant remodeling through the action of
osteoblasts, osteoclasts and osteocytes. Julius Wolff published in 1892 the Wolff’s Law which
describes that the bony architecture, in particular the orientation of the trabeculae bone, is
based on the mechanical forces the bone is exposed to. Meaning, the bone adapts to the
applied forces from the mechanical environment [24].
1.1.2.1 Osteoblasts
Bone tissue is formed by osteoblasts. Under the stimulation by e. g. bone morphogenetic
proteins (BMPs) and members of the Wnt pathway, mesenchymal stromal cells (MSCs)
differentiate into osteoblasts. One of the master transcription factors that have to be
expressed in the early stage of osteoblastic differentiation is the runt-related transcription
factor 2 (RUNX2) [25]. Mature osteoblasts are characterized by their production and secretion
of a non-mineralized organic bone matrix (osteoid), which consists among others of the
bone matrix proteins osteocalcin and collagen type I. In a following step, this bone matrix is
then mineralized. The final mineralized bone matrix mainly contains crystals of calcium
and phosphate, the hydroxyapatite crystals. Mature osteoblasts are located along the bone
surface having a cuboidal shape [25]. Time lapse fluorescence imaging approaches revealed
a movement of mature osteoblasts over the bone surface of around 4–5µm per hour [26].
The bone forming capacity of mature osteoblasts lasts about 100 days [21]. Afterwards,
aged osteoblasts can undergo the following destinies: buried in the mineralized matrix as
osteocytes (Chap. 1.1.2.2), rest on the bone surface as bone lining cells or undergo apoptosis.
Bone lining cells are flat shaped aged osteoblasts that are found well organized on the bone
surface where neither bone resorption nor bone formation are taking place. Thereby, they
functionally represent the resting phase of bone remodeling. However, they seem to have a
regulatory function in order to stimulate bone remodeling [27, 28].
1.1.2.2 Osteocytes
Osteocytes are star-shaped cells and are located within the mineralized bone matrix. They
derive from mature osteoblasts. It is still unclear how the transition from mature aged
osteoblasts to buried osteocytes takes place. In 2011, Dallas and Bonewald proposed a rather
active then passive transition process [26]. Osteocytes becoming osteoblasts have to process
dendrites, necessary for their viability and functionality which is an active process. It is
probably that osteoblasts first has to arrest in cell mobility before getting embedded into the
bone matrix and becoming an osteocyte. However, the elucidation of the exact mechanism
of this transition process is still missing. Osteocytes are long living bone cells [29]. In earlier
days it was thought that osteocytes are quiescent cells within the bone without specific
function. Nowadays, it is already well accepted that osteocytes play an important role in
regulating bone homeostasis through their function as mechanosensors [30]. They sense
the mechanical stimuli and translate them into biochemical signals to cells on the bone
surface through their canaliculi. Thereby, osteocytes regulate the activation of osteoblasts
and osteoclasts (Chap. 1.1.2.3) during bone homeostasis and remodeling.
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1.1.2.3 Osteoclasts
Osteoclasts present giant terminally differentiated multinucleated bone resorbing cells.
They originate from mononuclear hematopoietic stem cells (HSCs) and develop under the
stimulation by a variety of factors, of which the most important ones are macrophage colony-
stimulating factor (M-CSF) and receptor activator of NF-κ B ligand (RANKL). RANKL
binds to its receptor RANK on the surface of mononuclear pre-osteoclasts. M-CSF and
RANKL are expressed by a variety of cells, like osteoblasts, osteocytes, stromal cells but
also T cells as part of the adaptive immunity (Chap. 1.5). Another important factor in the
process of osteoclast differentiation and activation is the soluble decoy receptor for RANKL:
osteoprotegerin (OPG). Therefore, the RANK/RANKL/OPG axis is the regulator of osteoclast
differentiation, activity and function [31]. After activation by RANKL binding, osteoclasts
get polarized and a reorganization of their cytoskeleton occurs. Between the bone surface
and the osteoclast, a ruffled border with a sealing zone is formed, representing a resorption
pit named the Howship’s lacunae. The basolateral secretory domains are not in contact with
the bone surface [32, 33]. For bone resorption, lytic enzymes e. g. the collagenase Cathepsin
K are secreted into the Howship’s lacunae [34].
1.1.3 Development of the bone tissue
Bone tissue can develop via two different mechanisms: 1) through intramembranous
ossification or 2) through endochondral ossification. In the process of intramembranous
ossification, bone tissue develops directly out of MSCs that differentiated into osteoblasts
before. During embryonic development, parts of the flat cranial bone are created via
intramembranous ossification. During endochondral ossification, a cartilage template is first
build that is then replaced by newly formed bone. This is how e. g. long bones are formed.
1.2 Fracture healing
Bone has the unique capacity to fully regenerate without scar formation after an injury.
Under normal healing conditions, the regenerated bone possesses the same mechanical
properties as the original bone before injury. Fracture healing is a highly complex process
that involves different cells (e. g. MSCs, immune cells) and tissue types (e. g. bone, bone
marrow, periosteum, endosteum, connective tissue, cartilage and the surrounding muscles).
It has to be well organized for a successful healing outcome. Both, the bone healing process
itself but also the outcome depend on the cellular and cytokine composition within the
fracture area but also within the surrounding tissue serving as a rich source of migrating
cells with different cytokine profiles.
A fracture can heal either directly via intramembranous ossification (primary or direct
healing) or indirectly via endochondral ossification together with intramembranous bone
formation (secondary or indirect healing) [35].The prerequisite for direct healing is a correct
anatomical reduction of the fracture ends and a stable fixation [36]. Furthermore, it can
occur as contact or gap healing, whereas the gap size is restricted to less than 800µm to 1 mm
[37]. In addition, no external callus is formed during this direct healing process. In contrast,
indirect fracture healing benefits from micro-motions and weight-bearing. It occurs when
the fracture ends have no direct contact and the gap size is too large for a direct healing.
During secondary bone fracture healing, an external callus is formed in order to stabilize
the fracture area during the healing process. Secondary bone fracture healing is the most
common form of fracture healing and will be further illustrated in chapter 1.2.1.
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1.2.1 Different phases of the fracture healing process
Bone fracture healing can be divided into four consecutive, but overlapping steps: 1)
hematoma formation that is accompanied by an inflammation (divided into a pro- and an
anti-inflammatory phase), 2) soft callus formation, 3) hard callus formation and finally 4)
the remodeling phase (Fig. 1.2) [11]. A hematoma is formed in the injured area due to the
blood influx after vessel disruption. This early fracture hematoma is an indispensable step
for the whole healing cascade due to its highly angiogenetic and osteogenetic potential
[38, 39, 10, 40]. Immune cells, including neutrophils, granulocytes and macrophages, are one
of the first cells infiltrating the fracture area, already implicating their high impact for the
initiation and progression of the healing cascade. In the initial phase, they are responsible
for the clearance of the cell debris (macrophages) and for the recruitment of other cell types
necessary for the regenerative healing cascade. The early fracture hematoma is characterized
by hypoxia, an increase of lactate and the expression of the pro-inflammatory cytokines
interleukin (IL)-1, IL-6 and TNFα [40, 18]. A timely well defined revascularization of the
traumatized area is a prerequisite for a successful regenerated bone [41]. Low oxygen
leads to the expression of the hypoxia-inducible factors (HIF)1α which further triggers
the expression of pro-angiogenetic factors like vascular endothelial growth factor (VEGF)
and the glucose transporter Glut1. In 2014, Schmidt-Bleek et al. could show in a study
with a sheep osteotomy model that the two processes of inflammation and angiogenesis
are interdependent on each other and have to be temporally finely regulated to enable
regeneration [18]. After the occurrence of cells of the innate immunity, cells of the adaptive
immune system and MSCs infiltrate the traumatized area. Both invade the fracture gap
passively through the disrupted blood vessel but also by an active recruitment from the
cells already present in the fracture gap from the bone marrow and from the surrounding
tissue. After the initial inflammatory phase, granulation tissue refills the traumatized area
that is further replaced by fibro-cartilage tissue [22], serving as a template for the formation
of new bone. MSCs start to differentiate into cartilage producing chondrocytes that lead to
the formation of fibro-cartilage and thus to a stabilization of the fracture area visible as an
external soft callus. At the same time, intramembranous ossification happens periosteal at
the fracture ends to further stabilize the soft callus. The cartilage tissue matures, becomes
hypertrophic and starts to mineralize. Under the stimulation by e. g. TNFα, hypertrophic
chondrocytes undergo apoptosis and are replaced by newly formed woven bone [42]. This
step is the phase of hard callus formation. In the following remodeling phase, this woven
bone is reorganized to lamellar bone according to the mechanical constrains that closely
resembles the shape of the original bone. In humans, the remodeling phase can last up to
several years depending on the age and general condition of the patient.
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Figure 1.2: Schematic illustration of the different phases of the fracture healing process. The first
phase is the hematoma formation with an accompanied pro- and anti-inflammatory reaction; this
is followed by the soft callus formation, characterized by fibro-cartilage tissue in and around the
fracture area; the following is the ossification of the fibro-cartilage the hard callus phase; and finally
the remodeling phase; yellow = cortical bone, purple = bone marrow, red = blood vessels, green-blue
= cartilage, brown = newly formed bone. Picture from [11].
1.2.2 Problems in bone fracture healing and current therapeutic approaches
Bone repair is a well regulated process involving several cell and tissue types that have to
act together in consecutive but overlapping phases in order to enable the generation of a
fully regenerated bone. Especially in the aging population, disturbances in fracture healing
are a considerable problem for the patient itself but also for the socio-economic and health
system. The causes for delayed or non-unions are various: among others age, autoimmune
diseases (e. g. diabetes type 1), disturbed hormone homeostasis (estrogen decrease through
menopause) or lifestyle (smoking) [43, 44, 45]. Different approaches exist to help impaired
bone fracture healing. This includes the use of osteogenetic or osteoconductive materials,
biophysical enhancement, growth factors, cell therapy or immunomodulation [46, 5]. For
fractures of long bones with a critical size defect, the gold standard is still the transplantation
of autologous spongiosa (aspirated from the iliac crest of the patient). Even though this
is a successful treatment approach, a second surgery is necessary leading to further pain,
possible co-morbidities and healing time for the patient. In addition, autologous spongiosa
of a patient is not infinitely available. Another promising approach was the application
of growth factors like BMPs, particular BMP-2 and BMP-7. Although both BMPs were
approved by the U.S. Food and Drug Administration for e. g. clinical use of fresh open
tibial fractures, they are still under debate due to possible unwanted side effects [47].
Other growth factors are currently under investigation: fibroblast growth factor (FGF),
insulin-like growth factor (IGF), platelet-derived growth factor (PDGF) and transforming
growth factor (TGF)α [11]. Postmenopausal women have a higher risk for osteoporosis
due to a deficiency of estrogen that further leads to a disturbed mineral balance. Clinical
studies already illustrated a promising effect of the administration of parathyroid hormone
for this patient cohort [48]. MSCs are already well studied for their beneficial impact on
bone healing. MSCs possess pro-angiogenetic and pro-osteogenetic properties as well as
immunomodulatory functions [49]. First studies in humans already show the possible
positive potential of MSCs in bone repair [50, 51]. A wide range of further clinical trials was
initiated and partially already completed, however, the output is not published yet [52].
Modulation of the immune system is another approach that is more and more considered
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for bone repair [12]. A negative impact of terminally differentiated CD8+ T cells (TEMRA)
was shown to correlate with delayed fracture healing in patients with a closed tibia-head
fracture [4]. Therefore, a targeted immunotherapy could be a promising tool to treat patients
suffering from impaired bone regeneration. Although the mentioned findings implicate a
high impact of MSCs and immune cells in fracture healing, further knowledge and studies
about the exact mechanisms of the interactions and interdependencies of both in the field of
fracture healing are necessary. With this knowledge, new therapeutic treatment approaches
could be developed in order to improve the healing outcome and thereby the lifestyle of
patients with impaired bone repair.
1.3 Animal models for fracture repair
Patient material itself would reflect the best way the real healing situation in an injured
bone. The disadvantages of human biopsies are that they are a limited source of material
and that they just represent a snapshot in time (time point of surgery or harvest) of the
healing process. Thus, it is not possible to make a statement about the healing process
with its different phases. Furthermore, patient specific factors like age or diseases would
influence the validity of the material. Animal models are a useful tool in research in general,
but also for bone healing. In 2008, O’Loughlin published that rats are most often used
as a model system in fracture repair (38 %) [53]. But also other animals are utilized in
bone research: rabbit (19 %), mouse (15 %), sheep (11 %), dog (9 %), goat (4 %) and others
(4 %). In the context of bone biomechanics, mammals like goat and sheep would mimic
the human situation more effectively like rodents. However, these big animals have also
disadvantages like higher costs in comparison to rodent animal models (purchasing and
housing). Another important point for these animals is the fewer availability of research
analyzing tools like specific antibodies. Especially in the field of immunological research
questions, goats and sheep are less well explored due to their relative long breeding time,
the impossibility to produce inbred strains, their size and their handling. In immunology,
mouse is the best established animal model system. A high variety of different inbred strains
useful for different research questions are characterized and available. In addition, a variety
of knockout strains for components of the immune system are on the market. Furthermore,
a high diversity of specific antibodies for the analyses or in vivo intervention approaches
exists.
For the here presented study, the mouse strain C57BL/6N was used as a model system in
bone repair which was combined with an immunological research question. This inbred
strain was chosen because of its good fracture healing capacity and its strong immune
competence [54, 55]. Although the healing process in mice won’t completely reflect bone
repair in humans, it is a useful tool to better understand basic processes taking place in
the regenerating bone. Depending on the fracture type, a murine femur heals within 3–4
weeks after setting the fracture of a non-critical size defect. This allows the analysis of the
complexity of the different healing phases in a relative short time span. The here presented
study has next to its impact in the field of bone research also a high immunological aspect.
Although translational capacity of findings from mice studies into the human situation
is often under debate, we could already show that results from mice, especially from the
C57BL/6N strain, reflect very well the human patient situation [4].
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1.4 Osteoimmunology
The term osteoimmunology describes the interdisciplinary research field that combines the
molecular and cellular interaction as well as interconnectivity of two research areas: The
bone system and the immune system (Fig. 1.3, 1.4) [56]. The bone marrow is the place
where HSCs reside. HSCs are the precursors for e. g. T and B lymphocytes. Already in
1994, Taichman et al. proposed a regulation of the HSC niche by cells of the bone system
based on in vitro analyses with primary human osteoblasts [57]. A more up to date view of
the HSC niche is given by Morrison and Scadden. They propose a so far not explainable
important impact of the endosteal bone surface as well as close proximity to sinusoid blood
vessels within the bone marrow on the localization and function of HSCs [58]. Next to
harboring the precursor of T and B lymphocytes, the bone marrow is furthermore the place
where B cells develop and memory T and B cell are stored [59, 60, 61]. This close spatial
proximity of cells of the bone and of the immune system already strongly suggests that there
has to be an active interaction between both systems. A regulation of cells of the skeletal
system by cells of the immune system was for the first time described in the 1970s by the
discovery that T cells, as component of the adaptive immunity, stimulate osteoclastogenesis
by secreting osteoclast activating factors and thereby promote bone resorption [62, 63]. Arron
and Choi introduced the term "osteoimmunology" to combine the interactions between
the bone and the immune systems in 2000 after the detection that activated T cells express
RANKL which binds to RANK on osteoclast precursors. This leads to the activation of the
intrinsic signaling cascade and finally to osteoclastogenic differentiation [3]. Around the
same time, a regulatory mechanism to avoid an uncontrolled bone resorption by activated T
cells was shown by Takayanagi et al. [64]. Next to RANKL, activated T cells also secrete
interferon (IFN)-γ which inhibits osteoclastic differentiation of osteoclast precursor cells
after RANKL–RANK interaction.
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Figure 1.3: Illustration of the concept of bone destruction in the context of rheumatoid arthritis (RA).
In short, in RA, in the synovium existing Th17 cells are responsible for an enhanced osteoclastogenesis
and therefore for bone destruction under inflammatory conditions. They either produce RANKL
by themselves, or induce the production of RANKL by synovial fibroblasts via IL-17. IL-17
further induces the production of pro-inflammatory cytokines like TNFa which further support
osteoclastogenesis. Adapted from [56].
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Figure 1.4: Schematic depiction of the complex and highly interwoven and connected interplay
between the bone and the immune system on the cellular and molecular level. Upper picture:
Osteoclasts and osteoblasts have to communicate in order to maintain the bony structure during
normal bone homeostasis. This is realized e. g. via IGF-1 and TGF-β. Left lower picture: Besides
CXCL12-abundant reticular (CAR) and Leptin receptor positive perivascular cells, osteoblasts and
osteoclasts seem to interact in the maintenance of the HSC niche. Lower right picture: During
osteoclastogenic differentiation, bone and immune cells share molecules, e. g. the RANK/RANKL
axis. Adapted from [56].
Another important aspect underlying the strong interconnectivity between both systems is
the changing bone phenotype in the context of (auto)-immune diseases or of mice deficient
in distinct osteoimmunoregulatory molecules [65]. The strong and diverse interdependency
between the bone and the immune system on the tissue, cellular and molecular level is further
depicted in figure 1.3 and figure 1.4. In figure 1.3, the principle of the pathological mechanism
leading to rheumatoid arthritis (RA) is illustrated. Evaluation of the pathological mechanism
in RA was the beginning recognizing the interdependency between the immune and skeletal
systems. In RA, Th17 cells are responsible for the characteristic bone destruction under
inflammatory conditions [66]. In figure 1.4 illustrates the complex and highly interwoven
and connected interplay between the bone and the immune system on the cellular and
molecular level, including normal bone homeostasis (upper picture), the HSC niche (lower
left picture) and shared molecules between the bone and the immune system exemplarily
shown in the process of osteoclastogenesis (lower right picture). Both schemes clearly
illustrate the complexity of the research field of osteoimmunology.
CHAPTER 1. INTRODUCTION 10
1.5 The immune system: Innate and adaptive immunity
Organisms are permanently exposed to pathogens. The immune system of an organism
serves as a protection against theses potential disease agents.
In vertebrates, the immune system consists of two parts: the innate and the adaptive
immunity which are highly interdependent on each other. For an effective functioning of the
immune system, it has to be able to discriminate between self- and non-self-peptides. Both,
the innate and the adaptive immunity are participating in this well-defined discrimination
process. The discrimination between self- and non-self-peptides is a prerequisite for an
effective fight against potential disease agents without fighting against self-peptides and
thereby against the own body. The attack of body’s own structures and thus an incorrect
functional immunity is the cause for a variety of autoimmune diseases.
The innate immune system comprises the first line of defense via the pattern recognition
receptors (PRRs), which include Toll-like or NOD-like receptors that recognize conserved
molecular structures (like pathogen-associated molecular patterns (PAMPs)) on the surface
of invading pathogens. It presents an evolutionarily ancient part of the immune system of
vertebrates [67]. The following cell types belong to the innate immunity: mast cells, natural
killer cells, monocytes, macrophages, dendritic cells (DCs) and granulocytes.
The adaptive (acquired) immunity is characterized by highly antigen-specific immune
responses and the development of an immunological memory. The antigen-specificity is
mediated by a huge variability of specific receptors expressed on the surface of lymphocytes:
the T cell receptor (TCR) and the B cell receptor (BCR). T and B lymphocytes develop out
of in the bone marrow lying HSCs, either in the thymus (T cells) or bone marrow (B cells).
For both cell types, the specific antigen receptor consists of different gene segments (V, D
and J) that have to be rearranged during development [68]. This process is called somatic
recombination and enables the formation of the high variability of different T and B cell
receptors. The recognition of the receptor specific antigen is mediated by the presentation of
the antigen via specialized protein complexes on antigen presenting cells (APCs): the major
histocompatibility complex (MHC).
The huge receptor diversity is a prerequisite for the great potential of the human body to
recognize and react against a wide spectrum of different pathologic structures and peptides.
B cells mediate the humoral (antibody mediated) immunity and T lymphocytes the cellular
immunity.
1.5.1 T cells as part of the adaptive immunity
T cells are characterized by the expression of their antigen specific TCR that consists of
two chains: α/β or γ/δ. The α/β T cells also express one of the co-receptors CD4 or CD8.
Most of the T cells possess an α/β TCR and therefore the γ/δ T cells only present a minor
proportion of the human T cell pool [69]. Naïve CD4+ and CD8+ T cells mature in the
thymus. Functional single positive naïve T cells are released into the periphery after passing
two consecutive processes within the thymus: 1) positive selection, T cells have to be able
to recognize self-MHC molecules in a certain strength, and 2) negative selection, T cells
are eliminated that recognize self-peptides (autoreactive T cells) [70]. After encountering
their specific antigen due to an infection or immunization, naïve T cells get activated and
start to differentiate and to clonally expand [71, 72]. CD4+ T cells can differentiate into the
following effector subtypes, dependent on the type of pathogen and the time of antigen
presence: Th1, Th2, Th17, induced TReg (Chap. 1.5.2) as well as follicular T cells and Th9
cells, each with a characteristic cytokine profile and specific effector function [73]. Besides
CHAPTER 1. INTRODUCTION 11
naïve CD4+ T cells, also so called natural TReg (nTReg) were released into the periphery from
the thymus. These cells are characterized by the co-expression of CD25 (CD25++) and the
transcription factor forkhead box (FOX) P3. After antigen clearance, most of the effector cells
die but a small proportion resides as memory CD4+ or CD8+ T cells within the body. There
exist different types of memory T cells: fast reacting effector memory T cells (TEFM) and
slower reacting central memory T cells (TCM). The discrimination between TEFM and TCM
was first done based on their functionality and on the expression of the homing receptor
CC chemokine receptor (CCR) 7 [74]. CCR7- TEFM display immediate effector function
and migrate to inflamed tissue. In contrast, CCR7+ TCM are able to home and enter into
secondary lymphoid organs and display if any effector function. The existence of memory
T cells enables the body to react faster to a certain antigen in case of a second challenge
and provides long-term immunity against this pathogen. Naïve and memory T cells can be
distinguished based on the expression of certain surface molecules. In humans, it is done on
the basis of different isoforms of CD45, whereas naïve T cells express CD45RA and memory
cells CD45RO. In mice, this is done be the expression of the memory marker CD44: naïve T
cells are CD44- and memory T cells CD44+. The discrimination between TCM and TEFM is
further realized as already mentioned by the expression of CCR7 or/and the cell adhesion
molecule L-selectin (CD62L) for both, human and mouse (TCM: CD62L+; TEFM: CD62L-)
[74, 75].
1.5.2 Regulatory T cells
TReg are a subpopulation of CD4+ T cells. They are highly specialized cells due to their
immunosuppressive function and their importance in maintaining the immunological
self-tolerance of an organism. TReg represent 5–10 % of the peripheral CD4+ T cells in human
and in mice. They are characterized by the expression of the surface antigens CD4, CD25
(more precisely CD25high) and of the transcription factor FOX P3. FOX P3 is a member of
the forkhead/winged-helix family of transcription factors and is the master transcription
factor for the maintenance and function of TReg [76, 77]. These CD4+CD25highFOXP3+ TReg
either develop directly in the thymus (indicated as natural TReg, nTReg) or can be induced in
the periphery from naïve CD4+ T cells under different non-inflammatory and inflammatory
conditions (indicated as induced TReg, iTReg) [78]. Both TReg subtypes are distinguishable by
the methylation status of CpG islands in the promoter region within the foxp3 locus, the
TReg-specific demethylated region, TSDR. In nTReg, this locus is demethylated and in iTReg,
it is methylated. The demethylation correlates with a stable FOX P3 expression in these
cells and thus with the suppressive capacity of these cells [79]. The existence of a thymic
derived suppressive T cell population was first described by Sakaguchi et al. in 1982 [80]. In
this in vivo study in mice, the development of an autoimmune disease after thymectomy
of neonatal mice has been rescued by adoptive transfer of splenocytes or thymocytes from
healthy syngeneic adult mice. They had been further characterized for the expression of
the IL-2 receptor α chain (CD25) [81]. The knowledge that FOXP3 is indispensable for
the maintenance and function of developed TReg was gained at the beginning of the 21th
century by several studies [76, 77]. One of the studies was related to the human disease
immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrom, which
is a rare lethal disorder of male humans with a dysregulated adaptive immunity. The
mutant mouse model scurfy shares a wide range of phenotypical similarities with the human
IPEX syndrome [82]. For both, human and mice, FOXP3 (and its protein scurfin) was
identified as a new member of the forkhead/winged-helix family of transcription factors that
is responsible for the development of the disorder by a dysregulated activity of activated
CHAPTER 1. INTRODUCTION 12
T cells due to the absence of FOXP3 [83, 84]. A wide range of analyses followed in order
to elucidate the development and to understand the mode of action of TReg to suppress
excess immune responses to self- and non-self-antigens by other immune cells (Chap.
1.5.3). nTReg develop directly in the thymus due to an intermediate interaction between
the T cell receptor of single positive CD4+ T cells and self-peptides presented by MHC
II molecules on thymic APCs in special niches in the thymic medulla. This intermediate
recognition of self-antigens leads to an upregulation of CD25 and further to the expression
of FOXP3 and other TReg -related surface molecules (like cytotoxic T lymphocyte-associated
antigen (CTLA)-4 and the glucocorticoid-induced TNFR-related protein (GITR)) [85].
Besides the CD4+CD25highFOXP3+ TReg, there exist several other immunosuppressive,
partially TReg -like cell types in the body: CD4+ Tr1 and Th3 cells, as well as CD8+ and
CD8-CD4- suppressive T cells [86].
1.5.3 Mode of action of the suppressive capacity of regulatory T cells
TReg possess the capacity to suppress the proliferation and differentiation of CD4+ and
CD8+ effector T cells in vitro and in vivo. Several mechanisms of TReg suppression are
proposed so far: cell-cell contact dependent suppression, secretion of suppressive cytokines
and modification of the function/killing of APCs. Bopp et al. showed that TReg can directly
interact with activated T cells via gap junctions and can suppress their activity by the
transfer of cyclic adenosine monophosphate (cAMP) via these gap junctions [87]. As a
cell-cell contact independent pathway, TReg are able to produce adenosine via their surface
molecules CD39 and CD73 (ectonucleotidases) from present extracellular nucleotides [88].
Adenosine was already shown to lead to lymphocyte depletion and immune deficiency
by a T cell receptor triggered inhibition of T cell proliferation and upregulation of CD25.
Furthermore, extracellular adenosine leads to an intracellular accumulation of cAMP in T
cells [89]. Several in vitro studies carried out with human and murine TReg further implicated
a cell-cell contact dependent suppressive mechanism via the perforin/granzyme pathway.
In contrast, in vivo imaging studies rather revealed an indirect suppressive activity of TReg
against several cell types (among others: CD4+ and CD8+ T cells, B cells, monocytes,
DCs) via a direct interaction with APCs which further influence the activity of effector cells
[90, 91, 92, 93, 94]. TReg can interact with DCs via the CTLA-4-–B7 axis and can thereby
induce the expression of indoleamine 2,3-dioxygenase (IDO) of DCs which leads to an amino
acid starvation for effector T cells [95, 96]. Besides the effect of TReg on cells of the immune
system, they can further directly affect the function of non-immune tissue cells like visceral
adipocytes and skeletal muscle cells [97, 98]. In the context of bone regeneration, Lei and
colleagues proposed a model where TReg might promote tissue repair by a direct cell-cell
contact with tissue resident osteoblasts or/and their precursors (MSCs) via the CD39-CD73
axis and thereby creating a pro-regenerative microenvironment [99].
Taken together, the above illustrated studies and findings illustrate just in part the wide
spectrum of mechanisms applied by TReg in order to sustain the immunological balance in
an organism and their differences in in vitro and in vivo settings. Additional investigations
especially in in vivo conditions are needed to further enlighten the mode of action of
TReg suppression. However, it does not seem to exist this one mechanism how TReg
suppress the action of other (immune) cells. It is more likely to depend on the situation and
circumstances which pathway TReg are using in order to inhibit or counter act unwanted
immune reactions. This also enables their high flexibility to react to a variety of inflammatory
and disease conditions within the body.
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1.5.4 Impact of immune cells/ regulatory T cells in bone fracture healing
Several studies have already shown that immune cells play an essential role in tissue
regeneration and especially in the process of bone fracture healing. In fracture repair,
they are not only important in the early inflammatory but also in the later phases of the
regeneration process [8, 5]. We could already show in a mouse osteotomy model that the lack
of macrophages, a cell subpopulation of the innate immunity, disturbs bone fracture healing
due to a delayed resorption of hypertrophic cartilage [5]. Macrophages are a heterogeneous
cell population dependent on the microenvironment around them. Based on the Th1/Th2
nomenclature of T cells, they are also named M1 and M2 macrophages. M1 macrophages are
the "classically activated" pro-inflammatory ones. In contrast, M2 are named "alternatively
activated" macrophages. Based on their receptor and cytokine expression profile, they
can exhibit different functions: anti-inflammatory (M2a), immune-regulatory (M2b) and
pro-remodeling (M2c) [100]. Toben et al. showed in 2011 that in the absence of the adaptive
immune system, bone formation is accelerated but also altered in a murine femur fracture
model [101]. This finding indicates that the adaptive immune system could have at least in
partial a negative impact on the regeneration process after bone injury. Indeed, a negative
impact of CD8+ cytotoxic T cells was already shown by us in humans as well as in a murine
osteotomy model [4]. TReg are one potential counterpart of negative acting cells in fracture
repair and thereby represent a positively modulating cell population in bone healing. That
T cells play a key role in tissue regeneration was already shown [6, 13]. Further studies
implicate a positive effect of TReg on bone formation and regeneration. In an in vitro analysis,
Zaiss et al. demonstrated a TReg mediated inhibition of osteoclastogenesis [14]. In in vivo
follow up studies, a higher amount of TReg improved clinical signs of rheumatoid arthritis, led
to more bone formation as well as inhibited bone loss under physiological and pathological
conditions [15, 16]. Furthermore, TReg also led to advance bone healing in a murine calvarial
defect model where they were applied in combination with autologous bone marrow MSCs
[17]. A study realized in a sheep osteotomy model in which the early healing phase of a
scar forming soft tissue hematoma was compared to a regenerating bone hematoma clearly
demonstrated a higher amount of TReg in the bone hematoma in comparison to the soft
tissue hematoma [18]. So far, the exact mechanism of TReg action on bone and other cells in
fracture healing is not discovered (the question is: Is there just one mechanism?). However,
the aforementioned results highlight the importance and the postulated positive impact of
TReg in bone regeneration and bone disease related circumstances.
In the last few years, the pro-inflammatory Th17 cells, another subset of CD4+ T cells, was
defined as one counterpart of TReg in immune homeostasis in general, but also in the context
of bone related diseases. Th17 cells induce osteoclastogenesis either indirectly by inducing
the expression of the pro-osteogenetic factor RANKL in MSCs or synovial fibroblasts or
directly by producing high levels of the RANKL by themselves [102, 66]. Furthermore, Th17
cells are also promoting osteoblast differentiation, as shown in in vitro studies with human
MSCs [103]. It is postulated that an imbalance of the ratio of Th17 and TReg cells is the cause
for several bone disorders like RA, osteoporosis and periodontitis [104, 105].
CHAPTER 1. INTRODUCTION 14
1.6 Hypotheses and objectives of the project
Bone is the tissue where immune cells are formed, already implicating its impact on the
immune system. But, how does the immune system affect or even control the bone system?
Bone is a remarkable tissue due to its ability to fully self-repair after injury. Bone fracture
healing is a very complex mechanism involving different cell types and the bone matrix. In
the context of bone regeneration, so far, no study focused on a broader view on the tissue
and cellular level, including a variety of cell types of the immune and bone system in order
to better understand the underlying mechanism of the healing process.
Immunotherapy is a promising tool in order to improve the patient situation suffering from
pathological diseases. CD4+CD25++FOXP3+ TReg, a subset of CD4+ T cells, are of special
interest for immunotherapy due to their immunosuppressive function. They are furthermore
characterized by their importance in maintaining the immunological self-tolerance of an
organism. Their positive modulating effect in bone related diseases as well as in applications
together with bone marrow MSCs was already shown.
Hypothesis 1: Immune and bone cells interact during the specific bone healing phases. Specific
healing phases show distinct distribution patterns of immune and bone cells.
Hypothesis 2: CD4+CD25++FOXP3+ TReg have a positive modulating effect in bone repair and
improve the healing outcome after injury.
Hypothesis 3: The healing outcome after adoptive TReg transfer is dependent on the status of
the adaptive immune system prior to osteotomy (SPF vs. semi-sterile (non-SPF)
housing).
In order to proof the hypotheses, the following objectives had to be addressed during my
PhD thesis:
Objective 1: Analysis of the spatial and temporal distribution of distinct immune cell
subsets in correlation towards tissue types over the healing process in a
well-established mouse osteotomy model of a non-critical size defect.
Using a murine osteotomy model with a non-critical size defect of the left femur, the
distribution of certain tissues within the fractured bone was analyzed via histology and
micro-computed tomography (µCT). Furthermore, from the same animals, the local and
temporal distribution of selected cellular components of the immune and bone system were
investigated on consecutive bone sections via fluorescence-based immunohistochemistry. In
addition, systemic changes of the immune cell composition during the healing process were
investigated by flow cytometry.
Objective 2: Analysis of the ratios of selected cellular subsets of the adaptive immunity
in mice without osteotomy housed under SPF and semi-sterile (non-SPF)
conditions, respectively.
Objective 3: Analysis of the healing outcome of mice after adoptive transfer of TReg prior
to osteotomy.
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An immunomodulatory approach of adoptive transfer of murine TReg prior to osteotomy
was chosen in order to analyze their impact in bone repair. This approach also included
the status of the adaptive immune system of the osteotomized mice prior to surgery. In the
here presented study, the healing outcome of the treated mice (adoptive transfer of TReg)
was investigated via µCT and histology. An analysis of systemic changes was included and
selected immune cell subsets were systemically analyzed via flow cytometry.

2 Materials
2.1 Chemicals
Chemical Company
0.9 % Sodium Chloride Fresenius Kabi Germany GmbH, Bad Homburg, Ger-
many
Aceton Sigma-Aldrich Chemie GmbH, München, Germany
ACK Lysing Buffer Gibco-Life Technologies GmbH, Darmstadt, Germany
Alcian blue Chroma GmbH & Co. KG, Münster, Germany
β-Mercaptoethanol Sigma-Aldrich Chemie GmbH, München, Germany
Brilliant crocein acid fuchsin Chroma GmbH & Co. KG, Münster, Germany
BSA, protease free Sigma-Aldrich Chemie GmbH, München, Germany
Cell Proliferation Dye eF450 eBioscience, San Diego, CA, USA
EDTA Carl Roth GmbH & Co. KG, Karlsruhe, Germany
FBS Superior Biochrom AG, Berlin, Germany
Iron hematoxylin (after
Weigert)
Chroma GmbH & Co. KG, Münster, Germany
n-hexane Carl Roth GmbH & Co. KG, Karlsruhe, Germany
PBS (1x) Gibco-Life Technologies GmbH, Darmstadt, Germany
PBS 10x, pH 7.2 Waldeck GmbH & Co. KG, Münster, Germany
Penicillin/Streptomycin
(10.000 U Penicllin/ml,
10 mg Streptomycin/ml)
Sigma-Aldrich Chemie GmbH, München, Germany
Phosphotungstic acid Chroma GmbH & Co. KG, Münster, Germany
RPMI 1640 with 2.0 g/l
NaHCO3, with stable Glu-
tamine
Biochrom AG, Berlin, Germany
Saffron du Gâtinais Chroma GmbH & Co. KG, Münster, Germany
Sodium Azide, extra pure Merck KGaA, Darmstadt, Germany
Sodium Chloride Merck KGaA, Darmstadt, Germany
Trizma Base Sigma-Aldrich Chemie GmbH, München, Germany
Trizma Hydrochloride Sigma-Aldrich Chemie GmbH, München, Germany
Tween-20 Merck KGaA, Darmstadt, Germany
2.2 General equipment
Product Company
BD Vacutainer blood collec-
tion tube, EDTA coated
Becton Dickinson Bioscience, Heidelberg, Germany
cell strainer Corning, Sigma-Aldrich, München, Germany
CellTrics filter, 30µm Sysmex Partec GmbH, Görlitz, Germany
culture dish (60 mm ) Corning, Sigma-Aldrich, München, Germany
15 ml Polypropolyne Conical
Tube
Becton Dickinson Bioscience, Heidelberg, Germany
50 ml Polypropolyne Conical
Tube
Becton Dickinson Bioscience, Heidelberg, Germany
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Product Company
5 ml Polystyrene Round-
Bottom Tube
Becton Dickinson Bioscience, Heidelberg, Germany
Syringe Discardit II 2 ml Becton Dickinson Bioscience, Heidelberg, Germany
Tissue Culture Plate, 96 Well,
Flat Bottom
Becton Dickinson Bioscience, Heidelberg, Germany
2.3 Equipment for the isolation of regulatory T cells
Product Company
CD4+CD25+ Regulatory T
Cell Isolation Kit, mouse
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
LD Columns Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
MidiMACS Seperator Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
MiniMACS Seperator Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
MS Columns Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
2.4 Equipment for histology
Product Company
Cryofilm 2C (10) Section-Lab Co. Ltd., Hiroshima, Japan
Cryofilm 2C (9) Section-Lab Co. Ltd., Hiroshima, Japan
Embedding Medium SCEM Section-Lab Co. Ltd., Hiroshima, Japan
Microtome Blades SEC 35 Fisher Scientific, Schwerte, Germany
Object slide superfrost Thermo Scientific Fisher, Waltham, MA, USA
Paraformaldehyde Solution
20 %, EM grade
Electron Microspcopy Sciences, Hatfield, PA, USA
Tissue Tek, OCT compound Sakura Finetek Germany GmbH, Staufen, Germany
2.5 Media and buffer
Media/Buffer Company
Cell culture medium complete (500 ml)
RPMI 1640 450 ml
FBS 50 ml
Penicillin/Streptomycin 100 U/ ml each
β-Mercaptoethanol 50 µM
Flow cytometry buffer PBS/BSA (500 ml)
PBS (1x) 500 ml
BSA 5.0 g
Sodium Azide 0.5 g
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Media/Buffer Company
MACS buffer (500 ml)
PBS (1x) 500 ml
BSA 2.5 g
EDTA 2 mM
Tris buffer (1 l)
Trizma Hydrochloride 6.60 g
Trizma Base 0.90 g
Sodium Chloride 8.78 g
2.6 Medication and materials for the mouse osteotomy model
Product Company
Bepanthen (+5 % Dexpan-
thenol)
Bayer Vital GmbH, Leverkusen, Germany
Buprenorphin RB Pharmaceuticals Ltd, Berkshire, UK
Clindamycin ratiopharm GmbH, Ulm, Germany
Fixator MouseExFix RISystem AG, Davos, Switzerland
Gigli saw wire (0.66 mm) RISystem AG, Davos, Switzerland
Inject® -F Tuberkulin-Spritze,
1 ml
B. Braun Melsungen AG, Melsungen, Germany
Isoflurane FORENE, Abott GmbH & Co. KG, Wiesbaden, Ger-
many
Ketamin Actavis Switzerland AG, Regensdorf-Zürich, Switzer-
land
Medetomidine Janssen-Cilag GmbH, Neuss, Germany
Sterican® Kanüle (size 18; 0.45
x 25 mm)
B. Braun Melsungen AG, Melsungen, Germany
Suture material Prolene 5.0 Ethicon, Norderstedt, Germany
Tramadol (100 mg/ml) Gruenenthal, Brunn am Gebirge, Austria
2.7 Antibodies
2.7.1 Flow cytometry
Specificity/Antigen/Labeling Company Clone
α-mouse CCR7 Biotin BioLegend, San Diego, CA, USA 4B12
α-mouse CD3 PerCP BioLegend, San Diego, CA, USA 145-2C11
α-mouse CD4 AF700 eBioscience, San Diego, CA, USA RM4-5
α-mouse CD8a eF450 eBioscience, San Diego, CA, USA 53-6.7
α-mouse CD16/ CD32 Purified eBioscience, San Diego, CA, USA 93
α-mouse CD25 APC BioLegend, San Diego, CA, USA PC61
α-mouse CD25 APC-Cy7 BioLegend, San Diego, CA, USA PC61
α-mouse CD44 APC-Cy7 Becton Dickinson Bioscience, Heidelberg,
Germany
IM7
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Specificity/Antigen/Labeling Company Clone
α-mouse CD44 PE-Cy7 Becton Dickinson Bioscience, Heidelberg,
Germany
IM7
α-mouse CD62L APC BioLegend, San Diego, CA, USA MEL-14
α-mouse CD127 PE-Cy7 BioLegend, San Diego, CA, USA A7R34
α-mouse/ rat FOXP3 FITC eBioscience, San Diego, CA, USA FJK-16s
α-mouse/ human Helios PE BioLegend, San Diego, CA, USA 22F6
α-mouse NK-1.1 FITC BioLegend, San Diego, CA, USA PK136
α-mouse TCRβ chain PE BioLegend, San Diego, CA, USA H57-597
LIVE/DEAD Fixable Aqua
Dead Cell Stain Kit (excitation:
405 nm)
Thermo Fisher Scientific, Waltham, MA,
USA
-
Streptavidin PE-Texas Red Becton Dickinson Bioscience, Heidelberg,
Germany
-
2.7.2 Immunofluorescence histology
Specificity/Antigen/Labeling Company Clone
α-mouse B220 PE Deutsches Rheumaforschungzentrum,
Berlin, Germany
RA3.6B2
α-mouse CD4 AF594 Deutsches Rheumaforschungzentrum,
Berlin, Germany
GK1.5
α-mouse CD8 PE Abcam, Cambridge, United Kingdom 53-6.7
α-mouse CD68 FITC AbD Serotec, Kidlington, United Kingdom FA-11
α-mouse CD80 AF647 BioLegend, San Diego, CA, USA 16-10A1
α-mouse CD105 eBioscience, San Diego, CA, USA MJ7/18
α-mouse CD206 PE BioLegend, San Diego, CA, USA C068C2
α-mouse Osteocalcin Enzo Life Sciences, Lörrach, Germany
α-rabbit AF647 Invitrogen, Karlsruhe, Germany
α-rat AF954 Invitrogen, Karlsruhe, Germany
α-CathepsinK Abcam, Cambridge, United Kingdom
α-Hif1α Novus Biologicals LLC, Littleton, CO,
USA
2.7.3 Treg suppression assay — T cell receptor stimulating antibodies
Specificity/Antigen/Labeling Company Clone
α-mouse CD28 purified
0.5 mg/ml
eBioscience, San Diego, CA, USA 37.51
α-mouse CD3e purified
0.5 mg/ml
eBioscience, San Diego, CA, USA 145-2C11
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2.7.4 CD25+ T cell depletion
Specificity/Antigen/Labeling Company Clone
α-mouse CD25, in vivo mab Bio X Cell, Lebanon, NH, USA PC-61.5.3
2.8 Recombinant protein
Product Company
Recombinant Mouse IL-2, CF R&D Systems, Minneapolis, MN, USA
2.9 Technical devices
Technical device Company
Computed tomography scan-
ner µCT Viva 40
SCANCO Medical AG, Brüttisellen, Switzerland
Confocal laser scanning micro-
scope LSM 710
Carl Zeiss, Jena, Germany
Cryotome Leica Biosystems, Nussloch, Germany
Flow cytometer LSR II Becton Dickinson Bioscience, Heidelberg, Germany
Light microscope Carl Zeiss, Jena, Germany
2.10 Software and analyzing programs
Software Function Company
Axiovision Imaging and processing (Movat Pen-
tachrome)
Carl Zeiss, Jena, Germany
FACS DIVA
6.1.3
Measurement software for flow cytometry Becton Dickinson Bioscience,
Heidelberg, Germany
FlowJo 9.6.4 Evaluation of flow cytometry data Tree Star, Ashland, OR, USA
ImageJ
1.45s
Processing of images/histomorphometry Open Source
MicroCT
evaluation
program
6.5-3
µCT evaluation SCANCO Medical AG, Brüt-
tisellen, Switzerland
PRISM 5.0 Graphics and statistics GraphPad, La Jolla, CA, USA
SPSS 22 Statistics IBM Deutschland GmbH,
Ehningen, Germany
Zen 2011 Processing of images (IHC) Carl Zeiss, Jena, Germany

3 Methods
3.1 Animal model
3.1.1 Mouse strain
For the in vivo analyses in this study, the mouse strain C57BL/6N (Charles River Laboratories,
Wilmington, MA, United States of America) was used. C57BL/6N mice were selected based
on their good fracture healing capacity and their strong immune competence [55, 54]. All
experiments were done with female mice. Earlier studies already revealed differences in the
healing capacity between male and female animals [106, 107]. In addition, in future studies,
the question of the influence of the hormone status might become an important question. All
animal experiments were carried out with ethical permission according to the policies and
principles established by the Animal Welfare Act, the National Institutes of Health Guide for
Care and Use of Laboratory Animals, and the National Animal Welfare Guidelines and were
approved by the local legal representative animal rights protection authorities (Landesamt
für Gesundheit und Soziales Berlin: G0008/12; T0119/14; T0249/11).
3.1.2 Mouse housing
Mice were housed in small groups in the Charité animal facility (Forschungseinrichtung für
experimentelle Medizin) on the Campus Virchow-Klinikum. They were kept under SPF or
semi-sterile (area in the animal facility without an additional barrier and without filtered air
supply for the mice cages) housing conditions, respectively. The temperature was controlled
(20± 2 ◦C), a 12 h light/dark circle was present and food and water were available ad libitum.
For the in vivo analyses, mice of an age of 12 weeks were used. The peak bone mass and the
material properties are almost achieved and reached at this age [108]. For mice kept under
SPF conditions, they were imported into our animal facility at least 1 week before usage in
order to allow the animals to acclimatize. Mice that were housed in the semi-sterile part
of the animal facility were imported at least 4 weeks before the experiment started. The
housing in the semi-sterile environment as well as the import of 4 weeks prior to use were
chosen to allow a moderate activation of the adaptive immune system of the animals.
3.1.3 Surgery: Setting of an osteotomy
In order to analyze the fracture healing process in our animal model, mice were narcotised
by the inhalation of the anaesthetic Isoflurane. Before starting the surgery, mice already
received an intraperitoneal injection of the analgesic Buprenorphin (Temgesic) (0.03 mg/kg)
and of the antibiotic Clindamycin (45 mg/kg). In addition, mice got an eye ointment for the
duration of the surgery (Bepanthene). Before opening the skin by a lateral longitudinal cut
(along an imaginary line from the knee to the hip), the operation area of the left femur was
shaved and disinfected. After the skin was opened (Fig. 3.1 A), the femur was exposed
by a blunt preparation of the surrounding muscles Musculus vastus lateralis and Musculus
biceps femoris without creating an additional muscle injury and without injuring the Nervicus
ischiadicus (peripheral nerve of the lower limbs) (Fig. 3.1 B). Before setting an osteotomy in
the middle of the left femur, the external fixator was mounted on the lateral side of the bone
for stabilization after surgery. Therefore, the first of the four pins was installed near the
knee, already with the bar of the external fixator attached to the pin, so that the bar of the
external fixator was in parallel to the bone (Fig. 3.1 C, D). The second pin was installed near
the hip and pin 3 and 4 were placed in between pin 1 and 2 (Fig. 3.1 E). Subsequently, the
osteotomy gap was created with a Gigli wire saw (size: 0.66 mm) between the two middle
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Figure 3.1: Illustration of the steps of the surgery in our mouse osteotomy model. Skin opening (A);
Exposure of the left femur (B); Drilling the hole for the first pin (C); Insertion of the first pin (D);
External fixator already fixed with four pins (E); Positioning of the Gigli wire saw (F); Osteotomy gap
between the two middle pins (G); Sutured skin after osteotomy (H)
pins, resulting in a gap size of 0.7 mm (Fig. 3.1 F, G). Afterwards, the wound was sutured (Fig.
3.1 H), followed by the application of spray dressing. After surgery, mice were brought back
into a cage and closely observed until they were fully mobile again. Tramadol hydrochloride
was added to the drinking water (25 mg/l) as postoperative analgesia for 3 days post-surgery.
3.1.4 Euthanasia of mice
To euthanize the mice, a mixture of the muscle relaxant Ketamine (60 mg/kg) and the sedative
Medetomidine (0.3 mg/kg) was intraperitoneally injected in order to induce deep narcosis.
After confirming that the mice showed no reflex anymore (pedal withdrawal reflex), a
cervical dislocation was done in order to ensure the death of the animal. For samples
collected for flow cytometry, histology and µCT (Chap. 3.2.1), full blood was taken out of
the heart prior to the cervical dislocation.
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3.1.5 Experimental design
Table 3.1: Experimental design of the mice used, organized by the treatment, including the number
of used animals, analyzed time points and the usage of the fractured bones
Group Time points Mice Fractured femur Fractured femur
for histology for µCT
WT
1 d n= 6 yes no
2 d n= 6 yes no
3 d n= 6 yes no
7 d n= 6 yes no
14 d n= 6 yes no
21 d n= 6 yes yes
SPF TReg + 21 d n= 6 no yes
semi-sterile TReg + 21 d n= 8 yes yes
CD25- 21 d n= 6 yes yes
POC TReg + 21 d n= 7 no yes
3.2 Sample collection
3.2.1 Sample collection for flow cytometry, histology and µCT
Mice were euthanized by an intraperitoneal injection of a mixture of Ketamine and Medeto-
midine (Chap. 3.1.4). As soon as the mice showed no reflex anymore (pedal with-
drawal reflex of the hind paw), blood was drawn directly out of the heart and kept in an
ethylenediaminetetraacetic acid (EDTA) coated blood collection tube. Afterwards, a cervical
dislocation of the mice was performed to ensure the death of the animal. The skin of the
abdomen was opened by a longitudinal cut with a scalpel and the spleen was taken out.
Around three quarters of the spleen were immediately put into a falcon tube filled with
phosphate buffered saline (PBS) and placed on ice (flow cytometry). The fourth quarter
was put into a falcon filled with a freshly prepared solution of 4 % paraformaldehyde (PFA)
(histology) (also placed on ice). Subsequently, the fractured left femur still stabilized by the
external fixator was taken out of the mouse, the most part of the surrounding muscles was
carefully removed and the bone was put into the falcon filled with 4 % PFA. The complete
contralateral leg and both humeri were taken for bone marrow analysis by flow cytometry
(in PBS placed on ice).
3.2.2 Sample collection for the isolation of regulatory T cells
Regulatory T cells were isolated out of the spleen and the following lymph nodes from
C57BL/6N mice: inguinal nodes, axillary nodes, brachial nodes and mesenteric nodes. After
confirming that the narcotised mouse did not show any reflex anymore (pedal withdrawal
reflex), a cervical dislocation was performed to ensure the death of the animal. The skin was
removed to enable access to the underlying lymph nodes. Inguinal, axillary and brachial
lymph nodes were carefully detached from the mice with the help of fine forceps and put into
a falcon tube filled with PBS (placed on ice). Afterwards, the abdominal muscles including
the peritoneum were opened and the spleen was taken out and put in PBS. Finally, the
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mesenteric lymph nodes were removed from the mouse and put into the same falcon with
the other lymph nodes.
3.3 Flow cytometry
The flow cytometry method allows the measurement of the biological properties (e. g. size,
granulation, expression of surface and intracellular markers) of a single cell in suspension.
The basic principle is the highly specific antigen-antibody interaction that is visualized by
fluorescence labeled antibodies. The measurement of the biological properties is realized via
a packed laser beam. Every single cell is passing the laser beam due to their organization
like on a bead chain and is thereby analyzed [109].
3.3.1 Sample preparation
Prior to staining for flow cytometry analyses, a single cell suspension of the organs was
prepared. For the evaluation of the systemic cell distribution in the osteotomized mice
post-osteotomy, the following tissues were analyzed: spleen, bone marrow (tibia and femur
of the contralateral leg, both humeri) and full blood.
Spleen: The spleen was cut into small pieces with a scalpel und was carefully pressed
through a cell strainer (size: 40 µm) with the plunger of a syringe. The isolated cells were
collected in a culture dish. The cell strainer was washed with PBS for several times in order
to obtain all of the isolated splenocytes. Bone marrow: The ends of the bones were carefully
cut off to open the medullary canal. Further, the bone marrow was flushed out with a
syringe. Afterwards, the bone marrow was carefully pressed through a cell strainer (size:
40µm) with the plunger of a syringe. The isolated cells were collected in a culture dish. The
cell strainer was washed with PBS for several times in order to obtain all of the isolated bone
marrow cells.
The full blood was centrifuged (10 min at 500x g) and the obtained supernatant was removed.
The cellular part of the full blood was resuspended in erythrocyte lysis (EL) buffer and
incubated for 10 min at room temperature (RT). For the bone marrow and the spleen, the
prepared single cell suspension was centrifuged for 10 min at 500x g at 4 °C. The supernatant
was removed and the cell pellet was resuspend in EL buffer and incubated for 8 min at RT.
Afterwards, all tissue samples were centrifuged (10 min at 500x g at 4 °C) and washed twice
with PBS. The following preparation and centrifugation steps were done on ice and with
the already mentioned parameters, besides otherwise indicated. After the second washing
step, the cell number from the prepared organs was determined by using a hemocytometer.
The cell suspensions of the organs were resuspend in PBS in the following concentration:
1x106 cells in 100 µl.
3.3.2 Antibody staining for flow cytometry
From each organ, 2 different antibody panels were stained (Tab. 3.2). For panel 1 which
only included surface staining antibodies, 100µl of the cell suspension was transferred to
a fluorescence-activated cell sorting (FACS) tube. Due to the fact that panel 2 included
an intranuclear staining and thus more washing steps, 200µl of the cell suspension was
transferred to a second FACS tube. For both panels, a negative control was taken composed
of a mixture of spleen and bone marrow cells.
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Table 3.2: Overview of the antibodies used including their specificity, clone and dilution for the flow
cytometry analysis of panel 1 and 2.
Antibody Dilution
Panel 1
α-mouse CCR7 Biotin 1:100
α-mouse CD3ε PerCP 1:20
α-mouse CD4 AF700 1:100
α-mouse CD8a eF450 1:100
α-mouse CD25 APC-Cy7 1:25
α-mouse CD44 PE-Cy7 1:200
α-mouse CD62L APC 1:200
α-mouse CD127 PE-Cy7 1:100
α-mouse NK-1.1 FITC 1:50
α-mouse TCRβ chain PE 1:50
Streptavidin PE-Texas Red 1:50
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (405 nm) 1:50
Panel 2
α-mouse CD3ε PerCP 1:20
α-mouse CD4 AF700 1:100
α-mouse CD8a eF450 1:100
α-mouse CD16/ CD32 Purified 1:100
α-mouse CD25 APC 1:100
α-mouse CD44 APC-Cy7 1:100
α-mouse CD127 PE-Cy7 1:50
α-mouse/ human Helios PE 1:50
α-mouse/ rat FOXP3 FITC 1:50
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (405 nm) 1:50
First, the dead cells were stained by the application of a LIVE/DEAD dye for 30 min on
ice. After the washing step (FACS tube was filled up with PBS, centrifuged for 10 min at
500x g at 4 °C, the supernatant was decanted), all further washing and staining steps were
performed in a PBS based buffer: 1x PBS with 1 % BSA and 0.1 % sodium azide (PBS/ BSA).
For panel 1, cells were washed, the pellet resuspended and stained for 15 min at 37 °C for
the surface marker CCR7 (biotin coupled α-mouse CCR7). Cells were washed in PBS/ BSA,
resuspended and a mixture of all other surface marker antibodies was applied to the cell
suspension and incubated for 20 min on ice: α-mouse CD3ε, α-mouse CD4, α-mouse
CD8, α-mouse CD25, α-mouse CD62L, α-mouse CD127/ α-mouse CD44, α-mouse NK1.1,
α-mouse TCRαβ and streptavidin (Tab. 3.2). After the following washing step in PBS/ BSA,
the cell pellet was resuspended in a 2 % formaldehyde solution and fixed for 20 min at RT in
the dark. Finally, the cells were washed in PBS/ BSA, resuspended and measured with the
flow cytometer LSR II from Beckman Coulter.
For panel 2, after washing off the LIVE/DEAD dye, the cells were resuspended. Immediately
afterwards, a mixture of all surface marker antibodies was added to the cells and incubated
for 20 min on ice: α-mouse CD3ε, α-mouse CD4, α-mouse CD8, α-mouse CD25, α-mouse
CD44 and α-mouse CD127 (Tab. 3.2). Cells were washed in PBS/ BSA, resuspended and
incubated with 250µl of a fixation/permeabilization buffer for 1 h on ice. Cells were washed
twice with 2 ml each of a permeabilization buffer, resuspended, and stained for 30 min
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on ice with α-Foxp3 and α-Helios. Cells were washed in PBS/ BSA, resuspended and
filtered through a CellTrics filter, in order to get rid of deoxyribonucleic acid (DNA) protein
complexes formed due to the permeabilization process. After filtration, cells were washed
again in PBS/ BSA, resuspended and measured with the flow cytometer LSR II.
3.3.3 Performed quality controls for flow cytometry
For flow cytometry analysis, different indispensable quality controls were performed prior to
the experimental measurement. For the used antibodies, the correct dilution was determined.
Therefore, different dilutions of each antibody were prepared, stained on murine cells and
analyzed with the flow cytometer LSR II. The optimal dilution was defined as the best
signal to background staining. In addition, isotype controls were tested in order to exclude
an unspecific binding of their immunoglobulin backbone and thus to ensure the specific
binding of the used antibodies. Before the flow cytometry analysis of the experimental
samples could be performed, the used antibody panels (Tab. 3.2) had to be compensated
at the flow cytometer. The panels comprised multiple antibodies coupled with different
fluorochromes. Each fluorochrome is characterized by a specific excitation and emission
wavelength. The emission signal of each fluorochrome will be measured in a different filter
of the flow cytometer. However, the emission signals often do not emit light in only one
special wavelength but in a spectrum of wavelength. This spectrum of emission light can
also be detected in the filter of another fluorochrome. The false positive signal has to be
subtracted from the true emission light of the respective fluorochrome. This is done via
a compensation measurement. In parallel to the compensation analysis, a single staining
of every used antibody was also done as well as fluorescence minus one (FMO) staining
(Fig. 3.2, 3.3). Both, the single and FMO-stainings are necessary especially for the data
analysis following the flow cytometry measurement (Chap. 3.3.4). In addition, a FC block
(α-CD16/CD32) was used for the stainings in order to exclude an unspecific binding of the
used antibodies.
3.3.4 Flow cytometry data analysis with the analyzing software FlowJo
The analysis of the measured data was realized with the FlowJo analyzing software. The
measured data were visualized by the software via dot plot diagrams or histograms. First,
the analyzed cell suspension was depicted in a dot plot diagram, in dependence of the
following cellular properties: the size and the granulation. This type of dot plot is known as
the forward scatter (FSC) (size) vs. sideward scatter (SSC) (granulation) (Fig. 3.2, 3.3, upper
row, left dot plot). After gating the lymphocyte cell population, identified by their size and
granularity within the FCS/SSC dot plot , singlets were gated to get rid of doublets and
triplets which falsify the obtained data. By using a live dead fluorescent dye (LIVE/DEAD,
LD), dead cells were then excluded from further analysis. Data of populations of interest
were either taken as the percentage of the prior gated cell population (frequency of parent)
or calculated on the basis of CD3+TCRαβ+ or CD3+CD4+ or CD3+CD8+ T cell populations.
An exemplary gating of panel 1 and panel 2 with FlowJo and the corresponding FMO
stainings are depicted in figure 3.2 and 3.3.
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Figure 3.2: Representative flow cytometry scheme of panel 1. Illustrated is the gating strategy from
the lymphocyte population, over the singlets, living cells, CD3+ T cells, CD3+TCRαβ+ T cells,
CD3+TCRαβ+CD4+ and CD3+TCRαβ+CD8+ T cells and the respective CD44/CD62L T cell subsets;
on the bottom, the corresponding gates of the fluorescence minus one (FMO) staining are presented.
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Figure 3.3: Representative flow cytometry scheme of panel 2. Illustrated is the gating strategy from
the lymphocyte population, over the singlets, living cells, CD3+ T cells, CD3+CD4+ and CD3+CD8+
T cells, the respective CD25+ T cell subsets as well as CD25++FOXP3+ T cells; on the bottom, the
corresponding gates of the fluorescence minus one (FMO) staining are presented (FMO: CD3, FMO:
CD4 and FMO: CD8 are already presented in figure 3.2).
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3.4 Therapeutic intervention in our mouse osteotomy model
3.4.1 Adoptive transfer of regulatory T cells
3.4.1.1 Magnetic activated cell sorting technology
Magnetic activated cell sorting (MACS) is a powerful tool for a microbead-based separation of
specific cell populations from a cell suspension [110]. The microbeads are superparamagnetic
particles of a size of 50 nm that are bound to antibodies specific for an antigen on the cell
surface. For the separation procedure, the labeled cell suspension is placed in a high-gradient
magnetic-field in a column filled with ferromagnetic stainless steel wool. Positive labeled
cells are kept in the column as along as it stays in the magnetic field. The unlabeled cells (the
negative fraction) run through the column and remain untouched. To separate the positive
fraction from the column, the column just has to be taken out of the high-gradient magnetic-
field and the positive fraction can be further collected in a collection tube. Therefore, the
MACS technology enables the collection of the unlabeled and labeled cells in a relative fast
and harmless procedure to receive a pure cell substrate.
3.4.1.2 Mouse housing for the therapeutic intervention approach
For the enrichment of TReg prior to surgery, two approaches were used: 1) TReg isolated
from SPF housed donor mice were adoptively transferred into SPF housed recipient animals;
2) TReg isolated from semi-sterile housed mice were transferred into semi-sterile housed
recipient mice. With the first approach (SPF housed conditions), the therapeutic potential
of TReg was tested. In the second approach, a more experienced immune system in the
experimental mice was included in the experimental design, bringing our mouse model
closer to the patient situation. By this approach, the validity of the therapeutic potential of
TReg was analyzed in a clinically more relevant model.
3.4.1.3 Sample collection
Murine TReg were isolated from spleen and the following lymph nodes: inguinal nodes,
axillary nodes, brachial nodes and mesenteric nodes. The used buffer for the preparation
of the single cell suspension and the following MACS (Chap. 3.4.1.4) separation was 1x
PBS including 0.5 % bovine serum albumin (BSA) and 2 mM EDTA. This MACS buffer was
sterile filtered before usage and kept at 4 °C. All the separation steps were done under a
clean bench and on ice or in the fridge at 4 °C, besides otherwise indicated. To get a single
cell suspension, the spleen was cut into small pieces and was carefully pressed through a
cell strainer (size: 100µm) with the plunger of a syringe. Afterwards, the erythrocytes were
lysed by ammonium-chloride-potassium (ACK) lysis buffer for 4 min at RT. The lymph
nodes were directly carefully pressed through a cell strainer (100µm). After the lysis of the
erythrocytes, the cells from the lymph nodes and the remaining splenocytes were combined
and the cell number was determined with a hemocytometer.
3.4.1.4 Regulatory T cell isolation
For the isolation of murine TReg, a combined separation procedure of a first negative
depletion of all CD4+ T cells and a following positive selection by an α-CD25 labeling,
was used. The isolation itself was done accordingly to the protocol of the CD4+CD25+
Regulatory T Cell Isolation Kit. After determination of the total amount of isolated cells,
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cells were resuspended in a concentration of 1x107 cells in 40µl MACS buffer. In a first step,
all non-CD4+ cells were marked by a biotin-labeled antibody mix for 10 min at 4 °C. Further,
bead-conjugated anti-biotin antibodies and an α-CD25 PE-labeled antibody were added
to the cell suspension for 15 min at 4 °C. After a washing and centrifugation step (8 min at
1 500 rpm at 4 °C), cells were resuspended in MACS buffer to a final concentration of up to
1.25x108 cells/500µl. An LD MACS column was equilibrated by rinsing it with 2 ml MACS
buffer. Afterwards, the column was placed in the magnetic field of the separator. The labeled
cell suspension was added to the column and the negative fraction (CD4+ T cells) was
collected in a falcon tube. The column was washed twice with 1 ml MACS buffer. In order to
elute the non-CD4+ T cells too, the column was removed from the magnetic field, 1 ml MACS
buffer was immediately added to the column and the cells were flushed out by pushing a
plunger into the column. The CD4+ fraction was centrifuged (8 min at 1 500 rpm at 4 °C)
and resuspended in 90µl MACS buffer for 1x107 cells. In addition, a microbead-conjugated
α-PE antibody was added to the cell suspension for 15 min at 4 °C. Cells were washed,
centrifuged (8 min at 1 500 rpm at 4 °C) and resuspended in 500µl MACS buffer for up to
1x108 cells. An MS MACS column was equilibrated by rinsing it with 500µl MACS buffer.
After equilibration, the column was placed in the magnetic field of the separator and the cell
suspension was added to the column. The negative fraction (CD4+CD25- T cells) passed
through the column and was collected in a falcon tube. The positive labeled cells were
retained in the column and were washed three times with 500µl MACS buffer. Afterwards,
the column was removed from the magnetic field, 1 ml of MACS buffer was added to it and
the cells were flushed out by pushing the plunger into the column. The cell number of the
isolated CD4+CD25+ TReg fraction was counted in a hemocytometer.
3.4.1.5 Flow cytometry for the evaluation of the purity of MACS isolated
regulatory T cells
In order to confirm the successful purification of TReg, a flow cytometry analysis was done
following the MACS isolation. Therefore, two samples of the cell suspension prior to
the MACS separation were taken for a negative and positive control, respectively, of the
original cell population. In addition, samples from the CD4- fraction, as well as from the
negative fraction of the second purification step (CD4+CD25- T cells) and from the isolated
TReg fraction were taken. All 5 samples were washed with PBS and stained for 30 min on
ice with a LIVE/DEAD staining dye. Afterwards, cells were washed, centrifuged (10 min
at 500x g at 4 °C) and resuspended in PBS/BSA. A mixture of surface antibodies (Tab. 3.3)
was added to the samples and incubated for 20 min on ice. After a following washing step,
cells were resuspended and incubated with 250µl of fixation/permeabilization buffer for 1 h
on ice. Cells were washed twice with 2 ml each of a permeabilization buffer, resuspended,
and stained for 30 min on ice with α-FoxP3. Following, cells were washed in PBS/BSA,
resuspended and filtered through a CellTrics filter (30µm). After filtration, cells were washed
again in PBS/BSA, resuspended and measured with the flow cytometer LSR II.
3.4.1.6 Pre-activation of isolated regulatory T cells
Pre-activation of freshly isolated TReg was realized by an α-CD3/α-CD28 T cell receptor
stimulation in addition with the supply of murine recombinant IL-2. Wells of a 96 well
plate were pre-coated with α-CD3/α-CD28 antibodies (each 5µg/ml), diluted in PBS. The
pre-coating was done by an incubation of 200µl of the antibody-PBS-solution per well for 3 h
in the incubator (37 °C, 5 % CO2) or overnight in the fridge at 4 °C. Subsequently, wells were
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rinsed two times with PBS. 3x105 freshly isolated TReg were transferred to the pre-coated
wells in a volume of 200µl. The used medium was RPMI 1640 including 10 % FBS superior,
50µM β-Mercaptoethanol and 1 % Penicillin/Streptomycin. Two different concentrations
of IL-2 were tested for the pre-activation: 50 ng/ml and 360 ng/ml. Pre-activated TReg were
harvested after 12 h, 24 h, 48 h and 72 h. The pre-activation was analyzed via flow cytometry
using the following antibodies: α-mouse CD3ε, α-mouse CD4, α-mouse CD25, α-mouse
FoxP3 and α-mouse CD69. In addition, a LIVE/DEAD staining was included in order
to exclude the dead cells from the analysis. The marker CD69 was used to evaluate the
activation status of the TReg. An activation of TReg corresponds to an upregulation of the
expression of CD69. Flow cytometry analyses were done at the moment of setting up the
pre-activation culture (prior to pre-activation) and at the corresponding time points of the
harvest. The staining for flow cytometry was done equivalent to chapter 3.4.1.5.
3.4.1.7 Regulatory T cell suppression assay
In order to analyze the suppressive capacity of MACS separated murine TReg and thereby
their functionality, a TReg suppression assay was performed. Therefore, isolated TReg were in
vitro co-cultured in different ratios with CD4+CD25- responder T cells (TResp) [111], adapted
from [112]. The basic principle of this suppression assay is to evaluate the proliferation of
the TResp. The proliferation should be suppressed dependent on the amount of co-cultured
TReg if TReg are functional (the more TReg, the more suppression).
TResp were isolated by MACS as described before (Chap. 3.4.1.4). After determining the
isolated cell number using a hemocytometer, 1x107 TResp were stained with a cell proliferation
dye eFluor 450 as described in the protocol. In short: Isolated TResp were washed twice with
PBS (centrifugation step: 8 min at 1 500 rpm at RT) to get rid of the serum of the MACS buffer.
Afterwards, cells were resuspended in pre-warmed PBS to a concentration double as high
as the final concentration. For a final concentration of 10x106 cells/ml, 10x106 TResp were
resuspended in 500µl of pre-warmed PBS (2x cell suspension). 500µl of a 10µM eFluor 450
Cell Proliferation Dye solution was added to the 2x cell suspension while vortexing. Stained
cells were incubated for 20 min in the dark at RT. The staining was stopped by adding 10 ml
of ice cold complete cell culture medium (RPMI 1640 including 10 % FBS superior, 50µM
β-Mercaptoethanol and 1 % Penicillin/Streptomycin). After 5 min incubation on ice, cells
were washed three times with pre-warmed complete cell culture media. The cell number
was determined by hemocytometer. For the setup of the suppression assay, 0.75x105 labeled
TResp were co-cultured with the following amounts of freshly isolated or pre-activated TReg:
1.5x105 (1 to 2; TResp to TReg ) and 0.15x105 (1 to 0.2), respectively. As internal controls,
labeled TResp were also cultured either alone or in co-culture with unlabeled TResp. In order
to stimulate the proliferation of the TResp, the co-culture was realized in flat bottom 96 well
plates that were pre-coated with α-CD3e (5µg/ml) and α-CD28 (5µg/ml) antibodies diluted
in PBS. As negative controls, labeled and unlabeled TResp were also cultured in wells without
antibody coating. From every co-culture sample, two wells of a 96-well plate were filled.
The setup for the suppression assay is exemplary shown in figure 3.4. The suppression assay
was done in complete cell culture media as described above. The suppression assay was
examined every day by a microscopic control and the assay was harvested after 2–3 days,
dependent on the velocity of the proliferation of the TResp. The percentage of suppression
was calculated based on the proliferation of labeled TResp that were cultured alone. The
proliferation of labeled TResp was set to 100 and the proliferation of the co-culture setups
was calculated relative to the TResp. The percentage of the suppression of proliferation was
further calculated as follows: 100 minus the relative value of the proliferation.
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Figure 3.4: Overview of the pipette scheme and applied cell number of cell proliferation dye labeled
TResp (TResp eF450), freshly isolated or pre-activated TReg and unlabeled TResp for the TReg suppression
assay; α-CD3/α-CD28 indicates that the wells were stimulated in this column.
3.4.1.8 Flow cytometry for the evaluation of the regulatory T cell
suppression assay
The suppressive capacity of freshly isolated murine TReg was evaluated by flow cytometry.
From every co-culture sample, a small aliquot was taken at the moment of co-culture setup
(t= 0) for flow cytometry analysis in order to confirm the labeling of the TResp and the right
ratio between TReg and TResp. The samples prior to the suppression assay and the harvested
cells after the end of the assay were first washed with PBS and stained for 30 min with
LIVE/DEAD (Tab. 3.3). After washing with PBS/BSA (Chap. 3.3.2), cells were stained for
the surface marker α-CD3, α-CD4 and α-CD25 for 20 min on ice (antibody were diluted in
PBS/BSA). Cells were washed in PBS/BSA, resuspended and fixed for 20 min (in the dark, at
RT) with a 2 % formaldehyde solution. After a final washing step with PBS/BSA, cells were
resuspended and analyzed with the LSR II.
3.4.1.9 Adoptive transfer of regulatory T cells
For the adoptive transfer of TReg, isolated cells were washed in a sterile solution of 0.9 %
sodium chloride following the MACS separation. Washed cells were resuspended in 0.9 %
sodium chloride and filled in a volume of 150–200µl in a syringe. After confirming the purity
of the isolated TReg via flow cytometry, 5–8x105 TReg were directly adoptively transferred
into the tail vein of recipient mice. Furthermore, the mice directly underwent the osteotomy.
During the time needed to confirm the purity, isolated TReg were kept at 4°C.
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3.4.2 Depletion of CD25+ T cells
3.4.2.1 Depletion of CD25+ T cells - Procedure
CD25+ T cells were depleted prior to surgery. For the depletion, an α-CD25 antibody was
applied to the animals by four consecutive intraperitoneal injections of 200µg diluted in
0.9 % sodium chloride, starting three days prior to surgery. The depletion of the CD25+ T
cells was confirmed via flow cytometry at the day of surgery. The healing outcome of CD25+
depleted animals was evaluated after 21 d by µCT and histological analysis.
3.4.2.2 Flow cytometry analysis to confirm CD25+ T cell depletion
In order to confirm the depletion of CD25+ T cells prior to surgery, flow cytometry analysis
were done at the day of surgery. 1–2 drops of peripheral blood were taken from the Vena
facialis (in the cheek of the animal) of the depleted animals and directly lysed in erythrocytes
lysis buffer for 5 min at RT. After washing with PBS/BSA (centrifugation: 10 min at 500x g at
4 °C), the samples were resuspended in an in PBS/BSA diluted antibody mix (α-CD3, α-CD4
and α-CD25 (Tab. 3.3)) and incubated for 20 min on ice. Afterwards, the samples were
washed and analyzed with the LSR II as described previously.
Table 3.3: Overview of the antibodies used including their specificity, clone and dilution for the flow
cytometry analysis of the MACS check, the TReg suppression assay and the confirmation of the CD25+
T cell depletion.
Antibody Dilution
MACS check
α-mouse CD3εPerCP 1:20
α-mouse CD4 AF700 1:400
α-mouse CD8a eF450 1:100
α-mouse CD25 APC 1:100
α-mouse/ rat FOXP3 FITC 1:50
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (405 nm) 1:50
TReg suppression assay
α-mouse CD3ε PerCP 1:20
α-mouse CD4 AF700 1:400
α-mouse CD8a eF450 1:100
α-mouse CD25 APC 1:100
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (405 nm) 1:50
CD25+ T cell depletion
α-mouse CD3εPerCP 1:20
α-mouse CD4 AF700 1:400
α-mouse CD25 APC 1:100
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3.5 Histology
The term histology derives from the Greek words histos and logia which means "tissue" and
"science", respectively. It studies the microscopic anatomy of cells and tissues of plants and
animals.
In the framework of my PhD thesis, histological methods were used in order to analyze
the healing outcome and distribution of different tissue types within the healing bone. The
immunohistochemical staining methods were used to evaluate the spatial and temporal
localization of selected immune cell types in the healing mouse femur.
3.5.1 Collection of bone samples
Fractured murine bones were taken out of the animal at the indicated time points (Chap.
3.1.5). They were directly placed in 4 % PFA fixation solution for 4 h at 4 °C. Afterwards, the
4 % PFA was removed and replaced by a freshly prepared 10 % sucrose solution and kept
for 24 h at 4 °C. The sucrose solution was exchanged by a 20 % and 30 % one, respectively,
each after 24 h incubation at 4 °C. The bones from the 21 d animals were now prepared for
the micro–computed tomography (µCT) analysis (Chap. 3.7). Subsequently, all bones were
cryo-embedded (Chap. 3.5.2).
3.5.2 Embedding of bone samples
Cryo-embedding is a useful method in order to keep the tissue architecture intact during the
embedding process. Another big advantage for the histological analysis of cryo-embedded
bone tissue is that it does not have to be decalcified in order to be cut. A decalcification
procedure can alter the tissue structure and thereby can cause a loss of biological information
of the treated tissue. For the process of tissue cryo-embedding and further cutting, the
method modified and optimized by Prof. Tadafumi Kawamoto (Section-Lab Co. Ltd.,
Hiroshima, Japan) was used [113, 114]. The basic principle of this method is to freeze the
calcified fixed bone tissue sample in ice cold n-hexane and to further cut it in a cryotome
with the help of a special adhesive film on the cutting plane (Chap. 3.5.3).
For the embedding procedure, a dewar vessel was half filled with acetone and dry ice. A
beaker filled with n-hexane was placed into the acetone dry ice mixture and was allowed to
cool down for 10-15 min. The bone sample was placed in a metallic embedding form (Fig.
3.5 A) and embedding media (SCEM media, Section-Lab Co. Ltd., Hiroshima, Japan) was
filled into the form. For the bone samples in which the external fixator was still in (time
points 1–14 d), the embedding media was just filled into the embedding form till the lower
part of the bone was covered with media. Now, the embedding form with the bone sample
in it was placed into n-hexane, till the media got frozen. The form was taken out off the
n-hexane and the external fixator was swiftly but carefully removed from the bone with a
respective instrument. The embedding form was filled up with embedding media till the
bone was completely covered, was put back into n-hexane and completely frozen (Fig. 3.5
C). For the samples that went into µCT analysis before and which therefore had no external
fixator anymore, the embedding form with the bone samples was directly completely filled
with embedding media (Fig. 3.5 B) and placed into n-hexane till it was completely frozen
(Fig. 3.5 C). The bone sample was placed in the embedding form having the pin holes
perpendicular aligned to the cutting plane (Chap. 3.5.3). Afterwards, the frozen sample
block was removed from the embedding form and stored at -80 °C till further use.
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Figure 3.5: Illustration of the embedding procedure of murine femora by cryo-embedding. Metallic
embedding form of different sizes (A); Embedding form, filled with embedding media (SCEM) and
murine femur, placed into a beaker filled with n-hexane; the embedding media is already frozen at
the edges of the embedding form (B); Cryo-embedded bone sample (frozen cryo tissue block) (C)
3.5.3 Cutting of bone samples
Embedded and frozen bone samples were cut in a cryotome (LEICA CM3050S). Before
starting the cutting procedure, the frozen bone samples and the knife were placed into the
cryotome in order to allow them to acclimatize to the temperature of the cryotome (around
-23 °C). The frozen bone was glued on a pre-cold sample holder with embedding media
(Tissue Tek). The sample holder was installed in the cryotome. The knife was carefully
placed into the knife holder of the cryotome. After trimming the sample block till the bone
became visible, the plane of the cut surface was adjusted to be planar so that the whole bone
was cut along the longitudinal axis. As soon as the whole medullary canal was opened,
sections of 7µm thickness were taken. In order to enable the cutting of the calcified bone, a
piece of cryofilm was glued onto the surface of the bone and the section was taken. From
each bone, serial sections were taken in order to enable histological and immunohistological
stainings (Chap. 3.5.4; 3.6) on consecutive slices. The cryofilm with the bone section was
fixed with adhesive tape on an object slide. Object slides were stored at -80 °C till further
use.
3.5.4 Histological staining: Movat Pentachrome
Movat Pentachrome is a histological staining method for bony tissue that allows the diffe-
rentiation of the following tissue types due to the different staining solutions used: calcified
bone/collagen and mineralized cartilage (Saffron du gatinais; yellow), hyaline cartilage
(Alcian blue; green-blue), connective tissue (Alcian blue; blue-grey), cytoplasm (Brilliant
crocein acid fuchsine; reddish) and cell nuclei (Iron hematoxylin (after Weigert); blue-black)
[115]. The surrounding muscles are colored in reddish (Brilliant crocein acid fuchsine).
Movat Pentachrome gives a good overview about the tissues presented within the bone
and especially within the fracture area and about their distribution. The staining protocol
including all the solutions and incubation times is presented in table 3.4.
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Table 3.4: Staining protocol of the histological Movat Pentachrome staining.
Step Incubation time
Thawing of the frozen sections 1 h at RT
Rehydration of the sections in 1x PBS 20 min
3 % Acetic acid 3 min
Alcian blue (1 % solution)in 3 % acetic acid (pH 2.5) 30 min
3 % Acetic acid rinsing
Aqua dest. rinsing
Ethyl alcohol 1h
Tap water 10 min
Iron hematoxylin (after Weigert) 10 min
Tap water 10 min
Brilliant crocein acid fuchsine 15 min
0.5 % Acetic acid rinsing
5 % Phosphotungstic acid 20 min
0.5 % Acetic acid 1 min
96 % Alcohol 3x 2 min
Saffron du gâtinais 1 h
96 % Alcohol 3x 2 min
Xylol 2x 5 min
3.5.5 Histomorphometric analysis of the Movat Pentachrome staining
Based on the Movat Pentachrome staining, histomorphometrical analyses were done in
order to elucidate the proportional distribution of the different tissue types within a defined
region of interest (ROI) including the fracture gap. The ROI was defined as twice the size
of the osteotomy gap, going from the center of the fracture area 0.7 mm to the left and to
the right side (ROI= 1.4 mm). In the image processing program ImageJ, a MACRO tool
especially written for these animals was used in order to determine the following parameter
and tissue types: total callus area, cortical bone, new mineralized bone, cartilage, connective
tissue and bone marrow. In figure 3.6, a scheme of the histomorphometrical evaluation of the
MACRO is shown, representing the ROI as well as the different tissue types, indicated by the
different colors (cortical bone = light yellow, new mineralized bone = yellow, bone marrow
= violet and void area = white). The MACRO itself worked with a taken picture of the
Movat Pentochrome stained bone section. The picture was taken with a light microscope in
a 2.5x magnification and the program Axiovision. In order to ensure a correct identification
and determination of the different tissue types, a microscopic view of the respective stained
bone slice was done by me in parallel to the MACRO evaluation. The proportion of the
tissues of interest (cortical bone, new mineralized bone, cartilage, connective tissue and bone
marrow) were calculated as percentages based on the total callus area.
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2 mm
Figure 3.6: A scheme of the histomorphometrical MACRO evaluation is presented. Depicted is the
region of interest, including the different analyzed tissue types, indicated by distinct colors: cortical
bone = light yellow, new mineralized bone = yellow, bone marrow = violet and void area = white
3.6 Immunohistochemical staining with fluorescence-coupled
antibodies
The basic principle of immunohistochemistry (IHC) stainings is the specific antigen-antibody
interaction between a structure of interest in tissue sections and a specific antibody recog-
nizing and binding to it. To visualize these interactions, the antibodies are either enzyme-,
fluorescence- or ion-linked [116]. Albert Coons is one of the pioneers in IHC. After having
published his first paper in the 1950s about the detection of cellular antigens by fluorescence
labeled antibodies as a histochemical staining method, he quickly went on to further improve
this technique [117, 118]. There are two different ways how the detection method of IHC
stainings can be realized: it can be either direct (the used antibody is directly labeled with a
reporter molecule) or indirect (the primary antibody is not directly labeled with a reporter
molecule; therefore a labeled secondary antibody is needed for the signal visualization).
The IHC staining used in this work were all done with fluorescence-coupled antibodies,
either directly or indirectly. The advantage of using fluorescence-labeled antibodies is that
multiple structures of interest can be simultaneously analyzed on one tissue section. This is
based on the usage of antibodies labeled with different fluorochromes. In table 3.5, a general
staining protocol is presented. Individual modifications are listed in the protocols for the
specific stainings (Tab. 3.6). All steps were done at RT. From the blocking step on, all further
steps were done in the dark (in a metallic section staining box). Finally, the stained tissue
sections were embedded with mounting media (DAKO, Hamburg, Germany) and stored in
the dark at 4°C till analysis.
Table 3.5: Basic protocol for the staining of bone sections with fluorescence-coupled antibodies (IHC).
Step Incubation time
warming up the tissue section to RT 1 h
rehydration of the tissue section in 1x PBS 20 min
blocking of the tissue section 1 h
staining with the primary antibody 1 h
washing of the tissue section 3x 10 min
if necessary: staining with the secondary antibody 1 h
washing of the tissue section 3x 10 min
cell nuclei staining with DAPI 5 min
washing with 1x PBS 2x 15 min
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3.6.1 Staining of macrophage subsets
The macrophage subsets M1 and M2 were stained using the following antibodies: CD68,
CD80 and CD206. CD68 was used as a pan macrophage marker. Cells co-stained for CD68
and CD80 were identified as M1 macrophages, and a co-staining for CD68 and CD206 as M2
macrophages. After thawing and rehydration of the tissue sections as described in table 3.5,
tissue sections were blocked for 1 h at RT with 1x tris-buffered saline (TBS) (pH 7.6) + 5 %
fetal bovine serum (FBS) + 10 % rat serum and 0.1 % Tween. Afterwards, the tissue sections
were stained with an antibody cocktail containing all three antibodies (Tab. 3.6) diluted
in 1x TBS (pH 7.6) + 5 % FBS + 0.1 % Tween (this was also used as washing buffer) and
the staining followed the given protocol (washing, 4’,6-diamidino-2-phenylindole (DAPI)
staining, washing, embedding). Due to the direct labeling of all three antibodies, no step for
staining of a secondary antibody was necessary. The stained tissue sections were analyzed
with a confocal laser scanning microscope 710 (LSM 710).
3.6.2 Staining of CD4+ T cells, CD8+ T cells and osteoblasts
CD4+ and CD8+ T cells, as well as osteoblasts were stained simultaneously on one tissue
section. After thawing and rehydration (Tab. 3.5), tissue samples were blocked in 1x TBS +
10 % FBS and 0.2 % Tween. Then, tissue sections were stained for osteocalcin, as a marker for
osteoblasts, in 1x TBS + 5 % FBS and 0.2 % Tween (Tab. 3.6). All the following washing and
staining steps were realized in this buffer. After washing, a secondary antibody α-rabbit
was applied to the section. After the next washing step, the staining of CD4 followed.
The staining signal of CD4+ T cells was improved by the application of a secondary α-rat
antibody after washing. Tissue samples were washed, stained for CD8 and finally for DAPI
and embedded. The stained tissue sections were analyzed with a confocal laser scanning
microscope 710 (LSM 710).
3.6.3 Staining of B cells and osteoclasts
B cells and osteoclasts were also stained together on one tissue slide. After thawing and
rehydration (Tab. 3.5), sections were blocked in 1x PBS + 10 % FBS + 10 % rat serum and
0.1 % Tween. An antibody cocktail containing α-B220 (B cell marker) and α-cathepsinK
(marker for osteoclasts) (Tab. 3.6) diluted in 1x PBS + 10 % FBS and 0.1 % Tween was applied
to the sections. The staining buffer was also used as the following washing buffer. After the
washing, an α–rabbit antibody was applied to the tissue sample to visualize the staining for
osteoclasts. The following steps of the staining corresponded to the above described general
staining protocol (washing, DAPI staining, washing). The embedded tissue sections were
analyzed with a confocal laser scanning microscope 710 (LSM 710).
3.6.4 Staining of hypoxic areas and newly formed vessels
Hypoxic areas were identified by the staining of the transcription factor Hif1α and newly
formed vessels by the surface marker CD105 (Tab. 3.6). Both targets of interest were stained
subsequently on one tissue slide. After washing and rehydration (Tab. 3.5), the blocking
step with 1x TBS (pH 7.6) + 0.2 % Tween-20 followed. This buffer was also used for the
following staining and washing steps. First, new vessels were stained. After washing, a
secondary staining step with an α-rat antibody followed in order to visualize the staining
for CD105. Subsequently, hypoxic areas were stained and further visualized by an α-rabbit
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antibody. Tissue samples were washed, stained for DAPI and embedded. The stained tissue
sections were analyzed with a confocal laser scanning microscope 710 (LSM 710).
Table 3.6: Overview of the antibodies used including their specificity, clone and dilution for the
immunofluorescence staining of frozen bone sections
Antibody Dilution
IHC
α-mouse B220 PE 1:100
CathepsinK 1:200
CD4 AF594 1:25
α-mouse CD8 PE 1:100
CD68 FITC 1:100
α-mouse CD80 AF647 1:50
α-mouse CD105 1:100
α-mouse CD206 PE 1:100
DAPI 1:1 000
Hif1a 1:100
α-mouse Osteocalcin 1:400
α-rabbit AF647 1:1 000
α-rat AF594 1:1 000
3.6.5 Performed quality controls for immunofluorescence stained bone
sections
For the IHC staining, the following quality controls were performed prior to the staining of the
experimental bone sections. First, the correct dilution of the used antibodies was determined.
The used antibodies were tested in different dilutions on bone test slices. The best antibody
dilution was defined as the best signal to background staining. Furthermore, in the case
of an indirectly staining (the first antibody was not directly coupled to a fluorochrome), a
staining just containing the primary or the secondary antibody, respectively, was done in
parallel to a full stain (primary and secondary antibody together on one slide). This was
the case for the staining of osteoblasts (osteocalcin), osteclasts (cathepsinK), hypoxic areas
(Hif1α) and newly formed vessels (CD105). In addition, for all used staining panels, single
staining were done in parallel to the full stain in order to exclude an unspecific binding of
one antibody to another one in the full stain antibody solution.
3.6.6 Imaging of immunofluorescence stained bone sections
Immunofluorescence stained tissue sections were imaged with a confocal laser scanning
microscope from Carl Zeiss (LSM 710). The scan area was defined as the area including
the osteotomy gap and the ends of the four cortical bones, corresponding to the ROI of the
histomorphometric analysis (Fig. 3.6). By using the microscope software ZEN, the scan
area was determined in the X and Y axis. If necessary, Z stacks were taken in order to take
into account non-flatness of the tissue section. The acquisition of the determined scan area
was done using the following parameters: frame size: 2 400 x 2 400, averaging number:
2. Afterwards, first, the imaged Z stacks were combined and then the imaged tile scans.
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The final image was also further processed and analyzed with the ZEN software for the
appearance and distribution of the stained targets of interest (Chap. 3.6.7).
3.6.7 Processing of taken images
Taken immunofluorescence images were further processed and analyzed with the microscope
software ZEN (Version 11). In a first step, the intensity of the individual laser was readjusted
in order to obtain a strong signal for the respective fluorochrome, without increasing the
background signal too. In a second step, each target of interest was evaluated integrating
the localization within the scan area (periosteal, endosteal, within the osteotomy gap, within
the bone marrow). Consecutive sections were stained for different targets of interest. This
allowed the subsequently interpretation of possible co-localization not only for targets
stained on the same section, but also for ones on the adjacent sections.
3.7 Micro-Computed tomography
The µCT is a high-resolution imaging technique in order to visualize the 3D microarchitecture
and morphology of cortical and trabecular bone by X-rays. The basic principle of X-ray
measurement is the tissue specific absorption of X-rays based on its density. A tissue with a
higher density like mineralized bone is less transparent for X-rays and will be represented
by a lighter color in the visualized depiction. Therefore, tissues of different densities can be
non-invasively visualized and evaluated by µCT analysis. For the first time introduced by
Feldkamp et al., µCT analyses are nowadays the "gold standard" in research for in vivo and
ex vivo analyses of bony structures, especially in rodents and small animals [119, 120].
3.7.1 Ex vivo measurement of murine femora by µCT
The µCT measurement of the murine left femur of the 21 d animals was done ex vivo in a
30 % sucrose solution in a Viva µCT 40. In the Viva µCT 40, the sample is fixed within the
device and the X-ray images are taken from different angles around the sample. Concerning
the scan resolution, the highest possible resolution of 10.5µm voxel size was chosen for the
analysis. In order to also highly visualize fine structures of newly formed (woven) bone, an
energy peak voltage of 55 keVP was applied to the sample. Based on the chosen energy, a
current of 145µA was applied to the sample. For the scan, a region of around 2 mm around
the center of the osteotomy gap was taken, corresponding to the area between the two
middle pins of the external fixator. In order to be able to distinguish between mineralized
and non-mineralized bone, a grey value threshold for mineralization has to be defined in
the analyzing software. The threshold in order to segment the data sets into background
and mineralized bone was determined on the distribution of grey values of data sets of
µCT analysis of different mice [120]. For this study, female C57BL/6N mice of an age of 12
weeks were used to determine the grey value threshold. This result was confirmed using a
mathematical grey value evaluation [121]. The threshold was set to 242, corresponding to a
mineralization of 369.9 mg hydroxyapatite per cm².
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3.7.2 Reconstruction and analysis of the µCT measurement
The reconstruction and analysis of the measured 2D slices (X-rays) were realized by using
the evaluation software "µCT Evaluation Program v6.5-3". The automatically reconstructed
X-rays (Feldkamp algorithm) were loaded into the program and the volume of interest (VOI)
for the evaluation was determined, which correspond for this analysis to 190 slices à 10.5µm.
Therefore, the center of the (former) fracture gap was defined. The final VOI included 95
slices in the direction of the femur head and 95 slices in the direction of the knee. The total
callus was encircled on each X-ray as the region of interest and the proportion of mineralized
bone within the total bone callus was calculated by using the defined threshold of 242.
Afterwards, a 3D reconstruction of the µCT scan was obtained by the encircled X-rays and
the used mineralization threshold. This 3D image was the basis to define a bone as bridged or
non-bridged. The following also obtained parameters were used for the quantification of the
µCT results and therefore the healing outcome: total callus volume (TV), bone volume (BV),
ratio of BV and TV (BV/TV) and bone mineral density (BMD). BMD is equal to the mean of
TV.
3.8 Statistics
For the statistical evaluation of the obtained data, the statistic program SPSS was used. Data
were presented as box plots, including the median (50 % quartile) and the 25 % and 75 %
quartiles. All three quartiles are combined in the box of the box plot. This box is bounded by
two “T” lines, the Whisker, on the top and on the bottom of the box. The Whisker includes all
the values outside of the box, besides the outlier and extreme values. Outliers are depicted
as circles, extreme values as arrows.
For all statistical analysis, the Mann-Whitney U test was utilized. Due to the small sample
sizes used in this study, a normal distribution of the data was not assumed. If more than just
one data pair was compared in one analysis, the Bonferroni correction was also included
and indicated in the respective figure. Data were statistically significant if p≤ 0.05. Using the
Bonferroni correction, the significance level p had to be adapted as follows: p≤ 0.05/n, n=
number of comparing samples. If, for example, three samples were compared, the lowest
significance value had to be p≤ 0.05/3 = 0.017 in order to be statistically significant. In the
respective graphs, statistical significances were indicated by * above a line. A trend was
defined if p was between 0.051–0.1, indicated by # above a line. For the Bonferroni corrected
data sets, a trend was defined if p was above the calculated significance niveau and ≤ 0.1.

4 Results
Bone fracture healing is a highly complex process consisting of different but overlapping
phases in which different cell and tissue types have to work together in order to enable a
complete regeneration of the injured bone. Under normal healing conditions, a fractured
bone regenerates completely without scar tissue formation, possessing in the end the same
biomechanical properties as before. Between the bone and the immune system, there is a
tight interplay and interconnectivity. Therefore, the bone healing process is highly influenced
by the immune system.
In order to characterize the occurrence and composition of immune cells of an unaltered
healing process during the healing cascade, a non-critical size defect osteotomy model
in mice was used. By immunohistology, the immune cell composition was analyzed
locally within the osteotomized bone. For the sake of convenience, the osteotomized
bone will be further also termed as fractured bone. Simultaneously, the immune cell
composition was also investigated systemically, both in the spleen and in the bone marrow
(the lymphoid organs), as well as in the peripheral blood. After analyzing the impact of
the immune system on the bone regeneration process under normal healing conditions, a
possible therapeutical approach to improve the healing outcome via immunomodulation
was investigated. Therefore, an adoptive transfer of TReg prior to surgery was done. In the
frame work of this approach, the impact of the environment was also analyzed (SPF vs.
semi-sterile (non-SPF) housing) as to consider the status of the adaptive immune system prior
to surgery. Under SPF housing conditions, the adaptive immune system is less experienced
than in a semi-sterile environment. In this respect, we could already show that the housing
of mice influences the outcome of an unaltered healing process [4]. At the end of the project,
a potential identified biomarker could be confirmed in a proof of concept study. The validity
of this possible biomarker in a human setup will be further investigated in following clinical
research studies.
4.1 Analysis of an unaltered healing process in a mouse
osteotomy model
The here presented study is the first attempt to link the appearance of immune cells, bone
cells, vascularization and hypoxic areas within the specific bone healing phases in a mouse
model. The different phases of bone regeneration during an unaltered healing process after
injury were analyzed and characterized, within the fractured bone itself but also systemically.
This analysis included the evaluation of the spatial and temporal distribution of different
tissue and cell types during the consecutive healing phases within the osteotomy gap as well
as within the injured organism. The outcome of this part of my thesis is a clearer picture
and a deeper understanding of the interconnectivity of the different tissue and cellular
components within the regenerating bone during a normal healing process, focusing on
components of the adaptive immunity. The analyzed wild type (WT) mice also worked as
controls for the immunomodulatory approach to enhance bone healing (Chap. 4.2, 4.3).
4.1.1 Characterization of the different phases of the fracture healing process
The harvested bones of the 21 d mice underwent µCT analysis. µCT measurements are used
in order to reconstruct the shape of the healed bone in a certain volume of interest in a 3D
image and to determine the amount of newly formed mineralized tissue.
In figure 4.1, a representative image of such a reconstruction of one of the 21 d WT bones is
shown.
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Figure 4.1: µCT evaluation of the healing outcome of WT mice revealed no complete bridging after
21 d. Shown is a representative image of one of the 21 d bones. There was no complete bridging after
21 d. In the right picture, the 3D image of the healing bone is cut sagittally/ frontally to demonstrate
the progress of the remodeling process. The color code indicates the mineralization state, with an
increasing mineralization from black to white (left) and from blue to red (right), respectively.
After 21 d, the WT bones are not completely bridged. Since the used model is an osteotomy
model of a non-critical size defect, the bones would completely heal after a certain time. The
21 d time point was chosen as the last time point of analyzing the healing process in order to
be still able to evaluate an improved healing outcome after therapeutic intervention in the
immune system of the experimental mice (Chap. 4.2, 4.3).
In general, the bones were harvested and cryo embedded. Serial sections were cut for further
histological and immunohistological analysis. The different tissues of the regenerating
bone were analyzed based on Movat Pentachrome (MP) stainings. The MP coloration is a
useful histological method in order to visualize different tissue components in one staining.
Representative pictures of all six investigated time points are displayed in figure 4.2. In
addition, magnifications of the fracture area of the later phases of the healing process are
presented in order to depict more clearly the predominant tissues present at the respective
time points. Following the MP staining, a histomorphometrical evaluation of the fracture
gap, including also a defined area around it, was performed (Fig. 4.3).
The different phases of a classical secondary bone healing process were recapitulated in
the mouse model: after the early hematoma formation, the fracture gap was filled with
connective tissue and further fibrocartilage that was then replaced by maturing cartilage
tissue and finally newly formed mineralized bone. In order to evaluate the progression of
the healing process by histomorphometry, the following parameters were considered: total
callus area, cortical bone, newly mineralized bone, cartilage, bone marrow and connective
tissue. The total callus area increased from day 1, showed a peak at day 3 and 7 and
decreased again till day 21 (Fig. 4.3). At day 1–3 (hematoma phase), connective tissue and
bone marrow cells were dominant in the fracture area. In particular, the relative amount of
bone marrow increased from day 1 to day 3, whereas a simultaneously decreasing proportion
of mature granulation tissue (evaluated as connective tissue) was seen. At day 7, small isles
of cartilage appeared in the investigated area embedded in mature granulation tissue. This
represents the phase of fibrocartilage tissue formation, also termed soft callus phase. This
soft callus is then replaced by hard callus, consisting of newly formed woven bone (Fig. 4.2,
21 d, bottom). This phase began after 14–21 d. Between day 7 and 14, the whole fracture
area was filled with cartilage tissue that became hypertrophic and finally mineralized (Fig.
4.2, MP picture 14 d, bottom). In the hard callus phase that is followed by the remodeling of
the newly formed woven bone, the relative amount of newly mineralized bone increased.
Furthermore, the area filled with bone marrow also increased, showing the rebuilding of the
former medullary canal. In contrast, the percentage of connective tissue as well as cartilage
decreased again from day 14 to day 21.
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Figure 4.2: The different phases of a classical secondary healing process were recapitulated in the
fractured femora. Representative Movat Pentachrome images of the different time points of healing
are shown: 1 d post-surgery, 2 d, 3 d, 7 d, 14 d and 21 d. At the bottom, enlarged pictures of the fracture
area from the time points 7 d, 14 d and 21 d are depicted, enlighten the predominant tissues present
at the respective phases of the healing process: 7 d mature granulation tissue; 14 d cartilage/soft
callus; 21 d woven bone. Coloration of the following tissues: mineralized bone and cartilage = yellow,
cartilage = blue/green, connective tissue = bluish, bone marrow = purple and cell nuclei = black.
Scale bar (bottom): 200µm
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Figure 4.3: Histomorphometrical evaluation of the Movat Pentachrome stainings confirmed the
cha-racteristic tissue distribution of the different healing phases. Displayed are the total callus area
and the calculated proportions of the investigated tissues types (in and around the fracture gap) at
the different healing phases of the osteotomyzed bones: 1 day (d) post-surgery, 2 d, 3 d, 7 d, 14 d and
21 d. n= 4
In addition to the analysis of the different tissue types present in the fractured bone over the
healing process, certain populations of cellular subsets of the innate and adaptive immune
system, osteoblasts, osteoclasts, as well as hypoxic areas and newly formed vessels were
investigated by immunohistological stainings using fluorescence-coupled antibodies (Chap.
4.1.2).
4.1.2 Spatial and temporal distribution of distinct immune cell subsets in the
healing mouse femur
This is for the first time that the interplay of both, immune and bone cells, and their context
during all bone healing phases are shown. The spatial and temporal distribution of distinct
immune cell subsets was investigated by IHC stainings of the tissue sections. The results are
presented in the figures 4.4–4.10. A scheme of the investigated fracture area is depicted in the
figures. In figure 4.4, the corresponding area of the schemes is depicted in a representative
MP staining of a murine fractured femur.
Macrophages expressed different polarization states during healing: MΦ (CD68+, visualized
by a green fluorescence signal), M1 (CD68+ and CD80+, light blue) and M2 (CD68+
and CD206+, red). The macrophages changed over the healing process from a first pro-
inflammatory (Fig. 4.4, 4.5, indicated by an arrow; hematoma phase) to an anti-inflammatory
phenotype (Fig. 4.6, 4.7, indicated by an arrow). M2 macrophages started to appear 3–7 d
post-surgery, at the transition from the ending inflammatory/ hematoma to the fibrocartilage
phase. They also seemed to enter the fracture side from the surrounding muscle tissue (Fig.
4.7). During the cartilage and hard callus/remodeling phases, predominantly CD68 single
positive macrophages were detectable within the osteotomy area (Fig. 4.8, 4.9, indicated by
an arrow).
Concerning the distribution of the T cell subsets, they seemed to disappear in the investigated
area after day 1/day 2 but directly started to reappear in the bone marrow around the fracture
zone (Fig. 4.4–4.7, indicated by an arrow; CD4+ T cells: red; CD8+ T cells: green).
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Figure 4.4: Hypoxia induced the expression of Hif1α in the fracture gap. Immunohistological staining
within a murine fractured femur 1 day post-surgery. Depicted is a scheme of the analyzed area after
osteotomy. On top, a MP stained murine femur and the corresponding area of the scheme are shown
(indicated by a black rectangle). The following cellular targets were stained: osteoblasts (osteocalcin,
OC, light blue), osteoclasts (cathepsin k, CK, green), CD4+ T cells, (CD4, red), CD8+ T cells (CD8,
green), B cells (B220, red), macrophages at different polarization states (MΦ, green; M1, light blue;
M2, red), Hif1α as an indicator of hypoxia (Hif1α, red) and newly formed vessels (CD105, green).
Stainings were done on consecutive bone sections, also including co-stainings on one slice. Arrows
indicate the stained target shown in the respective image. Coloration of the MP picture: mineralized
bone and cartilage = yellow, cartilage = blue/green, connective tissue = bluish, bone marrow = purple
and cell nuclei = black. Color code of the scheme: cortices = yellow, periosteal callus = blue/green.
Scale bar = 20µm.
In this early healing phase, a direct spatial co-localization of CD4+ T cells and osteoblasts
(osteoblasts identified by osteocalcin (OC) staining, visualized by a light blue fluorescence
signal) and CD8+ T cells and osteoblasts, respectively, could be visualized. However, both
T cell subsets did not seem to directly co-localize. During the later phases of the healing
process, CD4+ and CD8+ T cells were consistently present in the bone marrow around the
fracture gap.
CHAPTER 4. RESULTS 50
Figure 4.5: T cells seemed to evade from the fracture area. Immunohistological staining within
a murine fractured femur 2 days post-surgery. Depicted is a scheme of the analyzed area after
osteotomy. The following cellular targets were stained: osteoblasts (osteocalcin, OC, light blue),
osteoclasts (cathepsin k, CK, green), CD4+ T cells, (CD4, red), CD8+ T cells (CD8, green), B cells (B220,
red), macrophages at different polarization states (MΦ, green; M1, light blue; M2, red), Hif1α as an
indicator of hypoxia (Hif1α, red) and newly formed vessels (CD105, green). Stainings were done
on consecutive bone sections, also including co-stainings on one slice. Arrows indicate the stained
target shown in the respective image. Color code of the scheme: cortices = yellow, periosteal callus =
blue/green. Scale bar = 20µm
The B cell subset (B220, red) was present over the whole healing cascade within the analyzed
area. Often, they could be detected in a direct co-localization with cathepsin k+ osteoclasts
(Fig. 4.4, 4.5, 4.7–4.9, indicated by an arrow; osteoclasts: CK, green). Osteoclasts, the bone
resorbing cells, were first predominantly found at the endosteum and periosteum. Thus,
B cells were also often found at the endosteum. As soon as areas of newly formed woven
bone appeared in the osteotomy area, osteoclasts were also found around those isles (during
the hard callus/remodeling phases). In contrast, the bone forming osteoblasts were more
prominent at the periosteum and directly within the fracture gap during the early healing
phase (Fig. 4.4–4.6, indicated by an arrow). Later, they were also found at the endosteal site
of the cortices and around woven bone isles (Fig. 4.7, 4.8, indicated by an arrow). Hypoxic
cells indicated by expressing the hypoxia induced transcription factor Hif1αwere detectable
in the fracture gap directly after injury (Fig. 4.4, 4.5, indicated by an arrow; red signal).
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Figure 4.6: Vessel-like structures started to develop in the surrounding tissue. Immunohistological
staining within a murine fractured femur 3 days post-surgery. Depicted is a scheme of the analyzed
area after osteotomy. The following cellular targets were stained: osteoblasts (osteocalcin, OC, light
blue), osteoclasts (cathepsin k, CK, green), CD4+ T cells, (CD4, red), CD8+ T cells (CD8, green), B
cells (B220, red), macrophages at different polarization states (MΦ, green; M1, light blue; M2, red),
Hif1α as an indicator of hypoxia (Hif1α, red) and newly formed vessels (CD105, green). Stainings
were done on consecutive bone sections, also including co-stainings on one slice. Arrows indicate the
stained target shown in the respective image. Color code of the scheme: cortices = yellow, periosteal
callus = blue/green. Scale bar = 20µm
Although no Hif1α positive cells could be detected 3 days after surgery, strong signals were
again visible 7 d post-surgery (Fig. 4.6, indicated by an arrow). In the later healing phases,
no Hif1α signal was measurable in the regenerating bones.
The appearance of newly formed vessels and the necessary CD105+ precursor cells started
directly after osteotomy (CD105, green signal). The progenitor cells seemed to enter the
fracture area from the surrounding environment (Fig. 4.4–4.6). First, they were present as
single cells, later organized as vessel like structures (Fig. 4.7–4.9). In figure 4.10, a schematic
summary of the immunohistological findings is displayed, showing the characteristic
distribution of the analyzed targets over the healing cascade.
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Figure 4.7: M2 Macrophages infiltrated the fracture gap from the surrounding tissue. Immunohisto-
logical staining within a murine fractured femur 7 days post-surgery. Depicted is a scheme of the
analyzed area after osteotomy. The following cellular targets were stained: osteoblasts (osteocalcin,
OC, light blue), osteoclasts (cathepsin k, CK, green), CD4+ T cells, (CD4, red), CD8+ T cells (CD8,
green), B cells (B220, red), macrophages at different polarization states (MΦ, green; M1, light blue;
M2, red), Hif1α as an indicator of hypoxia (Hif1α, red) and newly formed vessels (CD105, green).
Stainings were done on consecutive bone sections, also including co-stainings on one slice. Arrows
indicate the stained target shown in the respective image. Color code of the scheme: cortices =
yellow, periosteal callus = blue/green. Scale bar = 20µm
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Figure 4.8: Cartilage was the predominant tissue within the fracture gap. Immunohistological
staining within a murine fractured femur 14 days post-surgery. Depicted is a scheme of the analyzed
area after osteotomy. The following cellular targets were stained: osteoblasts (osteocalcin, OC, light
blue), osteoclasts (cathepsin k, CK, green), CD4+ T cells, (CD4, red), CD8+ T cells (CD8, green), B
cells (B220, red), macrophages at different polarization states (MΦ, green; M1, light blue; M2, red),
Hif1α as an indicator of hypoxia (Hif1α, red) and newly formed vessels (CD105, green). Stainings
were done on consecutive bone sections, also including co-stainings on one slice. Arrows indicate the
stained target shown in the respective image. Color code of the scheme: cortices = yellow, periosteal
callus = blue/green, cartilage with hypertrophic chondrocytes = light blue area in the fracture gap.
Scale bar = 20µm
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Figure 4.9: The former cellular structure of the medullary cavity was almost reestablished. Im-
munohistological staining within a murine fractured femur 21 days post-surgery. Depicted is a
scheme of the analyzed area after osteotomy. The following cellular targets were stained: osteoblasts
(osteocalcin, OC, light blue), osteoclasts (cathepsin k, CK, green), CD4+ T cells, (CD4, red), CD8+ T
cells (CD8, green), B cells (B220, red), macrophages at different polarization states (MΦ, green; M1,
light blue; M2, red), Hif1α as an indicator of hypoxia (Hif1α, red) and newly formed vessels (CD105,
green). Stainings were done on consecutive bone sections, also including co-stainings on one slice.
Arrows indicate the stained target shown in the respective image. Color code of the scheme: cortices
= yellow, periosteal callus = blue/green. Scale bar = 20µm
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Figure 4.10: Schematic summary of the immunohistological findings. Displayed is the distribution of
the analyzed cell types over the healing cascade: 1-3 days (hematoma phase), 7 days (fibrocartilage
phase), 14 days (cartilage phase) and 21d (woven bone/remodeling phase). The different cell types
are displayed by the indicated color code which is defined in the respective scheme of the different
bone healing phases. Colors in the bone scheme: cortices = black, hematoma = rose, callus = blue,
cartilage with chondrocytes = light blue with black dots, and newly formed bone = yellow.
4.1.3 Systemic distribution of specific immune cell subsets over the healing
process
In addition to the tissue and cellular distribution within the fractured bone itself, possible
systemic changes in the organism over the healing process were also of interest for the study.
Therefore, the composition of distinct cellular subsets of the adaptive immune system was
analyzed by flow cytometry. The study focused on the population of CD4+ and CD8+ T cells.
The T cells were analyzed in total as well as the population of activated ones. Furthermore,
effector and memory T cell subsets and the subpopulation of CD4+ TReg were evaluated. In
addition, possible changes in the interplay of TReg and effector T cells were one of the main
interests during the evaluation of the therapeutic intervention approach of this study (Chap.
4.2, 4.3). In order to analyze changes in the cellular distribution of the above mentioned cell
populations, the following tissues were analyzed: spleen and bone marrow as parts of the
lymphoid system as well as the peripheral blood. The bone marrow is the place where most
of the memory T cells, but also TReg reside. A main proportion of TReg is further located
within the spleen, one of the main tissues of the lymphatic system. The peripheral blood was
also chosen for these analyses because it is directly interconnected to the vascular system of
the fractured bone. Thereby, cellular processes actually taking place, like the recruitment
of certain cell subsets as e. g. effector T cells, could be visualized in the organism over the
healing cascade.
The proportion of the population of total CD4+ and CD8+ T cells within the pool of
CD3+TCRαβ+ T cells clearly decreased directly after surgery in all three tissues (Fig. 4.11
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A). This decrease could also be detected in the bone marrow for CD4+CD25+ T cells, and in
all three organs for the subset of CD8+CD25+ T cells (Fig. 4.11 B). This clearly illustrates the
homogeneous impact of the surgery on the systemic cellular distribution. The percentage of
CD4+ T cells instantly increased in the early fracture healing phase, afterwards a constant
decrease was visible in all three tissues over the later healing phases. Nevertheless, the total
population of CD4+ T cells was not different in the three analyzed tissues during the healing
process. In contrast, the proportion of the CD8+ T cell population increased from day 1/2 in
the blood and spleen over the healing cascade. This increase was more distinct in the blood
regarding the pre-surgery value. In the bone marrow, in contrast, the percentage of CD8+ T
cells decreased over the healing period.
The compartment of CD4+CD25+ and CD8+CD25+ T cells (including activated T cells and
TReg) stayed relatively stable over the healing time in the blood and the spleen (Fig. 4.11
B). A different picture was detected for these cells in the bone marrow. The percentage
of CD4+CD25+ T cells first increased at 3 d and further strongly decreased again in the
granulation/fibrocartilage/cartilage phases. This was followed by an increase again till day
21, reaching almost the pre-osteotomy value (Fig. 4.11 B left). For the CD8+CD25+ T cells,
approximately the same picture was also seen; just to a higher extend (Fig. 4.11 B right).
The following T cell subpopulations of both T cell compartments were also investigated:
effector T cells, effector memory T cells and central memory T cells. For CD8+ T effector cells,
a negative impact in bone repair was already shown in human and mice samples [4]. The
three cell subpopulations were gated as follows: effector T cells (TEF): CD4+ or CD8+/CD62L-
CCR7-CD25+; effector memory T cells (TEFM): CD4+ or CD8+/CD62L-CCR7-CD25- and
central memory T cells (TCM): CD4+ or CD8+/CD62L+CCR7+.
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Figure 4.11: CD4+ and CD8+ T cells, as well as their CD25+ subsets showed different expression
pattern over the healing cascade of an unaltered bone repair process. Percentage of CD4+ and CD8+
T cells in blood, bone marrow and spleen (A), percentage of CD4+CD25+ and CD8+ CD25+ T cells
(activated T cells and TReg) in all three tissues (B). CD4+ and CD8+ T cells were calculated on the
basis of gated CD3+/TCRαβ+ T cells and CD25+ T cells on the basis of gated CD4+ and CD8+ T
cells. Blue: pre-surgery, green: 1 day post-surgery, beige: 2 d, purple: 3 d, yellow: 7 d, red: 14 d, light
blue: 21 d. n=5–6
For the CD4+ and CD8+ TEF, their proportions decreased in the hematoma phase (Fig. 4.12
A, 4.13 A, TEF). Afterwards, the percentages increased again, for the bone marrow and
the spleen even higher as the pre-surgery value. For all three tissues, the value of the pre-
osteotomy state was somewhere in between the values detected at the different harvesting
time points. The CD4+ and CD8+ TEFM subpopulation showed higher percentages directly
after surgery in all three tissues. This illustrates again the consistent impact of the surgery
on these cellular subsets (Fig. 4.12 A, 4.13 A, TEFM). Concerning their behavior over the
healing period, they stayed relative constant in all three tissue types.
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Figure 4.12: CD4+ effector T cells were upregulated during the regeneration of an unaltered bone
repair process. CD4+ TEF, TEFM and TCM distribution over the healing cascade of an unaltered bone
repair process. Flow cytometry analysis of the percentage of CD4+ TEF and TEFM (A), percentage
of CD4+ TCM (B) in blood, bone marrow and spleen. Cells were calculated on the basis of gated
CD3+/TCRαβ+/CD4+ T cells. Blue: pre-surgery, green: 1 day (d) post-surgery, beige: 2 d, purple:
3 d, yellow: 7 d, red: 14 d, light blue: 21 d. n=5–6
However, they slightly in- and decreased between the early and late healing phase in the
distinct organs. For all, the pre-surgery value was the lowest with regard to the one of the
other healing time points. This demonstrates a consistent tissue independent increase. The
subpopulation of TCM of the CD4+ and CD8+ compartments displayed a decrease due to the
surgery. This was followed by a further constant decrease in the bone marrow and spleen
(Fig. 4.12 B, 4.13 B, TCM). In contrast, in the blood, the percentage of TCM slightly increased
over the healing cascade, reaching the pre-surgery value after 21 d. The pre-surgery values
were almost equal in all three tissues. CD4+ TReg were identified by the marker set of CD4,
CD25 and FOXP3 (Fig. 4.14). In the bone marrow, their proportion constantly increased
over the healing process. This was not seen in the peripheral blood and spleen. In these
two organs, the percentage of TReg stayed relative constant during the regeneration process.
These findings clearly illustrate the different behavior of the three analyzed tissues regarding
the proportion of TReg during bone regeneration.
CHAPTER 4. RESULTS 59
Figure 4.13: CD8+ effector T cells were upregulated during the regeneration of an unaltered bone
repair process. CD8+ TEF, TEFM and TCM distribution over the healing cascade of an unaltered bone
repair process. Flow cytometry analysis of the percentage of CD8+ TEF and TEFM (A), percentage
of CD8+ TCM (B) in blood, bone marrow and spleen. Cells were calculated on the basis of gated
CD3+/TCRαβ+/CD8+ T cells. Blue: pre-surgery, green: 1 day (d) post-surgery, beige: 2 d, purple:
3 d, yellow: 7 d, red: 14 d, light blue: 21 d. n=5–6
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Figure 4.14: CD4+ TReg showed different expression pattern over the healing cascade of an unaltered
bone healing process. Percentage of CD4+ TReg in blood, bone marrow and spleen. CD4+ TReg were
calculated on the basis of gated CD3+/CD4+ T cells. Blue: pre-surgery, green: 1 day (d) post-surgery,
beige: 2 d, purple: 3 d, yellow: 7 d, red: 14 d, light blue: 21 d. n= 6
4.2 Therapeutic intervention in a mouse osteotomy model
In the here presented part of my thesis, I focused on the potential positive impact of TReg in
an unaltered fracture healing process. I also focused on the systemic distribution of TEF and
memory cells of CD4+ and CD8+ T cells in order to include their interaction in the healing
cascade as potential "bad guys" into my analyses. CD8+ TEMRA were already identified as
an unfavorable cell population for a successful healing outcome [4]. This was shown in
blood samples from human fracture patients with a delayed healing outcome as well as in
the also for this study used mouse osteotomy model.
4.2.1 Therapeutic intervention: Adoptive transfer of murine regulatory T
cells prior to surgery
4.2.1.1 Characterization of freshly isolated and pre-activated murine
regulatory T cells
The population of TReg consists of two main subpopulations: thymus-derived nTReg and
in the periphery induced iTReg. In addition, iTReg can also be induced in vitro out of
CD4+FOXP3-T cells, under T cell receptor (TCR) stimulation and a simultaneous presence
of TGF-β and rmIL-2. Although the phenotypical and functional discrimination between
nTReg and iTReg is still under debate, iTReg are described to be more involved in foreign
antigen driven immune reactions, chronic inflammatory conditions and tolerance of mucosal
surfaces. In contrast, nTReg exhibit more involvement in auto-antigen related circumstances
balancing the immune homeostasis [122, 123]. For the here presented study, murine TReg
isolated from spleen and lymph nodes of donor mice by MACS were used, representing the
pool of nTReg. After MACS, the purity of isolated TReg was validated by flow cytometry.
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Figure 4.15: MACS technique is a useful method to isolate murine CD4+ TReg. Representative flow
cytometry scheme of a MACS purification. Shown are the different cell fractions of the MACS
procedure: cells prior to isolation (A), CD4- T cell fraction (B), CD4+CD25- T cell fraction (C) and the
isolated TReg (D). The gating scheme was as follows: FCS/SSC→ living cells (LD-)→ CD3+CD4+→
CD25+FOXP3+. Percentages of the gated cells are indicated in the respective dotplots and represent
the proportion of cells based on the former gated cell population (frequency of parent).
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Figure 4.16: Murine CD4+ TReg were isolated with a high purity by MACS purification. The
percentage of purified murine TReg was based on the population of living cells. n= 12.
An exemplary flow cytometry analysis of one TReg isolation is presented in figure 4.15.
Depicted are the different fractions taken during the MACS purification procedure (sample
prior to purification; CD4- fraction; CD4+CD25- fraction and purified TReg (CD4+CD25+)
(Fig. 4.15 A–D). TReg were isolated with a purity of ≥ 85 % based on the living cells (Fig.
4.16).
After confirming the high purity of MACS isolated murine TReg, their functionality also had
to be evaluated prior to transfer into recipient mice. In human approaches of immunotherapy
where TReg are used, TReg are isolated from the peripheral blood of the patient, taken in
culture, expanded and transferred back to the patient [124, 125, 126]. Thus, TReg become
pre-activated prior to their use in the patient. Based on this procedure, the question arises
whether murine TReg also have to be pre-activated before adoptive transfer in my study.
Therefore, before testing their functionality, I established a pre-activation culture of freshly
isolated murine TReg using α-CD3/α-CD28 antibodies for the TCR stimulation and two
different concentrations of the interleukin rmIL-2: 50 ng/ml and 360 ng/ml, respectively.
Cultured cells were harvested at different time points: 12 h, 24 h, 48 h and 72 h. Already
after a cultivation of 12 h, the percentage of living cells decreased for both concentrations of
rmIL-2. This was even more clearly seen at the later cultivation time points. Furthermore,
the percentage of CD3+CD4+ T cells in the population of living cells decreased from 12 h
to 72 h by half from around 80 % to 40 % (also for both concentrations of rmIL-2) (Tab.
4.1). The percentage of CD25+FOXP3+ TReg cells within the CD3+CD4+ population stayed
relative stable over the different pre-activation periods (∼50–60 %). The surface marker
CD69 was included into the flow cytometry analysis after TReg cultivation in order to
evaluate the activation of cultured TReg. The expression of CD69 was only evaluated from
the CD25highFOXP3+ TReg (Fig. 4.17 B). An increase of the expression of CD69 was seen
as an indication of an activation of TReg due to the cultivation. For both concentrations of
rmIL-2, the expression of CD69 decreased from 12 h to 48 h (∼50 % to ∼20 %), followed by an
increase to 72 h (∼70 %).
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Table 4.1: Pre-activation of freshly isolated murine TReg. Two different concentrations of murine
recombinant IL-2 (mrIL-2) were used. Illustrated are the percentages of the different cell populations
after flow cytometry analysis as frequency of parent at the respective time points of harvest.
Approach Time CD3+CD4+ CD25+FOXP3+ CD25high CD69+
[%] [%] [%] [%]
rmIL-2 12 h 86.0 87.0 60.1 51.8
50 ng/ml 24 h 63.8 86.1 51.9 33.1
48 h 48.5 85.5 49.5 29.0
72 h 42.1 82.9 51.8 70.6
rmIL-2 12 h 86.6 86.9 64.5 55.6
360 ng/ml 24 h 62.5 84.8 56.9 24.0
48 h 52.4 84.0 42.7 24.9
72 h 43.3 85.3 59.0 70.7
Although there was a higher expression of CD69 after a pre-activation culture of 72 h, I
decided to test the functionality of pre-activated murine TReg after a cultivation of 12 h and
with the higher amount of rmIL-2 (360 ng/ml). The reason therefore was the rapid decrease
of living cells and of the proportion of the CD3+CD4+ cell population within an ongoing
cultivation. The rationale for the higher amount of rmIL-2 was that the CD25highFOXP3+
TReg showed a slightly higher percentage in the culture with the higher rmIL-2 (64.5 % vs.
60.1 %) as well as a slightly higher expression of CD69 compared to the culture with 50 ng/ml
rmIL-2 (55.6 % vs. 51.8 %) (Tab. 4.1). An exemplary flow cytometry analysis is shown in
figure 4.17, illustrating the gating for the freshly isolated (A) and further for the pre-activated
TReg (360 ng/ml) (B). Figure 4.17 C represents an overlay of the histogram for the CD69
expression of CD25highFOXP3+ TReg of freshly and pre-activated ones, showing clearly the
shift of the expression after pre-activation culture.
For the functionality test, the suppressive capacity of freshly isolated and pre-activated TReg
was evaluated in a TReg suppression assay. The basic principle of this suppression assay
is a co-culture setup of CD4+CD25- responder T cells (TResp) and TReg. If functional, TReg
suppress the proliferation of the TResp in a concentration dependent manner.
In figure 4.18, a gating scheme of a flow cytometry analysis of the 1 to 2 setup (TResp to TReg)
is exemplary illustrated. The proliferation of the TResp was visualized by a cell proliferation
dye (CPD eF450). After a culture of 2 days, the fluorescence signal of CPD eF450 shifts to
the left, indicating the proliferation of the labeled TResp cells (Fig. 4.18 E). To a lesser extent,
this shift was also seen when twice as much TReg as TResp were co-cultured in one well (Fig.
4.18 A–D). This illustrates the suppressive effect of freshly isolated TReg. In figure 4.18 B,
the different generations of the proliferating TResp cells are depicted in the CD25 APC/ CPD
eF450 gate. Pre-activated TReg did not show this concentration dependent suppressive effect
on the proliferation of TResp cells anymore (Fig. 4.19 A–D).
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Figure 4.17: Pre-activation of freshly isolated murine CD4+ TReg led to an upregulation of CD69.
Flow cytometry analysis of the pre-activation of freshly isolated murine TReg. Illustrated are the
freshly isolated TReg (A), the pre-actived ones (B) and an overlay of the histograms of the expression
of the surface marker CD69 of both (C).
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Figure 4.18: Freshly isolated CD4+ murine TReg suppressed the proliferation of co-cultured
CD4+CD25- responder T cells. Illustrated is the flow cytometry evaluation of the suppression
assay. A–C shows the gating scheme of the co-culture setup of CD4+CD25- TResp cells to TReg 1 to 2,
at 0 d (A), at the time point of harvest after 2 d (B) and the overlay of the cell proliferation dye eF450
signal (C). The co-culture setup of 1 to 0.2 is depicted by the respective histograms of the CPD eF450
signal (D). E–G represents internal assay controls: proliferation of TResp alone (E); labeled TResp to
unlabeled TResp 1 to 1 (F) and unstimulated TResp (G). Arrangement of histograms: left: 0 d, middle:
2 d, right: overlay of both time points. Color code of the overlay histograms: red = CPD eF450 signal
at 0 d; blue = CPD eF450 signal at the day of harvest (2 d).
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Figure 4.19: Pre-activated murine CD4+ TReg failed to suppress the proliferation of co-cultured
CD4+CD25- responder T cells. Illustrated are the histograms of the CPD eF450 signal of the different
culture setups. CD4+CD25- TResp cells to TReg 1 to 2 (A), CD4+CD25- TResp cells to TReg 1 to 0.2
(B), proliferation of TResp alone (C) and labeled TResp to unlabeled TResp 1 to 1 (D). Arrangement
of histograms: left: 0 d, middle: 2 d, right: overlay of both time points. Color code of the overlay
histograms: red = CPD eF450 signal at 0 d; blue = CPD eF450 signal at the day of harvest (2 d).
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Figure 4.20: Graphical evaluation of the TReg suppression assay confirmed the successful suppression
of the proliferation of CD4+CD25- responder T cells only when co-cultured with freshly isolated
murine CD4+ TReg. Illustrated is the suppression of proliferation of CD4+CD25- TResp cells using
freshly isolated TReg (left) or pre-activated TReg (right). Two different co-culture setups were performed:
TResp to TReg 1 to 2 and TResp to TReg 1 to 0.2. TResp cells were also cultured alone (Tresponder eF450).
n= 6
In figure 4.20, the graphical evaluation of the TReg suppression assays using fresh (left) and
pre-activated TReg (right), respectively, is shown (n= 6). Represented is the suppression of
the proliferation of TResp cells (after co-cultivation with TReg), based on the proliferation
of labeled TResp cells that were cultured alone. This graphic clearly illustrates that the
pre-activation of freshly isolated murine TReg correlated with a loss of their suppressive
capacity in relation to the proliferation of murine CD4+CD25- TResp that were cultured alone.
Based on the findings from the pre-activation culture and the TReg suppression assay, freshly
isolated murine TReg were used for the following therapeutic intervention approaches in
vivo.
4.2.1.2 Confirmation of adoptive transfer of regulatory T cells in recipient
mice
Prior to starting with the experimental mice to evaluate the potential positive impact of TReg
in bone healing after enrichment, the adoptive transfer of intravenously injected TReg (into
the tail vein) into recipient mice was confirmed. For this analysis, depletion of regulatory
T cell (DEREG) mice were used as donors [127]. In these mice, FOXP3+ TReg express an
enhanced green fluorescence protein (eGFP) signal under the control of the FOXP3 gene
locus. Therefore, the occurrence of TReg in the recipient C57BL/6N mice can be followed by
flow cytometry due to the present GFP signal. For the adoptive transfer, TReg were isolated
from spleen and lymph nodes of three DEREG donor mice via MACS. Prior to MACS
seperation, a small aliquot of the pooled splenocytes and lymph node cells, respectively, and
from the peripheral blood of the donor mice were taken in order to analyze the percentage
of GFP+ TReg in the respective tissues (Fig. 4.21 A). Around 80–90 % of the donor TReg
cells expressed a GFP signal in the respective tissues. Freshly isolated DEREG TReg were
adoptively transferred into two recipient mice (5x105 cells per animal) and the transfer was
checked after 24 h. In all three analyzed tissues, GFP+ TReg could be detected confirming the
transfer of donor cells (blood: ∼50 %; spleen: ∼20 %; LN: ∼10 %) (Fig. 4.21 A). In addition
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Figure 4.21: Adoptively transferred freshly isolated murine CD4+ TReg were detectable in recipient
mice. DEREG mice were used as donors (FOXP3+ TReg are eGFP labeled) (A). Status of CD4+CD25++
T cells in the peripheral blood of the experimental mice 1 d post-surgery WT vs TReg enriched mice
(TReg+) (B). Blue: percentage of eGFP signal in gated TReg in DEREG mice; green: percentage of eGFP+
TReg in recipient mice 24 h after adoptive transfer. The following organs were analyzed: Peripheral
blood (Blood), spleen and lymph node (LN). (A) n= 1–3, (B) n= 6; *p= 0.015; Mann-Whitney U test.
to the DEREG approach, the percentage of CD4+CD25++ T cells (representing the TReg
population) in the peripheral blood of mice was investigated at the following time points:
1 d post-surgery for WT mice and 1 d post-surgery for TReg enriched mice (Fig. 4.21 B). The
TReg enriched mice displayed a significantly higher proportion of CD4+CD25++ T cells with
regard to the WT 1 d post-surgery. This further confirms the successful adoptive transfer of
TReg.
4.2.1.3 Evaluation of therapeutic potential of regulatory T cells under SPF
conditions
The evaluation of the therapeutical potential of murine TReg in bone regeneration started
after confirming the purity of isolated TReg, their suppressive potential and the adoptive
transfer procedure (Chap. 4.2.1.1 and 4.2.1.2). From SPF housed donor mice, cells of the
spleen and lymph nodes were pooled, TReg isolated and equally distributed and adoptively
transferred into SPF housed recipient mice (5–7.5x105 TReg per mouse) (further termed: SPF
TReg+). All SPF TReg+ mice showed a complete bridging (n= 6) (Fig. 4.22 A, right). In
comparison, the corresponding wild type control (SPF WT, mice which were also housed
under SPF conditions and which also underwent an osteotomy) was not yet completely
bridged after 21 d (Fig. 4.22 A, left). The quantification of the µCT evaluation is depicted in
figure 4.22 B. SPF TReg+ mice showed a higher BV (p= 0.082), BV/TV (p= 0.017) and BMD
(p= 0.03) in comparison to the SPF WT mice. In conclusion, under SPF housing conditions,
I could confirm that an enrichment of TReg prior to surgery leads to a significantly better
healing outcome in our non-critical size defect mouse osteotomy model when compared to
an untreated but also fractured control group.
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Figure 4.22: Adoptive transfer of TReg in SPF housed mice improved the healing outcome after
21 d, µCT evaluation. In A, representative images of the analyzed volume of interest of the healing
bones are shown. TReg enriched mice showed complete bridging after 21 d (A, right, SPF TReg+),
whereas the control group did not completely heal after 3 weeks (A, left, SPF WT). In the two lower
pictures, the 3D images of the healing bones are cut sagittally/frontally to demonstrate the progress
of the remodeling process. The color code indicates the mineralization state, with an increasing
mineralization from black to white and blue to red, respectively. The quantification of the µCT data
revealed a significantly higher BV/TV and BMD (B). TV= total volume, BV= bone volume, BV/TV=
ratio of BV to TV, BMD= bone mineral density. *p= 0.017 (BV/TV), *p= 0.03 (BMD), #p= 0.082; n=
5–6; Mann-Whitney U test.
4.2.1.4 Changes in the murine immune system under SPF and semi-sterile
housing conditions
Using SPF housed mice, I could confirm the therapeutic potential of freshly isolated murine
TReg to improve bone fracture healing when adoptively transferred prior to surgery (Chap.
4.2.1.3). SPF housed animals are kept in a specific pathogen free environment. Therefore, the
immune system of these animals is less experienced in comparison to animals kept under
non-SPF conditions. Even more relevant, the immune system of these SPF housed animals is
less experienced with regard to the patient situation in the clinic. In order to have a clinically
more relevant situation, the positive potential of TReg enrichment prior to osteotomy was
analyzed under non-SPF housing conditions of the experimental mice.
Before repeating the adoptive transfer experiments, I investigated the changes of the murine
immune system due to the different housing conditions without creating an osteotomy in
these animals. The immune cell composition of differently housed mice was evaluated in
the peripheral blood, the spleen and the bone marrow by flow cytometry.
For CD4+ and CD8+ T cells, there were no differences detectable in animals kept under
different housing conditions for all three analyzed tissues (Fig. 4.23 A). In contrast, the per-
centage of CD4+CD25+ and CD8+CD25+ T cells was significantly higher in the semi-sterile
mice compared to SPF housed mice (p= 0.016) (Fig. 4.23 B).
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Figure 4.23: Semi-sterile housing led to an increase of CD4+CD25+ and CD8+CD25+ T cells in
comparison to SPF housed mice. CD4+ and CD8+ T cell distribution in SPF and semi-sterile housed
mice. Percentage of CD4+ and CD8+ T cells in blood, bone marrow and spleen (A), percentage of
CD4+CD25+ and CD8+CD25+ T cells (activated T cells and TReg) in all three organs (B). CD4+ and
CD8+ T cells were calculated on the basis of gated CD3+/TCRαβ+ T cells and CD25+ T cells on the
basis of gated CD4+ and CD8+ T cells. grey: SPF housing, red: semi-sterile housing, *p= 0.016, n=
5–6; Mann-Whitney U test.
The population of effector, effector memory and central memory T cells was also investigated
(Fig. 4.24 and 4.25). The marker CD44 was further included into this and the following anal-
yses, in order to distinguish more precisely between naïve and memory T cells (naïve: CD44-;
memory: CD44+). The three subpopulations were gated as follows: effector T cells: CD4+ or
CD8+/CD44+/CD62L-/CD25+ (TEF); effector memory T cells: CD4+ or CD8+/CD44+/CD62L-
/CD25- (TEFM) and central memory T cells: CD4+ or CD8+/CD44+/CD62L+ (TCM).
Semi-sterile housed mice displayed a higher percentage of CD4+ T effector cells in the
spleen (p= 0.052) when compared to the WT group (Fig. 4.24 A). The proportion of CD4+
effector memory T cells was higher in the SPF mice in comparison to the semi-sterile
animals (p= 0.032) (A, B). The CD4+ central memory T cells displayed a lower percentage
in the semi-sterile mice vs. the SPF animals in the spleen (p= 0.095). Regarding the CD8+
splenocyte population, semi-sterile housed mice possess a significantly higher percentage of
T effector cells (p= 0.008) (Fig. 4.25 A). The proportion of central memory CD8+ T cells was
significantly lower in the spleen in the semi-sterile mice vs. SPF mice (p= 0.016) (Fig. 4.25 B).
Further, I investigated the population of TReg in all three analyzed tissues. Interestingly,
in the bone marrow, a significantly higher proportion of CD4+ TReg was found in the
semi-sterile animals with regard to the SPF mice (p= 0.03) (Fig. 4.26). The blood and the
spleen showed an equal distribution of TReg between both housing conditions.
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Figure 4.24: Semi-sterile housing led to changing proportions of CD4+ effector, effector memory and
central memory T cells in comparison to SPF housed mice. CD4+ effector, effector memory and
central memory T cell distribution in SPF and semi-sterile housed mice. Flow cytometry anylsis of
the percentage of CD4+ T effector (TEF) and T effector memory T cells (TEFM) (A), percentage of CD4+
central memory T cells (TCM) (B) in blood, bone marrow and spleen. Cells were calculated on the
basis of gated CD3+/TCRαβ+/CD4+ T cells. grey: SPF housing, red: semi-sterile housing, *p= 0.032,
#p= 0.056 (A), #p= 0.095 (B), n= 5–6; Mann-Whitney U test.
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Figure 4.25: Semi-sterile housing led to changing proportions of CD8+ effector, effector memory and
central memory T cells in comparison to SPF housed mice. CD8+ effector, effector memory and
central memory T cell distribution in SPF and semi-sterile housed mice. Flow cytometry analysis of
the percentage of CD8+ T effector (TEF) and T effector memory T cells (TEFM) (A), percentage of CD8+
central memory T cells (TCM) (B) in blood, bone marrow and spleen. Cells were calculated on the
basis of gated CD3+/TCRαβ+/CD8+ T cells. grey: SPF housing, red: semi-sterile housing, *p= 0.008
(TEF) (A), *p= 0.016 (B), n= 5–6; Mann-Whitney U test.
Figure 4.26: Semi-sterile housing led to an increase of CD4+ TReg in comparison to SPF housed mice.
CD4+ TReg cell distribution in SPF and semi-sterile housed mice. Percentage of CD4+ TReg in blood,
bone marrow and spleen. CD4+ TReg were calculated on the basis of gated CD3+/CD4+ T cells. grey:
SPF housing, red: semi-sterile housing, *p= 0.03; n= 6; Mann-Whitney U test.
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4.2.1.5 Evaluation of the healing outcome after enrichment of regulatory T
cells under semi-sterile conditions
The housing of the experimental mice in a semi-sterile environment effectively influenced
the immune cell composition in these animals towards a higher experienced immune status
(Chap. 4.2.1.4). For a clinically more relevant approach, I repeated the evaluation of the
healing outcome after adoptive TReg transfer, this time using donor and recipient mice
housed in a semi-sterile environment.
A controversial picture was observed regarding the healing outcome of the TReg enriched
mice (Fig. 4.27, TReg+). Four of the eight operated mice showed a significantly better healing
and the other four a significantly less good healing compared to the WT group (Fig. 4.27
and 4.28 B). In figure 4.27, representative µCT images of the healing bones after 21 d are
presented. As comparison, the images from the SPF approach were also included into the
figure. Regarding the slightly better healing outcome of SPF WT in comparison to the WT
mice, it already demonstrated the improved healing outcome under SPF housing, already
implicating the partial negative impact of the adaptive immune system in fracture repair
[12]. But also between the good healer of the TReg+ mice (Fig. 4.27, TReg+ left) and the SPF
TReg+ animals, it seemed that the SPF TReg+ displayed a more progressed remodeling of the
fracture area, following the cut µCT images (Fig. 4.27, lower picture). Regarding the TReg+
animals as one group, without dividing between good and bad healing mice, no differences
in the quantification of the µCT results were observed with regard to the WT control group
(Fig. 4.28 A). After separating the different healing outcome of the TReg enriched mice into
two groups (good healer: TReg+ good; bad healer: TReg+ bad), a better healing of the TReg+
good mice could be observed in comparison to the WT which was even significant for TV
and BV (Fig. 4.28 B; p= 0.01 (TV and BV), p= 0.038 (BV/TV)). TReg+ bad mice revealed a
significantly poorer healing outcome vs. the WT animals (Fig. 4.28 B; p= 0.01 (TV and BV)).
Therefore, a better healing outcome was detected for all four analyzed parameters in the
TReg+ good with regard to the TReg+ bad mice (p= 0.029). Histomorphometrical analysis
confirmed the observed differences in the healing outcome between the TReg+ good and
TReg+ bad mice (Fig. 4.30). In figure 4.29, representative Movat Pentachrome pictures are
shown, illustrating the complete bridging in the TReg+ good group and the sealed medullary
canal of the non-bridging in the TReg+ bad healing group. Although the bone parameters
were not significantly different between the WT and the two TReg+ groups, the graphs
clearly support the observed findings of the µCT. The content of connective tissue in the
analyzed area was increased in the TReg+ bad mice with regard to the WT mice (p= 0.029).
This is a clear indication for the non-bridging of these TReg enriched mice characterized
by an accumulation of connective tissue between the closed fracture ends. The cartilage
fraction was higher in WT animals vs. the TReg+ bad and TReg+ good mice (p= 0.029 (TReg+
bad), p= 0.057 (TReg+ good)).
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Figure 4.27: Adoptive transfer of CD4+ murine TReg in semi-sterile housed mice led to a controversial
healing outcome after 21 d, µCT evaluation. Representative images of the analyzed volume of interest
of the healing bones are shown. WT mice, housed in a semi-sterile environment, showed no complete
bridging after 21 d (left, WT). In contrast, TReg enriched animals under semi-sterile housing conditions
displayed a controversial healing outcome: four mice showed complete bridging (TReg+ left), wheras
four mice showed no bridging (TReg+ right). µCT images from the corresponding groups under SPF
conditions are also depicted as comparison (SPF WT and SPF TReg+). In the lower pictures, the 3D
images of the healing bones are cut sagittally/frontally to demonstrate the progress of the remodeling
process. The color code indicates the mineralization state, with an increasing mineralization from
black to white and blue to red, respectively. n= 4–6
Figure 4.28: Adoptive transfer of CD4+ murine TReg in semi-sterile housed mice led to a controversial
healing outcome after 21 d, µCT quantification. The healing outcome of the TReg enriched mice
(TReg+) revealed a controversial healing outcome. Regarding the TReg+ animals as one group, no
differences were observed vs. the WT control (A). Separating the good and bad healing TReg+ mice,
TReg+ good displayed a significant better and the TReg+ bad a significant poorer healing outcome
with regard to the WT (B). TV= total volume, BV= bone volume, BV/TV= ratio of BV to TV, BMD=
bone mineral density. *p=0.01–0.029, #p= 0.029–0.038; n= 4–6; Mann-Whitney U test, Bonferroni
correction.
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Figure 4.29: Movat Pentachrome stainings confirmed the controversial healing outcome observed
after 21 d after adoptive TReg transfer in semi-sterile housed mice. Movat Pentachrome stainings
of regenerating murine femora of WT, TReg+ good and TReg+ bad mice after 21 d. Representative
images of each group are shown, on the left as the total femur, on the right as a magnification of the
gap area. Coloration of the following tissues: mineralized bone and cartilage= yellow, cartilage=
blue/green, connective tissue= bluish, bone marrow= purple and cell nuclei= black. Error bars of the
magnifications: 200µm.
Figure 4.30: Histomorphometrical analysis of the tissue distribution confirmed the controversial
healing outcome observed after 21 d after adoptive TReg transfer in semi-sterile housed mice. Based
on Movat Pentachrome stainings done on tissue cryo-sections from WT and TReg enriched mice, the
distribution of different tissue types within the fracture area was evaluated. n= 3–4; #p= 0.029–0.057;
Mann-Whitney U test, Bonferroni correction.
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Figure 4.31: Adoptively transferred TReg were still detectable after 21 d in the semi-sterile housed
mice, independent from the healing outcome. CD4+ TReg cell distribution in WT and TReg enriched
mice kept under semi-sterile housing conditions after 21 d. Percentage of CD4+ TReg in blood, bone
marrow and spleen. CD4+ TReg were calculated on the basis of gated CD3+/CD4+ T cells. green:
WT, pink: TReg+ good healer, purple: TReg+ bad healer, #p= 0.038–0.057; n= 3–6; Mann-Whitney U
test, Bonferroni correction.
One reasonable explanation for the observed controversial healing outcome could be an
unsuccessful adoptive transfer of TReg prior to osteotomy. Therefore, the percentage of TReg
was analyzed 21 days post-sugery in the adoptively transferred mice (Fig. 4.31). For both
TReg enriched groups (good and bad healer) a higher proportion of TReg was detected in
the spleen and bone marrow in comparison to the control WT group even after 21 d (bone
marrow: p= 0.057, spleen: p= 0.038). However, between both healing groups of the TReg
enriched mice, no differences in the percentage were detectable. Furthermore, also the
populations of total CD4+ and CD8+ T cells and their effector/effector memory and central
memory subsets were evaluated 21 d after surgery by flow cytometry. The total population
of CD4+ and CD8+ T cells was relative equal between the three groups in all three evaluated
tissues (Fig. 4.32 A). The highest percentage of CD4+ T cells was found in the spleen and the
lowest in the bone marrow. For the CD8+T cell subset, the highest percentage was detected in
the blood and a relative equal proportion in bone marrow and spleen. For CD4+CD25+ and
CD8+CD25+ T cells, the TReg enriched mice displayed a higher percentage in all three tissue
types, independent of the healing outcome (Fig. 4.32 B). Between both TReg enriched groups,
there was even a significantly higher proportion of the CD8+CD25+ T cells in the TReg+ bad
animals vs. the TReg+ good healer in the blood (p= 0.01) (CD4+CD25+: p= 0.029). Between
the WT and the TReg+ bad mice, the differences for both, CD4+CD25+ and CD8+CD25+ T
cells, were either significant (indicated by *) or a trend (indicated by #) in all three evaluated
tissues (CD4+CD25+: p= 0.01 (blood), p= 0.057 (bm), p= 0.01 (spleen); CD8+CD25+: p= 0.01
(blood), p= 0.057 (bm), p= 0.01 (spleen)). For the WT and the good healing TReg enriched mice,
differences in the percentage of CD4+CD25+ and CD8+CD25+ T cells, respectively, were
significant in the spleen (CD4+CD25+, p= 0.01; CD8+CD25+, p= 0.019) and blood (p= 0.038).
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Figure 4.32: WT and TReg enriched mice showed different expression pattern of CD4+CD25+ and
CD8+CD25+ T cells after 21 d under semi-sterile housing conditions. Percentage of CD4+ and CD8+
T cells in blood, bone marrow and spleen (A), percentage of CD4+CD25+ and CD8+CD25+ T cells
(activated T cells and TReg) in all three organs (B). CD4+ and CD8+ T cells were calculated on the
basis of gated CD3+/TCRαβ+ T cells and CD25+ T cells on the basis of gated CD4+ and CD8+ T
cells. green: WT, pink: TReg+ good healer, purple: TReg+ bad healer; *p= 0.01–0.038; #p= 0.029–0.057,
n= 4–6
The systemic distribution of CD4+ and CD8+ T effector, effector memory and central
memory T cells was further analyzed in peripheral blood, bone marrow and spleen. For this
analysis, only two of the six WT animals could be included into the evaluation. During my
thesis, we decided to modify the antibody panel for this staining by including the surface
marker CD44. This enabled me to distinguish more precisely between the naïve (CD44-)
and memory (CD44+) T cell subpopulations. However, four of the six WT animals had
already been operated and sacrificed and thus also measured by flow cytometry before
modifying the staining panel. Therefore, WT 1–4 were not included into the analysis of
the TEF/TEFM/TCM pool of CD4+ and CD8+ cells. In the CD4+ TEF subset, the WT was
higher in all three tissues (Fig. 4.33 A). In addition, the TReg+ bad mice displayed a higher
proportion in the blood and bone marrow vs. the TReg+ good mice (p= 0.029). The same
picture was seen in the CD8+ TEF cells (p= 0.057). The CD4+ TEFM subpopulation was
relatively equal distributed between the three groups in all three organs, showing the
highest percentage again in the bone marrow. A similar picture was seen in the corre-
sponding CD8+ T cells, whereas the WT displayed a slightly higher percentage in the
blood and spleen in comparison to the TReg enriched mice. For the central memory cells of
both T cell subsets, the TReg+ bad animals possessed a higher proportion in the bone mar-
row and spleen with regard to the TReg+ good mice (CD8+TCM: p= 0.029) (Fig. 4.33 B; 4.34 B).
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Figure 4.33: TReg enriched mice with a less good healing outcome had a higher proportion of CD4+
effector T cells in comparison to the good healing animals 21 d post-surgery. CD4+ effector, effector
memory and central memory T cell distribution in WT and TReg enriched mice kept under semi-sterile
housing conditions. Flow cytometry analysis of the percentage of CD4+ T effector (TEF) and T effector
memory T cells (TEFM) (A), percentage of CD4+ central memory T cells (TCM) (B) in blood, bone
marrow and spleen. Cells were calculated on the basis of gated CD3+/TCRαβ+/CD4+ T cells. green:
WT, pink: TReg+ good healer, purple: TReg+ bad healer, #p= 0.029; n= 2–4; Mann-Whitney U test,
Bonferroni correction.
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Figure 4.34: TReg enriched mice with a less good healing outcome had a higher proportion of CD8+
effector T cells in comparison to the good healing animals 21 d post-surgery. CD8+ effector, effector
memory and central memory T cell distribution in WT and TReg enriched mice kept under semi-sterile
housing conditions. Flow cytometry analysis of the percentage of CD8+ T effector (TEF) and T effector
memory T cells (TEFM) (A), percentage of CD8+ central memory T cells (TCM) (B) in blood, bone
marrow and spleen. Cells were calculated on the basis of gated CD3+/TCRαβ+/CD8+ T cells. green:
WT, pink: TReg+ good healer, purple: TReg+ bad healer, #p= 0.029; n= 2–4; Mann-Whitney U test,
Bonferroni correction.
4.2.2 Therapeutic intervention: CD25+ T cell depletion prior to surgery
The approach of the CD25+ T cell depletion prior to surgery was carried out in order to
evaluate the healing outcome after 21 d when TReg were absent at the moment of setting
the osteotomy. TReg are characterized by the expression of the surface marker CD25.
Several studies already reported a successful depletion of TReg by an anti-CD25 antibody
[128, 129, 130]. Thus, a specific monoclonal α-CD25 antibody was injected intraperitoneally
into semi-sterile housed mice for four consecutive injections, starting 3 days prior to
osteotomy (Fig. 4.35). The healing outcome was investigated after 21 d by µCT and
histomorphometry.
Before starting the experiment, the depletion of CD4+CD25+ T cells was confirmed (p=
0.008) (Fig. 4.36).
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Figure 4.35: Scheme of the experimental design of CD25+ T cell depletion. A monoclonal α-CD25
antibody was injected for four consecutive injections (intraperitoneal), starting 3 days prior to surgery
(-3 d). The healing outcome was evaluated after 21 days. ab= antibody
Figure 4.36: Confirmation of the depletion of CD25+ T cells. CD25+ T cells were depleted by four
consecutive injections of a monoclonal α-CD25 antibody. From depleted mice, blood samples were
taken pre- and post-depletion, respectively. The percentage of CD4+CD25+ T cells was investigated
by flow cytometry based on the population of CD3+CD4+ T cells. *p= 0.008; n= 5
Afterwards, the experimental mice were depleted and operated (further termed: CD25-).
After 21 d, the healing outcome was evaluated by µCT measurements (Fig. 4.37). In
comparison to the WT control group, no differences were observed in the CD25- mice
by µCT. This was also confirmed by the quantification of the µCT results (Fig. 4.37 B).
The histomorphometrical analysis of Movat Pentachrome stained cryo-sections confirmed
the picture of the healing outcome already observed by µCT (Fig. 4.39). In figure 4.38,
representative images of the Movat Pentachrome stained sections are displayed. A slight
increase of the proportion of mineralized bone was observed in the depleted animals with
regard to the WT. The presence of cartilage in the evaluated fracture area showed also
a higher proportion in the CD25- vs. the WT, however, again without being significant.
In addition to the µCT measurement and histomorphometrical analysis, flow cytometry
analyses were done 2 days post-surgery. The depletion of TReg was confirmed for all three
investigated tissues (Fig. 4.40). In accordance with the former flow cytometry analyses,
the proportion of effector and memory T cells were also investigated. The populations of
CD4+ and CD8+ effector T cells decreased or were even absent (Fig. 4.41). A clear decrease
was also observed for the effector memory T cell subpopulation after depletion (Fig. 4.42).
Statistical significances were not determined due to the small sample size of n= 3 for each
mice group.
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Figure 4.37: CD25+ T cell depletion did not lead to a changing healing outcome after 21 d in
comparison to the WT. µCT evaluation of the healing outcome after CD25+ T cell depletion under
semi-sterile conditions 21 d post-surgery. In A, representative images of the analyzed volume of
interest of the healing bones are shown (WT control group vs. CD25- mice). For both groups, no
complete bridging of the fractured bone was achieved after 21 d. In the two lower pictures, the 3D
images of the healing bones are cut sagittally/frontally to demonstrate the progress of the remodeling
process. The color code indicates the mineralization state, with an increasing mineralization from
black to white and blue to red, respectively. Quantification of the µCT data revealed no differences
between both groups (B). TV= total volume, BV= bone volume, BV/TV= ratio of BV to TV, BMD=
bone mineral density. n= 6
Figure 4.38: Movat Pentachrome stainings confirmed the unchanged healing outcome in the CD25+ T
cell depleted animals after 21 d in comparison to the WT. Movat Pentachrome stainings of regenerating
murine femora of WT and CD25- mice after 21 d. Representative images of each group are shown, on
the left as the total femur, on the right as a magnification of the gap area. Coloration of the following
tissues: mineralized bone and cartilage= yellow, hypertrophic cartilage= blue/green, connective
tissue= bluish, bone marrow= purple and cell nuclei= black. Error bars of the magnifications: 200µm.
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Figure 4.39: Histomorphometrical analysis of the tissue distribution confirmed the unchanged healing
outcome in the CD25+ T cell depleted animals after 21 d in comparison to the WT. Based on Movat
Pentachrome stainings performed on tissue cryo-sections from WT and CD25+ T cell depleted mice;
the distribution of different tissue types within the fracture area was evaluated. n= 4-6
Figure 4.40: CD4+ TReg depletion was confirmed in the CD25+ T cell depleted mice 2 d post-surgery.
CD4+ TReg cell distribution in WT and CD25- mice kept under semi-sterile housed conditions 2 d
post-surgery. Flow cytometry analysis in blood, bone marrow and spleen. CD4+ TReg were calculated
on the basis of gated CD3+/CD4+ T cells. green: WT, grey: CD25-. n= 3
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Figure 4.41: CD4+ effector and effector memory T cell depletion was confirmed in the CD25+ T cell
depleted mice 2 d post-surgery. CD4+ effector and effector memory T cell distribution in WT and
CD25- mice kept under semi-sterile housing conditions 2 d post-surgery. Flow cytometry analysis in
blood, bone marrow and spleen. Cells were calculated on the basis of gated CD3+/TCRαβ+/CD4+ T
cells. green: WT, grey: CD25-; n= 3
Figure 4.42: CD8+ effector and effector memory T cell depletion was confirmed in the CD25+ T cell
depleted mice 2 d post-surgery. CD8+ effector and effector memory T cell distribution in WT and
CD25- mice kept under semi-sterile housing conditions 2 d post-surgery. Flow cytometry analysis in
blood, bone marrow and spleen. Cells were calculated on the basis of gated CD3+/TCRαβ+/CD8+ T
cells. green: WT, grey: CD25-; n= 3
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4.3 Proof of concept approach: Prediction prior to surgery of
potential good and bad healer based on "immune balance"
Under 4.2, the impact of the adaptive immune system in fracture healing especially in
mice housed in a semi-sterile environment was investigated. A semi-sterile housing led
to a measurable activation of the adaptive immunity in comparison to housing under
SPF conditions: increasing percentage of CD4+CD25+, CD8+CD25+, CD4+ and CD8+
effector and regulatory T cells (Fig. 4.23, 4.24, 4.25, 4.26). Under semi-sterile conditions, a
controversial healing outcome was observed between the TReg enriched mice. 21 d post-
surgery, the ratio between CD8+ T effector and TReg was significantly higher in the TReg+ bad
vs. the TReg+ good animals (Fig. 4.43). In order to investigate whether the immune status of
a mouse prior to osteotomy is determining the healing outcome after TReg enrichment, a
proof of concept (POC) study was carried out. Therefore, blood samples were taken from
seven mice prior osteotomy to evaluate the ratio of CD8+ effector T cells to TReg. These ratios
are illustrated in table 4.2. The classification in a potential good or bad healing outcome
was done without knowing whether there is really a certain threshold that determines the
healing outcome and if yes, what value this threshold has. The cutoff was estimated to be
0.1 considering the ratios of the good and bad healing mice in the previous test. Mice with a
lower threshold were classified as a good healer and mice with a higher threshold as bad
healer.
Figure 4.43: TReg enriched mice with a less good healing outcome had a higher ratio of CD8+ effector
T cells to CD4+ TReg in comparison to the good healing animals. Ratio of CD8+ effector T cells to TReg
in the peripheral blood of TReg+ mice 21 d post-surgery. Mice housed under semi-sterile housing
conditions displayed a controversial healing outcome after TReg enrichment. Shown is the ratio
of the above mentioned T cell subpopulation of the TReg+ good healer and TReg+ bad healer mice,
respectively. *p= 0.029. n= 4
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Table 4.2: Ratio of CD8+ T effector cells to TReg in the peripheral blood of seven mice prior to surgery.
The predicted healing outcome is presented in the right raw. Numbers in the left raw represent the
internal mouse numbering.
Mouse Ratio CD8+ TEF/TReg Potential good or bad healer
1 0.048 good
2 0.078 good
5 0.107 bad
6 0.061 good
8 0.216 bad
13 0.060 good
16 0.049 good
TReg were freshly isolated, equally distributed to the recipient mice and the healing outcome
was investigated after 21 d. In figure 4.44, the resulting µCT pictures of the seven mice are
presented. A complete bridging was seen for mouse 1. Mice 6, 13 and 16 were still in the
process of bridging, but at the time point of harvest not yet completely bridged. Further,
a lack of bridging was observed for mice 2, 5 and 8. Comparing the µCT pictures and the
predicted healing outcome, the prediction was true for all mice except mouse 2. Based on
the estimated threshold of CD8+ effector T cells to TReg to 0.1, mouse 2 was determined as a
good healer. However, the healing outcome showed a lack of bridging, thus an unsuccessful
healing outcome. Mouse 2 showed the highest threshold regarding the predicted good
healer. Thus, the estimated threshold was eventually not correctly set in order to predict
the healing outcome. For the quantification of the µCT results, mouse 2 was included into
the group with a poor healing outcome (Fig. 4.45). The less good healing outcome of
the predicted non-healer was confirmed by the quantification of the µCT results. For the
quantification, the data of the WT mice from the study of TReg enrichment under semi-serile
conditions were used as controls (Chap. 4.2.1.5) (WT vs. bad healer; TV and BV: p= 0.024).
Also the improved healing outcome of the POC good healer was quantified with regard
to the WT animals (BV/TV: p= 0.038). For TV, BV and the ratio of both (BV/TV), the good
healer clearly displayed a higher value in comparison to the bad healer (p= 0.057).
In order to exclude that the poor healing outcome was the result of an unsuccessful adoptive
transfer of TReg, the proportion of TReg was determined 1 d post-surgery in peripheral blood
(Fig. 4.46). A higher percentage of TReg was detected in both healing groups after adoptive
transfer in comparison to the WT animals without a difference between the ensuing good
and bad healing animals.
In figure 4.47, the correlation of the pre-calculated ratio of CD8+ T effector and regulatory T
cells is demonstrated in a before-after-graph (graph for grouped data). The y-axis of the
ratio of CD8+ effector T cells/TReg is reverted in order to have a better graphical illustration.
This graphic clearly shows that the smaller ratio of both T cell subsets of the four mice with
a good healing outcome correlated with a higher BV/TV without any overlay with the mice
with a poorer healing outcome. Following, a linear regression analysis was performed with
these data (Fig. 4.47 B). The coefficient of determination was calculated as R2 = 0.6236.
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Figure 4.44: TReg enriched mice of the POC study displayed different healing outcomes after 21 d,
µCT evaluation. Mouse 1 was completely bridged; mice 6, 13 and 16 are still in the process of bridging
but not completely bridged yet; mice 2, 5 and 8 showed no bridging. In the lower pictures, the 3D
images of the healing bones are cut sagittally/frontally to demonstrate the progress of the remodeling
process. The color code indicates the mineralization state, with an increasing mineralization from
black to white and blue to red, respectively.
Figure 4.45: TReg enriched mice of the POC study displayed different healing outcomes after 21 d,
µCT quantification. TV= total volume, BV= bone volume, and BV/TV= ratio of BV to TV. #p=
0.024—0.057; n= 3–6
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Figure 4.46: TReg enriched mice of the POC study displayed an increased proportion of CD4+ TReg in
comparison to the WT 1 d post-surgery. Status of CD4+CD25++ T cells in the peripheral blood of
the POC mice. Displayed is the cellular percentage post-surgery of WT (WT 1 d post-surgery), POC
TReg+ good healer (POC TReg+ good 1 d post-surgery) and POC TReg+ bad healer (POC TReg+ bad
1 d post-surgery TReg+). n= 3–6
Figure 4.47: Confirmation of the relationship between the ratio of CD8+ effector T cells to CD4+ TReg
and the healing outcome in the mice of the POC study. A) Before-after-graph (graph for grouped data).
B) Linear regression analysis of the pre-defined ratio of CD8+ effector T cells and TReg. Illustrated are
the regression straight, the corresponding 95 % confidence interval and the calculated coefficient of
determination R2.
In the proof of concept study, I could show that the pre-surgery status of the ratio of CD8+
T effector to TReg cells predicted the healing outcome under the here used experimental
conditions. In the animals having a ratio above 0.075, the bad healing outcome could not be
compensated anymore by the transfer of TReg as positive modulating cells. For the predicted
bad healer of our mouse osteotomy model, the adoptive TReg transfer even led to a poorer
healing outcome with regard to the untreated WT mice and thus should not be performed.
However, the presented data are just preliminary and are therefore just indicating that the
pre-osteotomy status of certain populations of the adaptive immunity is a relevant factor
when immunomodulatory therapy is considered.
5 Discussion
Fracture healing is a highly complex process involving several tissues and cell types.
They have to interact in a spatiotemporally well defined interplay in order to ensure the
reconstitution of the injured bone [18]. Within secondary (indirect) healing, distinct but
overlapping phases have to proceed for a successful healing outcome. The immune system
plays an enormous role in bone homeostasis as well as in bone regeneration.
In the first part of my PhD study, an unaltered secondary healing process was characterized
in a murine osteotomy model. Animal model systems are a useful tool in order to evaluate
different phases of biological processes over a certain time period under comparable
animal strain specific and environmental conditions. In the context of this analysis, the
interplay between components of the bone and of the immune system was evaluated within
the fractured bone. Systemically, the composition of distinct immune cell subsets was
investigated. By immunohistology, specific distribution pattern were confirmed during
the different healing phases within the fracture area. While B and T cells were detectable
throughout the whole healing process, macrophages demonstrated a phenotype switch from
a pro- to an anti-inflammatory one at around day 3-7. Anti-inflammatory macrophages
seemed to invade the fracture area from the surrounding tissue. Their appearance further
coincided with the formation of new vessels. The revascularization of the fracture gap also
correlated with the disappearance of Hif1α+ cells, indicating the reestablishment of the
necessary oxygen supply. Bone forming osteoblasts were detectable in the fracture area
directly from the beginning on. As soon as small isles of newly formed bone were found in
the gap area, also bone resorbing osteoclasts were detectable around them.
In the second part of my thesis, an immunomodulatory approach was tested within the
characterized mouse model in order to improve the healing outcome after osteotomy.
This was done by an enrichment of TReg prior to osteotomy. Prior to the enrichment, the
pre-osteotomy immune status of the mice was analyzed, comparing animals housed under
SPF and semi-sterile housing conditions which enabled the maturation of the immune
system. These analysis revealed an increase of the proportion of the CD25+ T cell subset
under semi-sterile housing conditions. In addition, the percentage of effector T cells also
increased. Furthermore, an increase of TReg was specifically observed in the bone marrow of
the semi-sterile housed animals. The positive modulating effect of an enrichment of TReg
prior to osteotomy was confirmed in mice housed in an SPF environment. In contrast, mice
housed under semi-sterile housing conditions showed a controversial healing outcome. This
result clearly illustrates the importance to consider the individual immune status of the
recipient prior to the application of an immunotherapy.
5.1 Analysis of an unaltered healing process in a mouse
osteotomy model
5.1.1 Characterization of the spatial and temporal distribution of distinct
cellular subsets within the fractured bone
The murine osteotomy model of a non-critical size defect used for this study recapitulates
the classical and characteristic phases of a secondary healing process. After the initial
hematoma/inflammatory phase, fibrocartilage tissue was present within the fracture gap
that was further replaced by cartilage and finally newly formed woven bone. Concern-
ing the distribution of distinct cellular subtypes within the fractured bones analyzed by
immunohistology, macrophages, as component of the innate immune system, were de-
tectable over the complete healing duration. Macrophages are needed in order to direct
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the orchestrated formation of callus tissue. A complete depletion of macrophages at the
time point of surgery led to a disturbed fracture healing process, visible by an impaired
formation of soft and hard callus tissue [131]. In addition, after a chemically induced
reduction of macrophages, a prolonged cartilage phase with a disturbed transition from
soft to hard callus was detectable [5]. These studies highlight the important impact of
macrophages already from the early phase on. At day 1–3, the detectable presence of
pro-inflammatory macrophages represents the early inflammatory/hematoma phase of the
healing process (Fig. 4.4–4.6). Opal and colleagues already reported an interdependency
between pro-inflammatory signals, coagulation and the recruitment of cells of the innate
immunity (monocytes, macrophages) in wound healing [132]. Although pro-inflammatory
macrophages were detectable in the initial repair phase, no clear fracture hematoma was
visible by MP staining (Fig. 4.2). A reasonable explanation is that the fracture hematoma
was washed out by the sucrose solutions needed during the processing of the carefully
harvested bones for the embedding process. The proceeding to the anti-inflammatory
phase was detectable by the shift of M1 to M2 macrophages starting from day 3 [5]. The
shift from pro-inflammatory M1 to anti-inflammatory M2 is an indispensable step for bone
regeneration. M2 macrophages secrete pro-osteogenetic cytokines and thereby promote the
formation of new bone [133]. After 7 days, fibrous tissue was visible in the fracture gap
by MP stainings of the osteotomized mice femora that was further replaced by cartilage
(Fig. 4.2, 4.3). This represents the fibrocartilage/soft callus phase. By immunohistochemistry
stainings, predominantly anti-inflammatory M2 macrophages were detected in the fracture
area. This further indicates the probably necessary orchestrating function of macrophages
for the directed progression of the regeneration process during the soft and hard callus
phases. Hif1α positive cells were detected within the fracture gap from day 1 onwards,
illustrating the drop of the oxygen level within the fracture area due to the disruption of the
blood vessels. Progenitor cells for the revascularization of the disturbed area (identified
by CD105+ cells) were stained also directly from day 1 after fracture in the surrounding
tissue but also within the bone marrow adjacent to the fracture gap. Hypoxic cells were still
visible until day 7, except for day 3, but completely absent from day 14 on. The absence
of Hif1α+ cells at day 3 indicates the sufficient reestablishment of the necessary oxygen
supply for the fractured bone. This is further supported by the detection of vessel like
structures of CD105+ cells within the analyzed area. Thus, the disappearance of Hif1α+ cells
positively correlated with the onset of the vessel formation of CD105+ cells. The recurrency
of hypoxic cells at day 7 could be due to the onset of the cartilage differentiation where
again avascular conditions prevail. The appearance of newly formed vessels also coincided
with the invasion of M2 macrophages in the fracture gap. This further demonstrates the
participation of M2 macrophages in revascularization or the provision of macrophages
via the newly formed vessels. An important involvement of both macrophage subsets
in angiogenesis was already reported before [134]. T and B cells as parts of the adaptive
immunity were present throughout the whole healing cascade in the bone marrow around
the osteotomy gap. They showed a partial co-localization with osteoblasts and osteoclasts.
Regarding osteoclastogenesis, T and B cells can act pro- or anti-osteogenetic [3, 64, 8, 135].
Activated T cells express RANKL and thereby stimulate the formation of osteoclasts. But,
they can also inhibit osteoclastogenesis by the secretion of IFNγ. B cells express RANKL
and OPG, respectively. Thus, they can also either support or inhibit the formation of
osteoclasts. A supporting function of T cells in osteoblastogenesis was also reported before
[136]. Thus, B and T cells seem to be necessary throughout the whole healing cascade in
order to orchestrate the functioning of bone cells in fracture repair [135]. Osteoblasts, the
bone producing cells, were detectable at the periosteum and directly within the fracture gap
in the early healing phase. Their appearance in the fracture zone correlated with the invasion
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of M2 macrophages. This further highlights the orchestrating function of M2 macrophages
for osteoblast function and bone formation, as already mentioned above. During the soft
callus phase, osteoblasts were also visible at the endosteal side of the cortices around the
fracture area. This likely indicates the ongoing process of the production of new bone
from the endosteal side for the regeneration of the fractured bone. Osteoclasts, the bone
resorbing cells, were detectable on both sides of the cortices, directly from the beginning.
Both, osteoclasts and osteoblasts were found around isles of newly formed woven bone
as soon as they appear in the regeneration process. This demonstrates the remodeling of
newly formed woven bone in order to reestablish the bony architecture. In accordance
with already published findings, none of the investigated cell types was detected in areas
of cartilage tissue [8]. After 21 d, a hard callus was formed that was partially also already
remodeled, indicated by the observed lamellar structure of the newly formed bone tissue.
The bone marrow composition of this healing phase was characterized by CD80- and CD206-
macrophages, B cells, T cells and at the endosteum lying osteoclasts. Osteoblasts were again
only found at the periosteal surface of the cortices. The findings at day 21 could represent
the (beginning of the) reestablishment of the composition of the medullary canal as before
injury.
5.1.2 Characterization of the systemic changes of distinct cellular subsets
Besides cellular changes within and around the fracture area, also systemic changes were
detectable by flow cytometry, especially in the effector memory and central memory subset of
T cells. Presented flow cytometry data were calculated on the basis of CD3+/TCRαβ+/CD4+
and CD3+/TCRαβ+/CD8+ T cells or CD3+/CD4+ T cells (for TReg). Thus, the data are
presented as percentages and not amounts. In order to exclude false interpretation of
observed shifting percentages between compared mice groups due to a shift already in the
CD3+ T cell population, the percentages of CD3+ T cells were compared based on a defined
lymphocyte gate in the SSC/FSC. No differences were detected in the resulting CD3+ T cell
population between the groups of animals that were compared. In the spleen, the CD3+ T
cells were 37 % of the living cells of the lymphocyte population with a standard deviation of
3.5. Thus, differences in the calculated percentages of the evaluated T cell subsets can be
interpreted and discussed as real changes in the composition of T cell subsets.
Directly after injury, a decrease of the total CD4+ and CD8+ T cells, as well as their respective
CD25+ and central memory subsets, was detectable. Alterations of the hosts adaptive
immunity after injury, including a decrease in the systemic distribution of CD4+ and CD8+
T cell subsets, were already reported in the literature [137, 138]. These alterations are often
associated with a T cell dependent unresponsiveness of the adaptive immunity [139], leading
in the worst case to a multi organ failure of the patient. On the one side, the observed
changes are suggested to be a compensatory reaction of the body due to the high early
inflammatory phase caused by the injury [138]. However, on the other side, the early
inflammatory phase after injury can also function as an attractant for cells of the adaptive
immunity to the side of injury necessary for the repair process. This recruitment is probably
mediated via the production of a high proportion of prostaglandin E by macrophages [140],
further highlighting the tight interaction between the innate and adaptive immunity not
only at the injury side itself, but also in the periphery. For CD8+ T cells, a constant decrease
was observed in the bone marrow over the whole healing phase. This constant decrease was
in contrast to the observed findings in the blood and spleen where the percentage of CD8+ T
cells constantly increased from day 2/day 3. Also for the CD4+CD25+ T cell compartment,
which includes activated, regulatory and effector T cells, the systemic bone marrow reacted
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slightly different with regard to the peripheral blood and spleen. In the bone marrow, the
decrease of the cellular proportion was much stronger, especially in the later phase (day
7–day 14). Regarding the total population of CD4+ and CD8+ T cells, as well as their CD25+
subsets, differences in the distribution over the healing process have been observed in the
bone marrow for CD8+ and CD4+CD25+ T cells with regard to their distribution in the two
other tissues. These findings potentially indicate a tissue specific systemic response of the
body due to the injury. Thus, after bone fracture, reactions of the adaptive immune system
do not only occure in the regenerating bone itself but also in the systemic bone marrow.
The proportion of the fast reacting effector T cells stayed relatively constant in all three
analyzed tissues in the early healing phase. In the bone marrow, a constant increase was
further detected over the whole cascade, which was not seen in the blood and spleen. The
population of slower reacting effector memory T cells showed a clear increase in the first
days after trauma. This indicates a reactivation of these cells initiated by the osteotomy
and further supports the systemic involvement of the adaptive immunity during bone
regeneration. Over the whole healing cascade, CD4+ and CD8+ effector memory T cells
displayed an increased percentage, implicating their interaction in the regeneration process.
However, this interaction was not tissue dependent. A clear decrease in the proportion
of central memory T cells after osteotomy and further over the whole healing process in
comparison to the pre-surgery value was seen. In the blood, they increased again from day
7, which was not seen in the bone marrow and spleen. The early systemic decrease of central
memory T cells could be explained by the interdependency and plasticity of the different
T cell memory subsets in mice. Wherry and colleagues proposed a model of a continuum
lineage commitment of central and effector memory T cells rather than talking about distinct
subpopulations, seeing the central memory T cells as the real final memory subset: T effector
→ T effector memory → T central memory [141]. After antigen re-stimulation, central
memory T cells can convert back to the effector memory subset [142]. This re-conversion
could explain the observed decrease of the central memory subsets in bone marrow, spleen
and peripheral blood which occured simultaneously with the increase of the effector memory
T cells. However, all these analyses focusing on the plasticity and re-conversion of memory
T cell subsets were carried out with an antigen dependent effect on these cells. So far, little is
known about the role of memory T cells in bone repair. It is still unclear how theses T cells
exactly interfere and how they get activated in bone regeneration. Reinke and colleagues
clearly showed the high impact and negative correlation of an increased number of CD8+
TEMRA cells in the human peripheral blood and an impaired healing outcome after isolated,
closed tibia head fracture [4].
The population of regulatory T cells showed clear changes in the contralateral bone marrow
where the percentage constantly increased directly after fracture till 21 d post-surgery (Fig.
4.14). This observation indicates either a systemic involvement of TReg over the whole
healing cascade in bone regeneration or an influence of the regeneration process after
osteotomy on the TReg population in the contralateral and thus systemic bone marrow. An
injury dependent suppressive activity of TReg on cells of the innate immunity as well as their
positive impact in the healing outcome after burn injury was already reported [143, 144].
Thus, this could demonstrate a tissue specific effect of the osteotomy on the subpopulation
of TReg by inducing their systemic increase in the total bone marrow. This could further
imply that after bone injury, the TReg percentage is up-regulated in order to orchestrate the
well-defined repair process for a successful healing outcome. However, the frequency of TReg
within the fractured bone itself was not analyzed in this study. In this context, Al-Sebaei and
colleagues already showed in a mouse study that the TReg percentage is also upregulated in
the injured bone in comparison to the pre-injury value [145].
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In conclusion, this first part of my PhD thesis gives for the first time an overview of the
interplay of bone cells, immune reaction, hypoxia and vessel formation during secondary
bone healing which was investigated by immunohistology. This part further covers the
different healing phases and investigates all the tissues participating in the healing process
(bone, endosteum, periosteum, bone marrow, callus and muscle). The tight interplay of the
bone and the immune system within the injured femur as well as the systemic impact of the
adaptive immunity in bone regeneration is clearly demonstrated by the presented data.
5.2 Changes in the murine adaptive immune system comparing
SPF and semi-sterile housing
Within an aging population, the risk for fractures increases [146, 147]. In addition, fractures
of aged people show a higher percentage of impaired healing outcomes [148]. Throughout
life, the human immune system is constantly exposed to pathogens. This leads to an
activation of the adaptive immunity. Thus, an older person has a more experienced immune
system compared to a younger person. This is reflected by a higher amount of memory T
cells [149]. The question is how these changes in the immune cell composition will impact
bone fracture healing.
During this study, a more experienced immune system of the experimental mice was induced
by using different housing conditions and thereby mimicking an immune system of older
people. In the semi-sterile environment of our animal facility, mice were exposed to a higher
amount of pathogens in comparison to those animals housed under SPF conditions. As seen
in humans, a higher activation status of the immune system is detectable by an increasing
percentage of activated, as well as effector T cells within the experimental mice. For theses
mice, a more experienced immune system was confirmed by an increase of CD4+CD25+
and CD8+CD25+ T cells (activated T cells and TReg) as well as of the effector pool of both T
cell subsets in the spleen of mice in the semi-sterile housing. Effector cells are produced
following antigen stimulation of naïve T cells. Thus, a higher amount of effector cells is the
consequence of a higher antigen exposure to pathogens. Furthermore, the simultaneously
observed decrease of central memory T cells alone (CD8+ T cells) or both effector memory
and central memory T cells (CD4+ T cells) highlights again the proposed plasticity of these
three T cell subsets (effector, effector memory and central memory) [141]. Regarding bone
regeneration after injury, we are just at the beginning to elucidate the impact of effector and
memory T cells. One of the main questions is how effector and memory T cells can interact
in bone repair. Is it an antigen-driven process or bystander activation [150]? Bystander
activation means that memory T cells are indirectly activated during bone repair by e. g.
cytokines released by other cells and is thereby independent from antigen stimulation.
Another aspect of an increasing effector and memory T cell pool is a changing antigen
specificity. T cells are characterized by their antigen specific TCR. Thus, a higher amount of
effector T cells leads to a changing TCR repertoire of effector and central memory T cells
between mice housed under the two different housing conditions. Follow-up studies will
be needed in order to further investigate the differences in the TCR repertoire in depth.
This was not the focus of my project. However, a changing TCR repertoire would further
influence the specificity and recall response capacity between T cells from both housing
environments. For the subpopulation of TReg, semi-sterile housed mice displayed a higher
percentage in the bone marrow, whereas no changes were detectable in the peripheral blood
and spleen. This finding further highlights the importance of the bone marrow as a reservoir
for TReg, especially in an organism with a more experienced immune status.
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Different housing conditions effectively impacted the immune cell composition of the
analyzed mice. In the spleen, the semi-sterile environment caused a change in the ratio
of effector to effector memory to central memory T cells to TReg of both T cell subsets,
CD4 and CD8. These changing ratios are due to changes in the effector and memory
subsets but unaffected TReg. But also in the bone marrow, changes in the ratio of these
four subpopulations were revealed due to the higher percentage of TReg but an unchanged
proportion of effector, effector memory and central memory T cells between animals housed
under the different housing conditions. In the clinical situation, a changing immune cell
composition in older patients, as it was artificially mimicked in the semi-sterile housed mice,
could negatively influence the process of tissue regeneration by creating an unfavorable
cytokine milieu at the site of injury (inflammaging) [151]. This might further impair the
healing outcome which is already observed in a certain percentage of older patients [148].
5.3 Immunomodulation of the bone fracture healing process
5.3.1 Enrichment of regulatory T cells prior to osteotomy
The investigation of the healing outcome after adoptive TReg transfer was carried out with
freshly isolated murine TReg. Apart from the required high purity and functionality of the
isolated TReg for this immunomodulatory approach, the activation status of the used TReg
was considered. These parameters had to be tested and confirmed prior to adoptive transfer.
In order to obtain a highly purified cell population, magnetic activated cell sorting (MACS)
was used. This is an already well-established and accepted technique for the isolation of
murine cell subsets with a high purity. After MACS purification, I confirmed a purity of
around 85 % of mouse TReg from spleen and lymph nodes (Fig. 4.16). The functionality of
the freshly isolated TReg was analyzed in a TReg suppression assay. TReg are characterized
by their ability to suppress the proliferation of CD4+CD25- TResp in co-culture systems.
When cultured alone, several studies already reported an unresponsiveness of TReg to TCR
stimulation that was not observed to TCR-independent stimuli, like phorbol-12-myristat-
13-acetat (PMA). However, when co-cultured together with TResp, the same studies also
reported a TCR stimulation-dependent successful suppression of the proliferation of TResp by
TReg [152, 111]. These findings are in accordance with my data, showing a dose-dependent
suppressive capacity of freshly isolated murine TReg on the proliferation of TResp. Thus,
the freshly isolated TReg are still functional. Several reports in the literature state an even
superior suppressive activity after in vitro pre-activation of murine and human TReg on the
proliferation of TResp (consideration of the activation status of the used TReg). In contrast, in
my study, pre-activated TReg did no show a higher suppressive response but rather a loss
of their suppressive capacity. No standard protocol exists for the pre-activation of freshly
isolated TReg. Different groups used different media compositions, different cell numbers,
and different pre-activation time periods [153, 154, 112]. Thus, although I observed a higher
expression of the activation marker CD69 in the pre-activated TReg, it is still possible that
the used conditions in my pre-activation culture were at least partially unfavorable for
their suppressive capacity. In addition, after an in vivo pilot test of adoptive transfer of
freshly isolated and pre-activated TReg, respectively, prior to osteotomy in mice, an improved
healing outcome was only observed with freshly isolated TReg with regard to untreated WT
animals but not with pre-activated TReg (data not shown). Based on these preliminary data
and on the in vitro findings from the pre-activation and TReg suppression assay, the following
immunomodulatory in vivo approach was realized with freshly isolated murine TReg.
In this study, I have confirmed the capacity of freshly isolated murine TReg to improve
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fracture healing in the used mouse osteotomy model. However, this was only completely true
when TReg recipient mice were housed under SPF conditions. Under semi-sterile conditions,
the healing outcome was controversial; one half of the animals healed significantly better,
the other half showed a significantly poorer healing outcome. A higher percentage of
TReg 21 d post-surgery in the bone marrow and spleen of the TReg enriched with regard
to the WT animals confirmed the successful TReg enrichment in the good as well as bad
healing mice. However, the obvious controversial healing outcome of the adoptively
transferred TReg+ mice clearly demonstrates the impact of the housing condition on the
healing outcome. This could either be an impact of the transferred cells, thus of the donor
mice, an impact of the recipient animals or an impact of the process of the adoptive TReg
transfer. Regarding possible negative influences of the isolated TReg cells used for the
adoptive transfer, I have successfully confirmed that freshly isolated murine TReg via MACS
technology possessed a high purity and were still functional in their suppressive capacity.
Furthermore, the successful adoptive transfer was proven and confirmed. For an adoptive
transfer experiment, I always isolated TReg simultaneously from 2–4 mice, pooled them and
distributed them equally to the recipient mice. Thereby, the number of donor and recipient
mice was equal and up to 4 mice received the same TReg transfer. Within such a cell pool,
different healing outcomes were observed (good vs. bad). These observations exclude the
cell source per se as the cause for the controversial healing outcome of the TReg enriched
mice. The recipient mice were litter mates and had the same age at the time point of surgery.
Mice in one cage belonged to one delivery. Within one cage, there were good and bad
healing animals. The healing outcome was further independent of the surgical order of the
mice. Therefore, the remaining reasonable explanation for the observed different healing
outcomes are likely to be differences in the immune status of the recipient mice prior to
osteotomy due to the semi-sterile housing environment. As already shown in this study, the
semi-sterile environment leads to an activation of components of the adaptive immunity
which might further negatively impact the healing outcome.
Bone fracture healing is an inflammation mediated as well as immune cell dependent
regeneration process. In bone related diseases like rheumatoid arthritis, an overwhelming
pro-inflammatory reaction driven by activated T cells is responsible for the observed disease
phenotype of bone loss [155, 156]. TReg are characterized by the capacity to suppress the
pro-inflammatory activity and effector function of activated CD4+ and CD8+ T cells and
thereby balancing the immune reactions within an organism. Thus, a well-defined ratio and
interplay of TReg, as potential good cells, and activated/effector/memory T cells, as potential
bad cells, is indispensable for a well-balanced immune homeostasis. Also in fracture healing,
a too high amount of terminally differentiated CD8+ memory T cells correlates with impaired
fracture healing outcome [4]. TReg could represent one counteracting part by diminishing
the effector function of activated and memory T cells [99]. Thereby they could promote the
successful progression of the healing cascade. However, to my knowledge, this interplay has
not been analyzed in bone regeneration so far. Regarding the systemic flow cytometry data
after 21 d from the good and bad healers of the TReg enriched mice, the bad healers clearly
showed a higher percentage of activated and effector T cells (CD4+CD25+, CD8+CD25+,
CD4+ effector and CD8+ effector T cells) in comparison to the good healers. It remains
unclear if these differences had been already present before osteotomy or if they are a result
of the poor healing outcome after 21 days. Besides the different proportions of activated
and effector T cells, also the ratio between them and the present TReg was different for the
respective tissue (TReg distribution was equal in all three evaluated organs between good
and bad healer). Based on our previous findings [4], the ratio of CD8+ effector T cells and
TReg was of special interest. Both T cell subsets are present in the bone marrow as already
shown in the flow cytometry data obtained in the first part of my PhD thesis. This further
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supports the assumption that they might also be involved in fracture repair directly in the
injured bone. Regarding the different housing conditions, a shift in the ratio of CD8+ to
regulatory T cells was shown due to a changing TReg percentage in the bone marrow in
the semi-sterile environment (Fig. 4.26). This could further influence the progression of
the healing process after bone injury. Coming back to the controversial healing outcome,
a higher ratio of CD8+ T effector cells to TReg correlated with a poorer healing outcome,
demonstrating a shift of the balance between the two cell types towards CD8+ effector T
cells (Fig. 4.43). This further supports our assumption of a well-regulated interplay between
CD8+ effector and regulatory T cells for an organized regeneration process after bone injury.
It remains open how TReg can interact in bone regeneration. Zaiss and colleagues intensively
studied the interplay of TReg and osteoclasts and showed that TReg inhibit osteoclastogenesis
in a cell-cell-dependent mechanism. They further demonstrated that this interaction is
CTLA-4 dependent, but does not interfere with the RANKL-OPG homeostasis [14, 15, 16].
They also showed that TReg play a crucial role in normal bone homeostasis. In FoxP3
transgenic mice, a higher bone mass as well as a protection of ovariectomy-induced bone
loss was observed compared to a control group. This further highlights the importance
and impact of TReg in the bone metabolism independent from an injury. Going back to our
focus on the interplay between CD8+ effector and regulatory T cells, several in vitro and
in vivo studies already showed a possible suppressive effect of TReg on naïve CD8+ T cells
and their differentiation capacity [157, 158]. During the analysis of the characterization of
the unaltered healing process in the first part of my study, I showed an increase of CD8+
effector as well as effector memory T cells in the bone marrow over the healing process
(Fig. 4.13). An interference of TReg, especially in the early inflammatory fracture healing
phase, could be an indispensable step in order to balance this effector/effector memory
cell development as reported by the aforementioned studies. In a viral vaccine model,
Kastenmuller and colleagues further demonstrated a specific effect of TReg on effector CD8+
T cells, without affecting the memory pool [159]. In accordance with other studies, the TReg
mediated suppression was carried out via the limitation of IL-2, needed for effector T cell
differentiation and stability. In contrast to this study, a direct negative correlation between
the presence of TReg and CD8+ memory T cells was shown in an in vivo situation [160]. The
authors concluded a partial negative impact of IL-2 on the maintenance of CD8+ memory
T cells. TReg depletion by an anti-IL-2 treatment even led to an increase in the amount of
CD8+ memory T cells. I observed the opposite finding in my study. After TReg depletion by
anti-CD25 treatment, also the proportion of effector memory T cells markedly decreased
(Fig. 4.41, 4.42). A possible explanation for this contradictory finding is the definition of
a memory T cell subset. Murakami defined them by the expression of CD122, whereas I
used the marker set of CD44 and CD62L. It is highly possible that these could represent
two different subtypes of T cells, differently affected by the presence of TReg and by the
anti-CD25 treatment [161]. However, the described findings from the literature and my own
study clearly highlight the still missing depth in our knowledge of TReg action on CD8+
effector/memory T cells, especially in the context of fracture healing.
Our data do yet not explain the observed controversial healing outcome in the mice with
a more experienced adaptive immune system (semi-sterile housing) and the significantly
poorer healing outcome in the non-healers. At first glance, the non-bridging after TReg
enrichment indicates also a possible negative impact of TReg in bone regeneration. One
may assume that a well-defined interplay between CD8+ effector and regulatory T cells
is a prerequisite for a successful healing outcome. An enrichment of TReg prior to surgery
would shift the ratio towards the anti-inflammatory TReg which would thereby accelerate
the fracture healing process. This acceleration was observed in the SPF and partial in the
semi-sterile TReg+ animals (good healing mice). The faster healing of the fracture ends
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could be realized by a suppression of the action of CD8+ effector T cells. Now, one may
imagine a pre-surgery situation in which the ratio between the two is markedly shifted
towards the CD8+ effector T cell population and an enrichment of TReg, as done in my study,
would not be sufficient anymore to balance this ratio towards a regenerative setting. A
growing number of studies have challenged the previously stated opinion that TReg are
a committed stable cellular subpopulation. Then, under certain circumstances, TReg can
lose their FOXP3 expression and can, dependent on the present environmental stimuli;
convert to another CD4+ effector T cell subset [162, 163, 164, 165]. This conversion could
have a negative impact in bone healing. Among others, CD4+ effector cell types interact
differently in the process of osteoclastogenesis and can thereby modify bone regeneration.
For CD4+ T cell subpopulations, it was already shown that Th1 and Th2 cells inhibit the
differentiation of bone resorbing osteoclasts by the secretion of IFN-γ and IL-4, respectively.
In contrast, CD4+ Th17 T cells are pro-osteoclastogenic by their production of RANKL.
This can act directly on osteoclast precursors. In addition, Th17 cells can also induce the
secretion of RANKL by osteoblasts and synovial fibroblasts. Although Th17 cells also seem
to act pro-osteogenic, it is further postulated that the reason for several bone disorders like
rheumatoid arthritis, osteoporosis and periodontitis is an imbalance of the ratio of Th17 and
TReg cells [104, 105]. Several in vitro studies with human and murine cells revealed a possible
transition between TReg and IL-17 producing (Th17) T cells. Xu and colleagues reported an
IL-6 dependent shift of TReg to IL-17 producing cells in in vitro analyses with murine TReg
[162]. In further studies, murine TReg that also express Rorγt, the master transcription factor
of Th17 cells, were shown to be able to obtain the production of IL-17 after co-culture with
selectively activated dendritic cells [166]. This conversion between purified TReg to IL-17
producing T cells was also demonstrated with human cells [167, 168]. In this context, Beriou
and colleagues reported a possible stimulus dependent simultaneous loss of suppressive
capacity of IL-17 secreting TReg.
Recalling a pre-surgery situation of an unbalanced CD8+ effector to regulatory T cell ratio
towards the CD8+ T effector cells: If the amount of adoptively transferred TReg was not
sufficient in order to re-balance this ratio, effector/memory T cells and in particular CD8+
ones could have created such a pro-inflammatory and unfavorable cytokine environment
that the enriched TReg attracted to the site of injury could have been converted into a
negatively modulating effector cell population like IL-17 secreting TReg. This assumption,
of course, is highly provocative. However, the aforementioned publications reporting
the interplay between CD8+ and regulatory T cells as well as the plasticity between TReg
and IL-17 producing cells strongly support this possible conclusion. A totally different
explanation for the observed controversial healing outcome could be a too strong presence
of TReg in the fracture area after adoptive transfer. A too high amount of TReg could directly
suppress the indispensable pro-inflammatory reaction in the initial fracture healing phase
and could thereby promote an impaired regeneration process.
Follow up studies are already planned to analyze this apparently crucial interplay between
different cellular subtypes of the adaptive immune system and TReg as well as bone cells
and TReg in order to obtain a deeper knowledge about the underlying mechanism of TReg
interaction in bone regeneration.
5.3.2 Depletion of CD25+ T cells prior to osteotomy
In order to investigate the healing outcome when TReg are absent at the moment of osteotomy,
a CD25+ T cell depletion was performed prior to surgery. Anti-CD25+ T cell depletion is
a widely used approach to deplete specifically TReg in mice studies analyzing e. g. tumor
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immunology, transplantation tolerance and infection models [128, 129, 130]. All of these
studies reported a successful depletion of TReg and subsequently a successful immune-
based therapy. The depletion of TReg cells was also confirmed in the presented study by
flow cytometry 2 d post-depletion and post-surgery. In contrast to the expectation, this
depletion did not alter the healing outcome with regard to the WT control animals. A
poorer healing outcome was expected due to the missing TReg as positive modulating cell
population in bone regeneration. The evaluation of the healing outcome after 21 d by
µCT and histomorphometry was comparable to the one seen in the WT mice (Fig 4.37,
4.38, 4.39). In addition to the TReg depletion, a reduction or even absence after anti-CD25
antibody treatment was also observed for effector T cells. CD4+ and CD8+ effector as well
as activated and certain memory T cells also express the CD25 molecule on their surface.
Thus, these T cell subsets will also be depleted by this antibody as shown in this study for
the effector subpopulation. In accordance, there are also experimental approaches reported
in the literature showing a failure to consistently enhance the therapy outcome after TReg
depletion by an anti-CD25 antibody treatment. The authors consider an unspecific effect of
the anti-CD25 treatment on other CD25+ T cell populations [169, 170, 171]. They explain the
observed inconsistent therapy success after TReg depletion with a simultaneous unwanted
depletion of other CD25 expressing T cell subsets. Interestingly, the population of effector
memory T cells also decreased, indicating an effect of the CD25+ T cell depletion also
on this cell subpopulation although they do not express CD25. Thus, this antibody does
not specifically deplete CD25+ TReg, but also other T cell subsets expressing the surface
marker CD25 and affects furthermore CD25- cellular subsets. The observed decrease of
CD8+CD25- effector memory T cells could be an indirect effect of the depletion approach.
One explanation is that the organism tries to reconvert effector T cells from the memory pool.
If the antibody directly affects the already present as well as the reconverted CD25+ effector
T cells, the organism will carry on to reconvert more and more effector memory T cells to
effector cells. Thereby, the proportion of T effector memory T cells also decreases.
To conclude, the use of an anti-CD25 antibody as immunomodulatory approach does not
only deplete CD25+ TReg cells, but also other cell populations expressing CD25. Although
this depletion obviously changed the immunological homeostasis within the treated animals,
the balance between CD8+ effector T cells and TReg remained constant comparable to the WT
mice regarding the outcome of the bone regeneration process. This could be an explanation
for the investigated unchanged healing outcome of the depleted animals with regard to
the WT because both T cell subsets, TReg and CD8+ effetor T cells, lack at the moment
of osteotomy. This further supports the assumption that a balanced ratio between CD8+
effector T cells and TReg is required for a successful healing outcome in the used mouse
osteotomy model system.
5.4 Identification of a potential biomarker to predict the healing
outcome after adoptive transfer of regulatory T cells
The flow cytometry data after 21 d of the TReg enriched mice housed in a semi-sterile
environment showed an increased percentage of possible negative acting cells in bone repair
(CD8+ effector T cells) in the peripheral blood of the TReg+ bad vs. the TReg+ good animals
(Fig. 4.34 A). Due to the fact that the distribution of TReg was equal in these animals in the
blood after 21 d, the interplay and ratio of both CD8+ effector T cells and TReg might be
crucial for a successful healing process. This assumption is further supported by the findings
of Reinke and colleagues who already reported a negative impact of CD8+ effector T cells in
bone repair in patient samples [4]. Therefore, a proof of concept (POC) study was performed
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in which the healing outcome of a pre-surgery defined ratio between CD8+ effector and
regulatory T cells was analyzed 21 d after TReg enrichment in the murine osteotomy model.
Due to the small sample size and thus measurable and analyzable cell numbers in 1–2
drops of peripheral blood, only small ratios of CD8+ effector to regulatory T cells could
be calculated pre-osteotomy (Tab. 4.2). However, differences in the ratios were clearly
detectable, indicating different immune statuses in the experimental mice. Regarding the
healing outcome after 21 d, the pre-surgery defined healing outcome was confirmed for all
mice except mouse 2 (Fig. 4.44). The healing outcome was predicted using an estimated set
threshold. Mouse 2 showed the highest pre-surgery ratio from the predicted good healer.
In fact, we consider the set threshold to be not exactly true and consequently corrected
the threshold from 0.1 to around 0.075. Thus, based on the µCT pictures, mouse 2 was
included into the mice with a poorer healing outcome. The quantification of the µCT of the
POC animals clearly confirmed a better healing outcome in the good healers with regard to
the bad healers (Fig. 4.45). Furthermore, the bad healers demonstrated again even poorer
bone regeneration in comparison to the corresponding WT mice. An unsuccessful adoptive
TReg transfer as the cause of the observed non-bridging in the bad healing POC mice was
excluded due to the proof of the cell transfer 1 d post-osteotomy in peripheral blood. Both
healing groups of the POC animals showed a relative higher value of TReg with regard to
the WT. A direct linear correlation between the pre-osteotomy ratio of CD8+ effector T cells
and TReg and the healing outcome has not been determined in the POC study (R2 = 0.6236).
Nevertheless, the prediction of a healing outcome does not neccessarily follow a linear
behavior. The before-after-graph clearly shows the correlation between a higher ratio of
CD8+ effector T cells to TReg and the poorer bone regeneration without any overlap (Fig. 4.47
A). Obviously, this effect was not altered after adding the adoptively transferred TReg. We
conclude that there is a certain threshold for the animals of the POC approach that predicts
a poorer healing outcome when the ratio is higher 0.075. Thus, for the POC approach, I
confirmed that a pre-defined ratio of CD8+ effector memory T cells to TReg correlated with
the healing outcome after TReg enrichment in the given experimental conditions.
It is important to mention that only seven animals were analyzed for the experimental
setting in the POC study. More studies would be needed in order to confirm the observed
results. Thus, the observed findings are just indications for the evaluated data as well as
healing outcomes and have to be interpreted with caution. However, the herein defined
threshold clearly shows that there are differences in the cellular composition of the used mice
that influence the healing outcome and probably also the fate of the adoptively transfered
TReg. Likely, these cells do not act as TReg when cast into the high effector environment but
change into cells that are detrimental for the healing process and thus cause a significantly
poorer outcome.
5.5 Conclusion
The obtained and presented data of the immunomodulatory treatment approach clearly
demonstrate the impact of the immune status on the regenerative process of bone. This
impact is determined by the maturation/experience of the adaptive immune system due
to pathogen exposure. In figure 5.1, the findings are schematically illustrated, including
the state of the scientific knowledge my PhD thesis is based on (Fig. 5.1, upper picture).
Under SPF housing conditions and thus a lesser experienced immune system, adoptively
transferred CD4+ TReg led to a consistently improved healing outcome in our clinically
relevant mouse osteotomy model in comparison to the wild type control group (Fig. 5.1,
lower left picture). Semi-sterile housing led to a more experienced adaptive immunity of
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the immune system due to a higher pathogen exposure. Hereby, the healing outcome was
dependent on the ratio of CD8+ effector T cells and CD4+ TReg that was present in the mouse
before osteotomy and immunomodulation (Fig. 5.1, lower right picture). Therefore, the
immunomodulatory treatment approach shows the importance of considering the immune
status of each individual before applying an immunomodulatory therapy. Transferring these
findings to the clinical situation cautions how individual each patient could react to the same
immunomodulatory therapy and how this approach could affect the treatment outcome in
an unfavorable way. Therefore, for the clinic, it is even more important to develop and to
apply patient based treatment approaches in the field of immunotherapy considering the
individual immune status of each patient prior to treatment.
Figure 5.1: Interplay between the adaptive immune system, immunomodulation and bone fracture
healing. Schematic illustration of the scientific knowledge before I started my PhD thesis (upper
picture) and the gain of knowledge based on the findings of my PhD thesis (lower picture). Upper
picture: CD8+ TEMRA T cells were already shown to have a negative impact in bone repair (humans
and mouse model, long bones) whereas CD4+ TReg were shown to improve bone repair when
simultaneously transferred with bone marrow MSCs (mouse model, skull). Lower picture: In
bone repair, the healing outcome after immunomodulation by adoptively transferred CD4+ TReg
is dependent on the status of the adaptive immune system before therapy. Using mice with an
unexperienced immune system (SPF housing), the healing outcome was improved after CD4+ TReg
transfer. However, using mice with an exprienced immune system (semi-sterile housing), the healing
outcome after adoptive transfer of CD4+ TReg was dependent on the ratio of CD8+ effector T cells to
TReg. Colors in bone scheme: cortices = black, hematoma = rose, callus = blue, newly formed bone =
yellow, impaired healing = black in the fracture area; color code of the cells: CD8+ T cells = green,
CD4+ TReg = blue.
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5.6 Outlook
The here presented study clearly elucidates the tight interplay between the bone and the
immune system in bone regeneration. The data also shows a circumstance-dependent
positive modulating effect of murine TReg in fracture repair, as hypothesized at the beginning
of this project. However, one major unanswered question is how TReg exactly interact in
bone healing. Are tissue resident TReg responsible for the healing process? Are they recruited
from the periphery? If yes, is this attraction mediated by cytokines released in the fracture
area or in the periphery due to the injury? Furthermore, the functional mechanism of TReg
action in bone repair is not completely revealed. How do they interact in the injured bone
and with which cells do they interact?
In order to elucidate the spatial and temporal localization of TReg in bone healing, the
behavior of TReg would have to be monitored in in vivo models. This could be realized
by fluorescently labeled TReg and by a subsequent imaging analysis of the fracture area at
different time points of the healing cascade. Using in vitro co-culture setup systems of TReg
and different cell types of the innate and adaptive immunity, as well as bone cells, will allow
to further analyze the working mechanism of TReg. Such an approach also includes the use
of blocking antibodies or induced pro-inflammatory conditions in order to evaluate changes
in the TReg behavior or TReg-independent changes in the behavior of the co-cultured cell
type(s).
The here presented data clearly demonstrate the impact of the environment in which the
experimental mice are housed in on the status of their adaptive immune system. So far, only
the distribution of TReg was investigated between a lesser and a more experienced immune
system. Another big question is the influence of the environment and thus of the pathogen
exposure on the functionality of the respective TReg. This has not been investigated by any
study so far. Especially for the translational use of experimental model systems analyzing
immunomodulatory approaches with TReg, differences in the immune status of the used
animals have to be considered as shown in my study.

Bibliography
[1] T. A. Einhorn and J. M. Lane. Significant advances have been made in the way surgeons
treat fractures. Clin Orthop Relat Res, (355 Suppl):S2–3, 1998.
[2] C. Zeckey, P. Mommsen, H. Andruszkow, C. Macke, M. Frink, T. Stubig, T. Hufner,
C. Krettek, and F. Hildebrand. The aseptic femoral and tibial shaft non-union in
healthy patients - an analysis of the health-related quality of life and the socioeconomic
outcome. Open Orthop J, 5:193–7, 2011.
[3] J. R. Arron and Y. Choi. Bone versus immune system. Nature, 408(6812):535–6, 2000.
[4] S. Reinke, S. Geissler, W. R. Taylor, K. Schmidt-Bleek, K. Juelke, V. Schwachmeyer,
M. Dahne, T. Hartwig, L. Akyuz, C. Meisel, N. Unterwalder, N. B. Singh, P. Reinke,
N. P. Haas, H. D. Volk, and G. N. Duda. Terminally differentiated CD8(+) T cells
negatively affect bone regeneration in humans. Sci Transl Med, 5(177):177ra36, 2013.
[5] C. Schlundt, T. El Khassawna, A. Serra, A. Dienelt, S. Wendler, H. Schell, N. van
Rooijen, A. Radbruch, R. Lucius, S. Hartmann, G. N. Duda, and K. Schmidt-Bleek.
Macrophages in bone fracture healing: Their essential role in endochondral ossification.
Bone, 2015.
[6] A. Barbul, R. J. Breslin, J. P. Woodyard, H. L. Wasserkrug, and G. Efron. The effect of
in vivo T helper and T suppressor lymphocyte depletion on wound healing. Ann Surg,
209(4):479–83, 1989.
[7] C. J. Hauser, X. Zhou, P. Joshi, M. A. Cuchens, P. Kregor, M. Devidas, R. J. Kennedy,
G. V. Poole, and J. L. Hughes. The immune microenvironment of human fracture/soft-
tissue hematomas and its relationship to systemic immunity. J Trauma, 42(5):895–903;
discussion 903–4, 1997.
[8] I. Konnecke, A. Serra, T. El Khassawna, C. Schlundt, H. Schell, A. Hauser, A. Ellinghaus,
H. D. Volk, A. Radbruch, G. N. Duda, and K. Schmidt-Bleek. T and B cells participate
in bone repair by infiltrating the fracture callus in a two-wave fashion. Bone, 64:155–65,
2014.
[9] A. A. Naik, C. Xie, M. J. Zuscik, P. Kingsley, E. M. Schwarz, H. Awad, R. Guldberg,
H. Drissi, J. E. Puzas, B. Boyce, X. Zhang, and R. J. O’Keefe. Reduced COX-2 expression
in aged mice is associated with impaired fracture healing. J Bone Miner Res, 24(2):251–64,
2009.
[10] K. Schmidt-Bleek, H. Schell, P. Kolar, M. Pfaff, C. Perka, F. Buttgereit, G. Duda, and
J. Lienau. Cellular composition of the initial fracture hematoma compared to a muscle
hematoma: a study in sheep. J Orthop Res, 27(9):1147–51, 2009.
[11] K. Schmidt-Bleek, A. Petersen, A. Dienelt, C. Schwarz, and G. N. Duda. Initiation
and early control of tissue regeneration - bone healing as a model system for tissue
regeneration. Expert Opin Biol Ther, 14(2):247–59, 2014.
[12] C. Schlundt, H. Schell, S. B. Goodman, G. Vunjak-Novakovic, G. N. Duda, and
K. Schmidt-Bleek. Immune modulation as a therapeutic strategy in bone regeneration.
Journal of experimental orthopaedics, 2(1):1, 2015.
[13] J. E. Efron, H. L. Frankel, S. A. Lazarou, H. L. Wasserkrug, and A. Barbul. Wound
healing and T-lymphocytes. J Surg Res, 48(5):460–3, 1990.
103
Bibliography 104
[14] M. M. Zaiss, R. Axmann, J. Zwerina, K. Polzer, E. Guckel, A. Skapenko, H. Schulze-
Koops, N. Horwood, A. Cope, and G. Schett. Treg cells suppress osteoclast formation:
a new link between the immune system and bone. Arthritis Rheum, 56(12):4104–12,
2007.
[15] M. M. Zaiss, K. Sarter, A. Hess, K. Engelke, C. Bohm, F. Nimmerjahn, R. Voll, G. Schett,
and J. P. David. Increased bone density and resistance to ovariectomy-induced bone
loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis
Rheum, 62(8):2328–38, 2010.
[16] M. M. Zaiss, B. Frey, A. Hess, J. Zwerina, J. Luther, F. Nimmerjahn, K. Engelke,
G. Kollias, T. Hunig, G. Schett, and J. P. David. Regulatory T cells protect from local
and systemic bone destruction in arthritis. J Immunol, 184(12):7238–46, 2010.
[17] Y. Liu, L. Wang, T. Kikuiri, K. Akiyama, C. Chen, X. Xu, R. Yang, W. Chen, S. Wang,
and S. Shi. Mesenchymal stem cell-based tissue regeneration is governed by recipient
T lymphocytes via IFN-gamma and TNF-alpha. Nat Med, 17(12):1594–601, 2011.
[18] K. Schmidt-Bleek, H. Schell, J. Lienau, N. Schulz, P. Hoff, M. Pfaff, G. Schmidt,
C. Martin, C. Perka, F. Buttgereit, H. D. Volk, and G. Duda. Initial immune reaction
and angiogenesis in bone healing. J Tissue Eng Regen Med, 8(2):120–30, 2014.
[19] D. Pennig. [the biology of bones and of bone fracture healing]. Unfallchirurg, 93(11):488–
91, 1990.
[20] G. A. Rodan. Introduction to bone biology. Bone, 13 Suppl 1:S3–6, 1992.
[21] H. K. Datta, W. F. Ng, J. A. Walker, S. P. Tuck, and S. S. Varanasi. The cell biology of
bone metabolism. J Clin Pathol, 61(5):577–87, 2008.
[22] A. Remedios. Bone and bone healing. Vet Clin North Am Small Anim Pract, 29(5):1029–44,
v, 1999.
[23] J. A. Buckwalter, M. J. Glimcher, R. R. Cooper, and R. Recker. Bone biology. I: Structure,
blood supply, cells, matrix, and mineralization. Instr Course Lect, 45:371–86, 1996.
[24] J. Wolff. Das Gesetzt der Transformation der Knochen. Hirschwald Verlag, Berlin, 1892.
[25] M. Capulli, R. Paone, and N. Rucci. Osteoblast and osteocyte: games without frontiers.
Arch Biochem Biophys, 561:3–12, 2014.
[26] S. L. Dallas and L. F. Bonewald. Dynamics of the transition from osteoblast to osteocyte.
Ann N Y Acad Sci, 1192:437–43, 2010.
[27] S. C. Miller, L. de Saint-Georges, B. M. Bowman, and W. S. Jee. Bone lining cells:
structure and function. Scanning Microsc, 3(3):953–60; discussion 960–1, 1989.
[28] V. Everts, J. M. Delaisse, W. Korper, D. C. Jansen, W. Tigchelaar-Gutter, P. Saftig, and
W. Beertsen. The bone lining cell: its role in cleaning Howship’s lacunae and initiating
bone formation. J Bone Miner Res, 17(1):77–90, 2002.
[29] T. A. Franz-Odendaal, B. K. Hall, and P. E. Witten. Buried alive: how osteoblasts
become osteocytes. Dev Dyn, 235(1):176–90, 2006.
[30] L. F. Bonewald. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci,
1116:281–90, 2007.
Bibliography 105
[31] S. Khosla. Minireview: the OPG/RANKL/RANK system. Endocrinology, 142(12):5050–5,
2001.
[32] M. Mulari, J. Vaaraniemi, and H. K. Vaananen. Intracellular membrane trafficking in
bone resorbing osteoclasts. Microsc Res Tech, 61(6):496–503, 2003.
[33] V. E. Arana-Chavez and V. Bradaschia-Correa. Clastic cells: mineralized tissue
resorption in health and disease. Int J Biochem Cell Biol, 41(3):446–50, 2009.
[34] W. J. Boyle, W. S. Simonet, and D. L. Lacey. Osteoclast differentiation and activation.
Nature, 423(6937):337–42, 2003.
[35] L. C. Gerstenfeld, Y. M. Alkhiary, E. A. Krall, F. H. Nicholls, S. N. Stapleton, J. L. Fitch,
M. Bauer, R. Kayal, D. T. Graves, K. J. Jepsen, and T. A. Einhorn. Three-dimensional
reconstruction of fracture callus morphogenesis. J Histochem Cytochem, 54(11):1215–28,
2006.
[36] R. Marsell and T. A. Einhorn. The biology of fracture healing. Injury, 42(6):551–5, 2011.
[37] R. E. Kaderly. Primary bone healing. Semin Vet Med Surg (Small Anim), 6(1):21–5, 1991.
[38] K. Mizuno, K. Mineo, T. Tachibana, M. Sumi, T. Matsubara, and K. Hirohata. The
osteogenetic potential of fracture haematoma. Subperiosteal and intramuscular trans-
plantation of the haematoma. J Bone Joint Surg Br, 72(5):822–9, 1990.
[39] S. H. Park, M. Silva, W. J. Bahk, H. McKellop, and J. R. Lieberman. Effect of repeated
irrigation and debridement on fracture healing in an animal model. J Orthop Res,
20(6):1197–204, 2002.
[40] P. Kolar, K. Schmidt-Bleek, H. Schell, T. Gaber, D. Toben, G. Schmidmaier, C. Perka,
F. Buttgereit, and G. N. Duda. The early fracture hematoma and its potential role in
fracture healing. Tissue Eng Part B Rev, 16(4):427–34, 2010.
[41] J. Lienau, K. Schmidt-Bleek, A. Peters, F. Haschke, G. N. Duda, C. Perka, H. J. Bail,
N. Schutze, F. Jakob, and H. Schell. Differential regulation of blood vessel formation
between standard and delayed bone healing. J Orthop Res, 27(9):1133–40, 2009.
[42] L. C. Gerstenfeld, T. J. Cho, T. Kon, T. Aizawa, A. Tsay, J. Fitch, G. L. Barnes, D. T.
Graves, and T. A. Einhorn. Impaired fracture healing in the absence of TNF-alpha
signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner
Res, 18(9):1584–92, 2003.
[43] J. A. Kanis, O. Johnell, A. Oden, H. Johansson, C. De Laet, J. A. Eisman, S. Fujiwara,
H. Kroger, E. V. McCloskey, D. Mellstrom, L. J. Melton, H. Pols, J. Reeve, A. Silman,
and A. Tenenhouse. Smoking and fracture risk: a meta-analysis. Osteoporos Int,
16(2):155–62, 2005.
[44] P. Vestergaard, L. Rejnmark, and L. Mosekilde. Relative fracture risk in patients
with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on
relative fracture risk. Diabetologia, 48(7):1292–9, 2005.
[45] K. E. Ensrud. Epidemiology of fracture risk with advancing age. J Gerontol A Biol Sci
Med Sci, 68(10):1236–42, 2013.
[46] T. A. Einhorn and L. C. Gerstenfeld. Fracture healing: mechanisms and interventions.
Nat Rev Rheumatol, 11(1):45–54, 2015.
Bibliography 106
[47] R. Fu, S. Selph, M. McDonagh, K. Peterson, A. Tiwari, R. Chou, and M. Helfand.
Effectiveness and harms of recombinant human bone morphogenetic protein-2 in
spine fusion: a systematic review and meta-analysis. Ann Intern Med, 158(12):890–902,
2013.
[48] P. Peichl, L. A. Holzer, R. Maier, and G. Holzer. Parathyroid hormone 1-84 accelerates
fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am,
93(17):1583–7, 2011.
[49] T. K. Kovach, A. S. Dighe, P. I. Lobo, and Q. Cui. Interactions between MSCs and
immune cells: implications for bone healing. J Immunol Res, 2015:752510, 2015.
[50] R. Quarto, M. Mastrogiacomo, R. Cancedda, S. M. Kutepov, V. Mukhachev,
A. Lavroukov, E. Kon, and M. Marcacci. Repair of large bone defects with the
use of autologous bone marrow stromal cells. N Engl J Med, 344(5):385–6, 2001.
[51] I. Fernandez-Bances, M. Perez-Basterrechea, S. Perez-Lopez, D. Nunez Batalla, M. A.
Fernandez Rodriguez, M. Alvarez-Viejo, A. Ferrero-Gutierrez, Y. Menendez-Menendez,
J. M. Garcia-Gala, D. Escudero, J. Paz Aparicio, S. Carnero Lopez, P. Lopez Fernandez,
D. Gonzalez Suarez, and J. Otero Hernandez. Repair of long-bone pseudoarthrosis
with autologous bone marrow mononuclear cells combined with allogenic bone graft.
Cytotherapy, 15(5):571–7, 2013.
[52] E. Gomez-Barrena, P. Rosset, D. Lozano, J. Stanovici, C. Ermthaller, and F. Gerbhard.
Bone fracture healing: cell therapy in delayed unions and nonunions. Bone, 70:93–101,
2015.
[53] P. F. O’Loughlin, S. Morr, L. Bogunovic, A. D. Kim, B. Park, and J. M. Lane. Selection
and development of preclinical models in fracture-healing research. J Bone Joint Surg
Am, 90 Suppl 1:79–84, 2008.
[54] F. Roch and M. A. Bach. Strain differences in mouse cellular responses to Mycobac-
terium lepraemurium and BCG subcutaneous infections. II. Production of interleukins
2, 4, and 6 and of interferon-gamma by draining lymph node cells. Clin Immunol
Immunopathol, 60(3):443–54, 1991.
[55] M. B. Manigrasso and J. P. O’Connor. Comparison of fracture healing among different
inbred mouse strains. Calcif Tissue Int, 82(6):465–74, 2008.
[56] H. Takayanagi. SnapShot: Osteoimmunology. Cell Metab, 21(3):502 e1, 2015.
[57] R. S. Taichman and S. G. Emerson. Human osteoblasts support hematopoiesis through
the production of granulocyte colony-stimulating factor. J Exp Med, 179(5):1677–82,
1994.
[58] S. J. Morrison and D. T. Scadden. The bone marrow niche for haematopoietic stem
cells. Nature, 505(7483):327–34, 2014.
[59] P. W. Price and J. Cerny. Characterization of CD4+ T cells in mouse bone marrow.
I. Increased activated/memory phenotype and altered TCR Vbeta repertoire. Eur J
Immunol, 29(3):1051–6, 1999.
[60] P. C. Sandel, M. Gendelman, G. Kelsoe, and J. G. Monroe. Definition of a novel cellular
constituent of the bone marrow that regulates the response of immature B cells to B
cell antigen receptor engagement. J Immunol, 166(10):5935–44, 2001.
Bibliography 107
[61] I. B. Mazo, M. Honczarenko, H. Leung, L. L. Cavanagh, R. Bonasio, W. Weninger,
K. Engelke, L. Xia, R. P. McEver, P. A. Koni, L. E. Silberstein, and U. H. von Andrian.
Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T
cells. Immunity, 22(2):259–70, 2005.
[62] J. E. Horton, L. G. Raisz, H. A. Simmons, J. J. Oppenheim, and S. E. Mergenhagen.
Bone resorbing activity in supernatant fluid from cultured human peripheral blood
leukocytes. Science, 177(4051):793–5, 1972.
[63] M. Horowitz, A. Vignery, R. K. Gershon, and R. Baron. Thymus-derived lymphocytes
and their interactions with macrophages are required for the production of osteoclast-
activating factor in the mouse. Proc Natl Acad Sci U S A, 81(7):2181–5, 1984.
[64] H. Takayanagi, K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka,
T. Yokochi, H. Oda, K. Tanaka, K. Nakamura, and T. Taniguchi. T-cell-mediated
regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-
gamma. Nature, 408(6812):600–5, 2000.
[65] H. Takayanagi. Osteoimmunology and the effects of the immune system on bone. Nat
Rev Rheumatol, 5(12):667–76, 2009.
[66] K. Sato, A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka,
T. Kodama, S. Akira, Y. Iwakura, D. J. Cua, and H. Takayanagi. Th17 functions as an
osteoclastogenic helper T cell subset that links T cell activation and bone destruction.
J Exp Med, 203(12):2673–82, 2006.
[67] Jr. Janeway, C. A. and R. Medzhitov. Innate immune recognition. Annu Rev Immunol,
20:197–216, 2002.
[68] D. G. Hesslein and D. G. Schatz. Factors and forces controlling V(D)J recombination.
Adv Immunol, 78:169–232, 2001.
[69] Y. H. Chien and R. Jores. Gamma delta T cells. T cells with B-cell-like recognition
properties. Curr Biol, 5(10):1116–8, 1995.
[70] C. Viret and Jr. Janeway, C. A. MHC and T cell development. Rev Immunogenet,
1(1):91–104, 1999.
[71] S. L. Swain, M. Croft, C. Dubey, L. Haynes, P. Rogers, X. Zhang, and L. M. Bradley.
From naive to memory T cells. Immunol Rev, 150:143–67, 1996.
[72] S. M. Kaech and R. Ahmed. Memory CD8+ T cell differentiation: initial antigen
encounter triggers a developmental program in naive cells. Nat Immunol, 2(5):415–22,
2001.
[73] R. V. Luckheeram, R. Zhou, A. D. Verma, and B. Xia. CD4(+)T cells: differentiation
and functions. Clin Dev Immunol, 2012:925135, 2012.
[74] F. Sallusto, D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. Two subsets of
memory T lymphocytes with distinct homing potentials and effector functions. Nature,
401(6754):708–12, 1999.
[75] O. Bjorkdahl, K. A. Barber, S. J. Brett, M. G. Daly, C. Plumpton, N. A. Elshourbagy, J. P.
Tite, and L. L. Thomsen. Characterization of CC-chemokine receptor 7 expression on
murine T cells in lymphoid tissues. Immunology, 110(2):170–9, 2003.
Bibliography 108
[76] J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky. Foxp3 programs the development
and function of CD4+CD25+ regulatory T cells. Nat Immunol, 4(4):330–6, 2003.
[77] S. Hori, T. Nomura, and S. Sakaguchi. Control of regulatory T cell development by
the transcription factor Foxp3. Science, 299(5609):1057–61, 2003.
[78] A. M. Bilate and J. J. Lafaille. Induced CD4+Foxp3+ regulatory T cells in immune
tolerance. Annu Rev Immunol, 30:733–58, 2012.
[79] S. Floess, J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H.-D. Chang,
T. Bopp, E. Schmitt, et al. Epigenetic control of the foxp3 locus in regulatory T cells.
PLoS Biol, 5(2):e38, 2007.
[80] S. Sakaguchi, T. Takahashi, and Y. Nishizuka. Study on cellular events in post-
thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal
female mice for the prevention of oophoritis. J Exp Med, 156(6):1577–86, 1982.
[81] S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).
Breakdown of a single mechanism of self-tolerance causes various autoimmune
diseases. J Immunol, 155(3):1151–64, 1995.
[82] L. B. Clark, M. W. Appleby, M. E. Brunkow, J. E. Wilkinson, S. F. Ziegler, and
F. Ramsdell. Cellular and molecular characterization of the scurfy mouse mutant. J
Immunol, 162(5):2546–54, 1999.
[83] C. L. Bennett, J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell,
T. E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs. The immune dysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations
of FOXP3. Nat Genet, 27(1):20–1, 2001.
[84] M. E. Brunkow, E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. Yasayko,
J. E. Wilkinson, D. Galas, S. F. Ziegler, and F. Ramsdell. Disruption of a new
forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disor-
der of the scurfy mouse. Nat Genet, 27(1):68–73, 2001.
[85] M. S. Jordan, A. Boesteanu, A. J. Reed, A. L. Petrone, A. E. Holenbeck, M. A. Lerman,
A. Naji, and A. J. Caton. Thymic selection of CD4+CD25+ regulatory T cells induced
by an agonist self-peptide. Nat Immunol, 2(4):301–6, 2001.
[86] E. M. Shevach. From vanilla to 28 flavors: multiple varieties of T regulatory cells.
Immunity, 25(2):195–201, 2006.
[87] T. Bopp, C. Becker, M. Klein, S. Klein-Hessling, A. Palmetshofer, E. Serfling, V. Heib,
M. Becker, J. Kubach, S. Schmitt, S. Stoll, H. Schild, M. S. Staege, M. Stassen, H. Jonuleit,
and E. Schmitt. Cyclic adenosine monophosphate is a key component of regulatory T
cell-mediated suppression. J Exp Med, 204(6):1303–10, 2007.
[88] S. Deaglio, K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen,
K. Enjyoji, J. Linden, M. Oukka, V. K. Kuchroo, T. B. Strom, and S. C. Robson.
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells
mediates immune suppression. J Exp Med, 204(6):1257–65, 2007.
[89] S. Huang, S. Apasov, M. Koshiba, and M. Sitkovsky. Role of A2a extracellular adenosine
receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and
expansion. Blood, 90(4):1600–10, 1997.
Bibliography 109
[90] W. J. Grossman, J. W. Verbsky, W. Barchet, M. Colonna, J. P. Atkinson, and T. J. Ley.
Human T regulatory cells can use the perforin pathway to cause autologous target
cell death. Immunity, 21(4):589–601, 2004.
[91] D. C. Gondek, L. F. Lu, S. A. Quezada, S. Sakaguchi, and R. J. Noelle. Cutting edge:
contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme
B-dependent, perforin-independent mechanism. J Immunol, 174(4):1783–6, 2005.
[92] H. Y. Qin, R. Mukherjee, E. Lee-Chan, C. Ewen, R. C. Bleackley, and B. Singh. A
novel mechanism of regulatory T cell-mediated down-regulation of autoimmunity.
Int Immunol, 18(7):1001–15, 2006.
[93] Q. Tang, J. Y. Adams, A. J. Tooley, M. Bi, B. T. Fife, P. Serra, P. Santamaria, R. M.
Locksley, M. F. Krummel, and J. A. Bluestone. Visualizing regulatory T cell control of
autoimmune responses in nonobese diabetic mice. Nat Immunol, 7(1):83–92, 2006.
[94] D. M. Zhao, A. M. Thornton, R. J. DiPaolo, and E. M. Shevach. Activated CD4+CD25+
T cells selectively kill B lymphocytes. Blood, 107(10):3925–32, 2006.
[95] F. Fallarino, U. Grohmann, K. W. Hwang, C. Orabona, C. Vacca, R. Bianchi, M. L.
Belladonna, M. C. Fioretti, M. L. Alegre, and P. Puccetti. Modulation of tryptophan
catabolism by regulatory T cells. Nat Immunol, 4(12):1206–12, 2003.
[96] P. Puccetti and U. Grohmann. IDO and regulatory T cells: a role for reverse signalling
and non-canonical NF-kappaB activation. Nat Rev Immunol, 7(10):817–23, 2007.
[97] M. Feuerer, N. Kamei, D. Cipolletta, A. Li, J. Lee, S. E . Shoelson, C. O. Benoist,
and D. J. Mathis. PPARγ is a Major Driver of the Accumulation and Phenotype of
Adipose-Tissue Treg Cells. 2012.
[98] D. Burzyn, W. Kuswanto, D. Kolodin, J. L. Shadrach, M. Cerletti, Y. Jang, E. Sefik,
T. G. Tan, A. J. Wagers, C. Benoist, et al. A special population of regulatory T cells
potentiates muscle repair. Cell, 155(6):1282–1295, 2013.
[99] H. Lei, K. Schmidt-Bleek, A. Dienelt, P. Reinke, and H. D. Volk. Regulatory T cell-
mediated anti-inflammatory effects promote successful tissue repair in both indirect
and direct manners. Front Pharmacol, 6:184, 2015.
[100] A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. The chemokine
system in diverse forms of macrophage activation and polarization. Trends Immunol,
25(12):677–86, 2004.
[101] D. Toben, I. Schroeder, T. El Khassawna, M. Mehta, J. E. Hoffmann, J. T. Frisch, H. Schell,
J. Lienau, A. Serra, A. Radbruch, and G. N. Duda. Fracture healing is accelerated in
the absence of the adaptive immune system. J Bone Miner Res, 26(1):113–24, 2011.
[102] S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito,
K. Inoue, N. Kamatani, M. T. Gillespie, T. J. Martin, and T. Suda. IL-17 in synovial fluids
from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J
Clin Invest, 103(9):1345–52, 1999.
[103] M. Croes, F. C. Oner, D. van Neerven, E. Sabir, M. C. Kruyt, T. J. Blokhuis, W. J. Dhert,
and J. Alblas. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation.
Bone, 84:262–70, 2016.
[104] Q. Niu, B. Cai, Z. C. Huang, Y. Y. Shi, and L. L. Wang. Disturbed Th17/Treg balance in
patients with rheumatoid arthritis. Rheumatol Int, 32(9):2731–6, 2012.
Bibliography 110
[105] A. M. Tyagi, K. Srivastava, M. N. Mansoori, R. Trivedi, N. Chattopadhyay, and D. Singh.
Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new
candidate in the pathogenesis of osteoporosis. PLoS One, 7(9):e44552, 2012.
[106] M. Mehta, H. Schell, C. Schwarz, A. Peters, K. Schmidt-Bleek, A. Ellinghaus, H. J. Bail,
G. N. Duda, and J. Lienau. A 5-mm femoral defect in female but not in male rats leads
to a reproducible atrophic non-union. Arch Orthop Trauma Surg, 131(1):121–9, 2011.
[107] P. Strube, M. Mehta, A. Baerenwaldt, J. Trippens, C. J. Wilson, A. Ode, C. Perka, G. N.
Duda, and G. Kasper. Sex-specific compromised bone healing in female rats might be
associated with a decrease in mesenchymal stem cell quantity. Bone, 45(6):1065–72,
2009.
[108] M. D. Brodt, C. B. Ellis, and M. J. Silva. Growing C57Bl/6 mice increase whole bone
mechanical properties by increasing geometric and material properties. J Bone Miner
Res, 14(12):2159–66, 1999.
[109] D. J. Recktenwald. Introduction to flow cytometry: principles, fluorochromes, instru-
ment set-up, calibration. J Hematother, 2(3):387–94, 1993.
[110] S. Miltenyi, W. Muller, W. Weichel, and A. Radbruch. High gradient magnetic cell
separation with MACS. Cytometry, 11(2):231–8, 1990.
[111] A. M. Thornton and E. M. Shevach. CD4+CD25+ immunoregulatory T cells suppress
polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med,
188(2):287–96, 1998.
[112] L. W. Collison and D. A. Vignali. In vitro Treg suppression assays. Methods Mol Biol,
707:21–37, 2011.
[113] T. Kawamoto. Light microscopic autoradiography for study of early changes in the
distribution of water-soluble materials. J Histochem Cytochem, 38(12):1805–14, 1990.
[114] T. Kawamoto. Use of a new adhesive film for the preparation of multi-purpose
fresh-frozen sections from hard tissues, whole-animals, insects and plants. Arch Histol
Cytol, 66(2):123–43, 2003.
[115] H. Z. Movat. Demonstration of all connective tissue elements in a single section;
pentachrome stains. AMA Arch Pathol, 60(3):289–95, 1955.
[116] J. M. Lucocq and J. Roth. Applications of immunocolloids in light microscopy. III.
Demonstration of antigenic and lectin-binding sites in semithin resin sections. J
Histochem Cytochem, 32(10):1075–83, 1984.
[117] A. H. Coons and M. H. Kaplan. Localization of antigen in tissue cells; improvements
in a method for the detection of antigen by means of fluorescent antibody. J Exp Med,
91(1):1–13, 1950.
[118] A. H. Coons. The development of immunohistochemistry. Ann N Y Acad Sci, 177:5–9,
1971.
[119] L. A. Feldkamp, S. A. Goldstein, A. M. Parfitt, G. Jesion, and M. Kleerekoper. The direct
examination of three-dimensional bone architecture in vitro by computed tomography.
J Bone Miner Res, 4(1):3–11, 1989.
Bibliography 111
[120] M. L. Bouxsein, S. K. Boyd, B. A. Christiansen, R. E. Guldberg, K. J. Jepsen, and R. Muller.
Guidelines for assessment of bone microstructure in rodents using micro-computed
tomography. J Bone Miner Res, 25(7):1468–86, 2010.
[121] R. Muller, M. Hahn, M. Vogel, G. Delling, and P. Ruegsegger. Morphometric analysis
of noninvasively assessed bone biopsies: comparison of high-resolution computed
tomography and histologic sections. Bone, 18(3):215–20, 1996.
[122] M. A. Curotto de Lafaille and J. J. Lafaille. Natural and adaptive foxp3+ regulatory T
cells: more of the same or a division of labor? Immunity, 30(5):626–35, 2009.
[123] X. Lin, M. Chen, Y. Liu, Z. Guo, X. He, D. Brand, and S. G. Zheng. Advances in
distinguishing natural from induced Foxp3(+) regulatory T cells. Int J Clin Exp Pathol,
6(2):116–23, 2013.
[124] C. G. Brunstein, J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger,
T. Defor, B. L. Levine, C. H. June, P. Rubinstein, P. B. McGlave, B. R. Blazar, and J. E.
Wagner. Infusion of ex vivo expanded T regulatory cells in adults transplanted with
umbilical cord blood: safety profile and detection kinetics. Blood, 117(3):1061–70, 2011.
[125] N. Marek-Trzonkowska, M. Mysliwiec, A. Dobyszuk, M. Grabowska, I. Techmanska,
J. Juscinska, M. A. Wujtewicz, P. Witkowski, W. Mlynarski, A. Balcerska, J. Mysliwska,
and P. Trzonkowski. Administration of CD4+CD25highCD127- regulatory T cells
preserves beta-cell function in type 1 diabetes in children. Diabetes Care, 35(9):1817–20,
2012.
[126] P. Trzonkowski, M. Bieniaszewska, J. Juscinska, A. Dobyszuk, A. Krzystyniak,
N. Marek, J. Mysliwska, and A. Hellmann. First-in-man clinical results of the
treatment of patients with graft versus host disease with human ex vivo expanded
CD4+CD25+CD127- T regulatory cells. Clin Immunol, 133(1):22–6, 2009.
[127] K. Lahl, C. Loddenkemper, C. Drouin, J. Freyer, J. Arnason, G. Eberl, A. Hamann,
H. Wagner, J. Huehn, and T. Sparwasser. Selective depletion of Foxp3+ regulatory T
cells induces a scurfy-like disease. J Exp Med, 204(1):57–63, 2007.
[128] E. Jones, M. Dahm-Vicker, A. K. Simon, A. Green, F. Powrie, V. Cerundolo, and
A. Gallimore. Depletion of CD25+ regulatory cells results in suppression of melanoma
growth and induction of autoreactivity in mice. Cancer Immun, 2:1, 2002.
[129] W. Li, K. Carper, Y. Liang, X. X. Zheng, C. S. Kuhr, J. D. Reyes, D. L. Perkins, A. W.
Thomson, and J. D. Perkins. Anti-CD25 mAb administration prevents spontaneous
liver transplant tolerance. Transplant Proc, 38(10):3207–8, 2006.
[130] R. Rad, L. Brenner, S. Bauer, S. Schwendy, L. Layland, C. P. da Costa, W. Reindl,
A. Dossumbekova, M. Friedrich, D. Saur, H. Wagner, R. M. Schmid, and C. Prinz.
CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori coloniza-
tion in vivo. Gastroenterology, 131(2):525–37, 2006.
[131] L. J. Raggatt, M. E. Wullschleger, K. A. Alexander, A. C. Wu, S. M. Millard, S. Kaur,
M. L. Maugham, L. S. Gregory, R. Steck, and A. R. Pettit. Fracture healing via periosteal
callus formation requires macrophages for both initiation and progression of early
endochondral ossification. Am J Pathol, 184(12):3192–204, 2014.
[132] S. M. Opal. Phylogenetic and functional relationships between coagulation and the
innate immune response. Crit Care Med, 28(9 Suppl):S77–80, 2000.
Bibliography 112
[133] S. M. Abdelmagid, M. F. Barbe, and F. F. Safadi. Role of inflammation in the aging
bones. Life Sci, 123:25–34, 2015.
[134] K. L. Spiller, R. R. Anfang, K. J. Spiller, J. Ng, K. R. Nakazawa, J. W. Daulton, and
G. Vunjak-Novakovic. The role of macrophage phenotype in vascularization of tissue
engineering scaffolds. Biomaterials, 35(15):4477–88, 2014.
[135] G. Mori, P. D’Amelio, R. Faccio, and G. Brunetti. Bone-immune cell crosstalk: bone
diseases. J Immunol Res, 2015:108451, 2015.
[136] L. Rifas. T-cell cytokine induction of BMP-2 regulates human mesenchymal stromal
cell differentiation and mineralization. J Cell Biochem, 98(4):706–14, 2006.
[137] E. Faist, C. Schinkel, and S. Zimmer. Update on the mechanisms of immune suppression
of injury and immune modulation. World J Surg, 20(4):454–9, 1996.
[138] N. Ni Choileain, M. MacConmara, Y. Zang, T. J. Murphy, J. A. Mannick, and J. A.
Lederer. Enhanced regulatory T cell activity is an element of the host response to
injury. J Immunol, 176(1):225–36, 2006.
[139] J. A. Lederer, M. L. Rodrick, and J. A. Mannick. The effects of injury on the adaptive
immune response. Shock, 11(3):153–9, 1999.
[140] V. E. Strong, P. J. Mackrell, E. M. Concannon, H. A. Naama, P. A. Schaefer, G. W. Shaftan,
P. P. Stapleton, and J. M. Daly. Blocking prostaglandin E2 after trauma attenuates
pro-inflammatory cytokines and improves survival. Shock, 14(3):374–9, 2000.
[141] E. J. Wherry, V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von
Andrian, and R. Ahmed. Lineage relationship and protective immunity of memory
CD8 T cell subsets. Nat Immunol, 4(3):225–34, 2003.
[142] F. Sallusto, J. Geginat, and A. Lanzavecchia. Central memory and effector memory T
cell subsets: function, generation, and maintenance. Annu Rev Immunol, 22:745–63,
2004.
[143] K. J. Maloy, L. Salaun, R. Cahill, G. Dougan, N. J. Saunders, and F. Powrie. CD4+CD25+
T(R) cells suppress innate immune pathology through cytokine-dependent mecha-
nisms. J Exp Med, 197(1):111–9, 2003.
[144] T. J. Murphy, N. Ni Choileain, Y. Zang, J. A. Mannick, and J. A. Lederer. CD4+CD25+
regulatory T cells control innate immune reactivity after injury. J Immunol, 174(5):2957–
63, 2005.
[145] M. O. Al-Sebaei, D. M. Daukss, A. C. Belkina, S. Kakar, N. A. Wigner, D. Cusher,
D. Graves, T. Einhorn, E. Morgan, and L. C. Gerstenfeld. Role of Fas and Treg Cells in
Fracture Healing as Characterized in the Fas-Deficient (lpr) Mouse Model of Lupus.
Journal of Bone and Mineral Research, 29(6):1478–1491, 2014.
[146] J. A. Pasco, M. A. Kotowicz, M. J. Henry, G. C. Nicholson, H. J. Spilsbury, J. D. Box,
and H. G. Schneider. High-sensitivity C-reactive protein and fracture risk in elderly
women. JAMA, 296(11):1353–5, 2006.
[147] J. A. Cauley, M. E. Danielson, R. M. Boudreau, K. Y. Forrest, J. M. Zmuda, M. Pahor,
F. A. Tylavsky, S. R. Cummings, T. B. Harris, A. B. Newman, and A. B. C. Study Health.
Inflammatory markers and incident fracture risk in older men and women: the Health
Aging and Body Composition Study. J Bone Miner Res, 22(7):1088–95, 2007.
Bibliography 113
[148] R. Gruber, H. Koch, B. A. Doll, F. Tegtmeier, T. A. Einhorn, and J. O. Hollinger. Fracture
healing in the elderly patient. Exp Gerontol, 41(11):1080–93, 2006.
[149] A. H. Kverneland, M. Streitz, E. Geissler, J. Hutchinson, K. Vogt, D. Boes, N. Niemann,
A. E. Pedersen, S. Schlickeiser, and B. Sawitzki. Age and gender leucocytes vari-
ances and references values generated using the standardized ONE-Study protocol.
Cytometry A, 89(6):543–64, 2016.
[150] D. F. Tough, P. Borrow, and J. Sprent. Induction of bystander T cell proliferation by
viruses and type I interferon in vivo. Science, 272(5270):1947–50, 1996.
[151] C. Franceschi, M. Bonafe, S. Valensin, F. Olivieri, M. De Luca, E. Ottaviani, and
G. De Benedictis. Inflamm-aging. An evolutionary perspective on immunosenescence.
Ann N Y Acad Sci, 908:244–54, 2000.
[152] T. Takahashi, Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. Shimizu,
and S. Sakaguchi. Immunologic self-tolerance maintained by CD25+CD4+ naturally
anergic and suppressive T cells: induction of autoimmune disease by breaking their
anergic/suppressive state. Int Immunol, 10(12):1969–80, 1998.
[153] M. Stassen, H. Jonuleit, C. Muller, M. Klein, C. Richter, T. Bopp, S. Schmitt, and
E. Schmitt. Differential regulatory capacity of CD25+ T regulatory cells and preactivated
CD25+ T regulatory cells on development, functional activation, and proliferation of
Th2 cells. J Immunol, 173(1):267–74, 2004.
[154] X. Ren, F. Ye, Z. Jiang, Y. Chu, S. Xiong, and Y. Wang. Involvement of cellular death in
TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells.
Cell Death Differ, 14(12):2076–84, 2007.
[155] Y. Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li,
R. Elliott, S. McCabe, T. Wong, G. Campagnuolo, E. Moran, E. R. Bogoch, G. Van,
L. T. Nguyen, P. S. Ohashi, D. L. Lacey, E. Fish, W. J. Boyle, and J. M. Penninger.
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through
osteoprotegerin ligand. Nature, 402(6759):304–9, 1999.
[156] S. Cenci, G. Toraldo, M. N. Weitzmann, C. Roggia, Y. Gao, W. P. Qian, O. Sierra, and
R. Pacifici. Estrogen deficiency induces bone loss by increasing T cell proliferation
and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U
S A, 100(18):10405–10, 2003.
[157] A. McNally, G. R. Hill, T. Sparwasser, R. Thomas, and R. J. Steptoe. CD4+CD25+
regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2
homeostasis. Proc Natl Acad Sci U S A, 108(18):7529–34, 2011.
[158] K. Gobel, S. Bittner, N. Melzer, S. Pankratz, A. Dreykluft, M. K. Schuhmann, S. G. Meuth,
and H. Wiendl. CD4(+) CD25(+) FoxP3(+) regulatory T cells suppress cytotoxicity of
CD8(+) effector T cells: implications for their capacity to limit inflammatory central
nervous system damage at the parenchymal level. J Neuroinflammation, 9:41, 2012.
[159] W. Kastenmuller, G. Gasteiger, N. Subramanian, T. Sparwasser, D. H. Busch, Y. Belkaid,
I. Drexler, and R. N. Germain. Regulatory T cells selectively control CD8+ T cell
effector pool size via IL-2 restriction. J Immunol, 187(6):3186–97, 2011.
[160] M. Murakami, A. Sakamoto, J. Bender, J. Kappler, and P. Marrack. CD25+CD4+ T
cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci U S A,
99(13):8832–7, 2002.
Bibliography 114
[161] F. M. Mbitikon-Kobo, M. Vocanson, M. C. Michallet, M. Tomkowiak, A. Cottalorda,
G. S. Angelov, C. A. Coupet, S. Djebali, A. Marcais, B. Dubois, N. Bonnefoy-Berard, J. F.
Nicolas, C. Arpin, and J. Marvel. Characterization of a CD44/CD122int memory CD8 T
cell subset generated under sterile inflammatory conditions. J Immunol, 182(6):3846–54,
2009.
[162] L. Xu, A. Kitani, I. Fuss, and W. Strober. Cutting edge: regulatory T cells induce
CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of
exogenous TGF-beta. J Immunol, 178(11):6725–9, 2007.
[163] X. O. Yang, R. Nurieva, G. J. Martinez, H. S. Kang, Y. Chung, B. P. Pappu, B. Shah, S. H.
Chang, K. S. Schluns, S. S. Watowich, X. H. Feng, A. M. Jetten, and C. Dong. Molecular
antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity,
29(1):44–56, 2008.
[164] X. Zhou, S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Martinez-Llordella,
M. Ashby, M. Nakayama, W. Rosenthal, and J. A. Bluestone. Instability of the
transcription factor Foxp3 leads to the generation of pathogenic memory T cells in
vivo. Nat Immunol, 10(9):1000–7, 2009.
[165] Y. P. Rubtsov, R. E. Niec, S. Josefowicz, L. Li, J. Darce, D. Mathis, C. Benoist, and A. Y.
Rudensky. Stability of the regulatory T cell lineage in vivo. Science, 329(5999):1667–71,
2010.
[166] F. Osorio, S. LeibundGut-Landmann, M. Lochner, K. Lahl, T. Sparwasser, G. Eberl,
and C. Reis e Sousa. DC activated via dectin-1 convert Treg into IL-17 producers. Eur
J Immunol, 38(12):3274–81, 2008.
[167] H. J. Koenen, R. L. Smeets, P. M. Vink, E. van Rijssen, A. M. Boots, and I. Joosten.
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.
Blood, 112(6):2340–52, 2008.
[168] G. Beriou, C. M. Costantino, C. W. Ashley, L. Yang, V. K. Kuchroo, C. Baecher-Allan, and
D. A. Hafler. IL-17-producing human peripheral regulatory T cells retain suppressive
function. Blood, 113(18):4240–9, 2009.
[169] K. G. Elpek, C. Lacelle, N. P. Singh, E. S. Yolcu, and H. Shirwan. CD4+CD25+ T
regulatory cells dominate multiple immune evasion mechanisms in early but not late
phases of tumor development in a B cell lymphoma model. J Immunol, 178(11):6840–8,
2007.
[170] S. A. Quezada, K. S. Peggs, T. R. Simpson, Y. Shen, D. R. Littman, and J. P. Allison.
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity
of regulatory T cell depletion against established melanoma. J Exp Med, 205(9):2125–38,
2008.
[171] K. N. Couper, P. A. Lanthier, G. Perona-Wright, L. W. Kummer, W. Chen, S. T. Smiley,
M. Mohrs, and L. L. Johnson. Anti-CD25 antibody-mediated depletion of effector T
cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma
gondii infection. J Immunol, 182(7):3985–94, 2009.
